[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fX8Owl8Qx_g9ZQ_22c3bnusJTMMuiQeOkAxpvZ3LN9v4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"Weill Medical College of Cornell University",[4],867,false,195,35,979316,104,533,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Depression",47,{"name":18,"count":19},"Prostate Cancer",36,{"name":21,"count":22},"Breast Cancer",20,{"name":24,"count":25},"Hypertension",19,{"name":27,"count":28},"Infertility",15,{"name":30,"count":31},"Multiple Myeloma",14,{"name":33,"count":34},"Smoking",13,{"name":36,"count":37},"COPD",11,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT01559935","Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma","2016-06-07","carfilzomib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT02998268","Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","2021-02-10","Pembrolizumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03042468","Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC","2021-09-30","177Lu-PSMA-617",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT01054196","Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 \u002F 2 Study","2021-10","lenalidomide",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT00859781","177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer","2022-02-10","177Lu-J591",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04395222","Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation","2022-09-28","Tocilizumab",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT01810588","Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","2023-08-09","Fludarabine",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT03863184","Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL","2024-04-25","Acalabrutinib",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04302324","A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab","2024-05-31","Daratumumab SC",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT03837821","(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer","2024-07-02","Abemaciclib",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,139,187,225,252,270,288,313,338,356,384,402,431,457,484,538,565,583,610,639,657,675,703,721,824,1001,1169,1235,1344,1417,1455,1489,1523,1567,1601,1634,1656,1678,1713,1750,1772,1810,1847,1869,1926,1960,2006,2037,2064,2086,2118,2140,2164,2191,2209,2227,2252,2278,2296,2321,2339,2357,2375,2402,2420,2438,2456,2480,2498,2516,2534,2552,2577,2599,2617,2635,2658,2676,2694,2712,2735,2753,2781,2799,2817,2845,2863,2911,2947,2972,2990,3014,3040,3058,3076,3094,3119,3143,3166,3186,3211,3236,3260,3286,3304,3338,3369,3405,3443,3476,3506,3530,3548,3566,3590,3608,3626,3650,3675,3700,3724,3749,3767,3791,3815,3842,3860,3878,3896,3919,3943,3966,3984,4010,4028,4052,4079,4097,4115,4133,4151,4177,4201,4225,4249,4267,4290,4308,4326,4352,4370,4393,4416,4441,4465,4488,4512,4539,4557,4575,4599,4621,4639,4667,4685,4710,4728,4752,4770,4797,4815,4833,4856,4882,4905,4930,4956,4974,4996,5014,5038,5061,5079,5103,5130,5153,5177,5209,5248,5271,5289,5312,5336,5354,5378,5396,5422,5440,5465,5488,5513,5531,5557,5575,5604,5622,5645,5669,5729,5775,5805,5833,5871,5913,5935,5960,5982,6009,6037,6065,6092,6126,6148,6181,6215,6237,6262,6284,6322,6351,6377,6395,6418,6436,6454,6472,6497,6515,6537,6560,6578,6602,6626,6644,6670,6693,6723,6741,6765,6789,6814,6837,6855,6881,6899,6917,6941,6964,6982,7000,7024,7048,7066,7089,7107,7131,7152,7170,7194,7212,7230,7253,7271,7289,7307,7325,7349,7374,7392,7418,7436,7457,7475,7499,7517,7539,7561,7586,7609,7632,7650,7676,7694,7719,7737,7762,7786,7804,7822,7843,7867,7885,7903,7921,7939,7963,7981,8008,8035,8053,8071,8095,8118,8142,8169,8187,8205,8223,8246,8267,8285,8303,8321,8339,8357,8379,8397,8427,8452,8470,8494,8519,8537,8555,8588,8616,8638,8656,8677,8701,8719,8742,8768,8786,8811,8829,8847,8871,8889,8911,8929,8947,8965,8983,9001,9023,9041,9059,9077,9095,9118,9136,9154,9175,9198,9221,9243,9261,9279,9297,9315,9333,9351,9374,9398,9416,9449,9470,9496,9514,9538,9601,9635,9665,9695,9724,9746,9771,9789,9807,9825,9843,9866,9888,9912,9930,9951,9974,9998,10021,10044,10067,10092,10110,10128,10151,10175,10197,10220,10244,10262,10284,10302,10320,10338,10356,10379,10397,10421,10446,10464,10482,10500,10518,10536,10554],{"intervention":98,"totalTrials":99,"cells":100},"Beta blocker",2,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":137},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":103},[],{"trials":109,"activeCount":103},[],{"trials":111,"activeCount":99,"soonestReadout":130},[112,126],{"nctId":113,"briefTitle":114,"status":115,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":22,"conditions":119,"interventions":125},"NCT05585125","A Preliminary Study for INFORMED","ENROLLING_BY_INVITATION",[94],"2026-07","2024-02-07",[120,121,122,123,124],"Heart Failure","Heart Failure, Diastolic","Heart Failure With Preserved Ejection Fraction","Cardiac Failure","Heart Diseases",[98,98],{"nctId":127,"briefTitle":128,"status":115,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":22,"conditions":133,"interventions":136},"NCT05019027","N-of-1 for Beta-Blockers in Cardiac Amyloidosis",[94],"2026-03-30","2026-12-31","2024-01-31",[134,124,135],"Cardiac Amyloidosis","TTR Cardiac Amyloidosis",[98],{"trials":138,"activeCount":103},[],{"intervention":140,"totalTrials":141,"cells":142},"Beta blockers",3,{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":185},{"trials":144,"activeCount":103},[],{"trials":146,"activeCount":103},[],{"trials":148,"activeCount":103},[],{"trials":150,"activeCount":103},[],{"trials":152,"activeCount":184,"soonestReadout":175},[153,164,171],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT04757584","Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF","COMPLETED",[94],"2023-04-28","2021-04-01",9,[120,121,122,123,162],"Heart Disease",[140],{"nctId":165,"briefTitle":166,"status":156,"phases":167,"primaryCompletion":168,"completion":158,"start":159,"enrollment":160,"conditions":169,"interventions":170},"NCT04767061","Impact of Beta-blockers on Physical Function in HFpEF",[94],"2022-04-28",[120,121,122,123,162],[140],{"nctId":172,"briefTitle":173,"status":115,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":182},"NCT07252310","Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)",[94],"2027-02","2027-08","2026-02-10",5,[180,120,181,124],"HFrEF - Heart Failure With Reduced Ejection Fraction","Heart Failure, Systolic",[183],"beta blockers",1,{"trials":186,"activeCount":103},[],{"intervention":188,"totalTrials":99,"cells":189},"Ferrous Sulfate",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":207,"PHASE4":209,"NA":223},{"trials":191,"activeCount":103},[],{"trials":193,"activeCount":103},[],{"trials":195,"activeCount":103},[196],{"nctId":197,"briefTitle":198,"status":156,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT00450177","Efficacy of Enteral Iron Supplementation in Critical Illness",[92],"2007-12","2008-01","2006-01",200,[205],"Anemic, Critically Ill Patients",[188],{"trials":208,"activeCount":103},[],{"trials":210,"activeCount":184,"soonestReadout":216},[211],{"nctId":212,"briefTitle":213,"status":214,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":222},"NCT03991169","Oral Iron in Children With Chronic Kidney Disease","RECRUITING",[94],"2028-12-31","2019-04-19",40,[220,221],"Chronic Kidney Insufficiency","Chronic Kidney Diseases",[188],{"trials":224,"activeCount":103},[],{"intervention":226,"totalTrials":184,"cells":227},"Methotrexate",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":250},{"trials":229,"activeCount":103},[],{"trials":231,"activeCount":103},[],{"trials":233,"activeCount":103},[],{"trials":235,"activeCount":103},[],{"trials":237,"activeCount":184,"soonestReadout":243},[238],{"nctId":239,"briefTitle":240,"status":241,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":184,"conditions":245,"interventions":247},"NCT06578728","Local Methotrexate Injections for the Treatment of Nail Psoriasis","ACTIVE_NOT_RECRUITING",[94],"2026-06","2025-09-10",[246],"Nail Psoriasis",[226,248,249],"Triamcinolone Acetonide 10mg\u002FmL","Saline",{"trials":251,"activeCount":103},[],{"intervention":248,"totalTrials":184,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":268},{"trials":255,"activeCount":103},[],{"trials":257,"activeCount":103},[],{"trials":259,"activeCount":103},[],{"trials":261,"activeCount":103},[],{"trials":263,"activeCount":184,"soonestReadout":243},[264],{"nctId":239,"briefTitle":240,"status":241,"phases":265,"primaryCompletion":243,"completion":243,"start":244,"enrollment":184,"conditions":266,"interventions":267},[94],[246],[226,248,249],{"trials":269,"activeCount":103},[],{"intervention":249,"totalTrials":184,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":286},{"trials":273,"activeCount":103},[],{"trials":275,"activeCount":103},[],{"trials":277,"activeCount":103},[],{"trials":279,"activeCount":103},[],{"trials":281,"activeCount":184,"soonestReadout":243},[282],{"nctId":239,"briefTitle":240,"status":241,"phases":283,"primaryCompletion":243,"completion":243,"start":244,"enrollment":184,"conditions":284,"interventions":285},[94],[246],[226,248,249],{"trials":287,"activeCount":103},[],{"intervention":289,"totalTrials":184,"cells":290},"Adenosine",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":311},{"trials":292,"activeCount":103},[],{"trials":294,"activeCount":103},[],{"trials":296,"activeCount":103},[],{"trials":298,"activeCount":103},[],{"trials":300,"activeCount":184,"soonestReadout":305},[301],{"nctId":302,"briefTitle":303,"status":214,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT03218137","Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions",[94],"2025-12-31","2017-02-13",100,[309],"Premature Ventricular Contraction (PVC)",[289],{"trials":312,"activeCount":103},[],{"intervention":314,"totalTrials":184,"cells":315},"0.5 ml lidocaine + epinephrine 1:100,000",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":336},{"trials":317,"activeCount":103},[],{"trials":319,"activeCount":103},[],{"trials":321,"activeCount":103},[],{"trials":323,"activeCount":103},[],{"trials":325,"activeCount":184,"soonestReadout":330},[326],{"nctId":327,"briefTitle":328,"status":214,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":9,"conditions":332,"interventions":334},"NCT06694714","Split Face Study of the Duration of Local Anesthetics - Fourth Arm",[94],"2027-06-01","2025-01-21",[333],"Anesthesia, Local",[314,335],"1.0 ml lidocaine + epinephrine 1:100,000",{"trials":337,"activeCount":103},[],{"intervention":335,"totalTrials":184,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":354},{"trials":341,"activeCount":103},[],{"trials":343,"activeCount":103},[],{"trials":345,"activeCount":103},[],{"trials":347,"activeCount":103},[],{"trials":349,"activeCount":184,"soonestReadout":330},[350],{"nctId":327,"briefTitle":328,"status":214,"phases":351,"primaryCompletion":330,"completion":330,"start":331,"enrollment":9,"conditions":352,"interventions":353},[94],[333],[314,335],{"trials":355,"activeCount":103},[],{"intervention":357,"totalTrials":184,"cells":358},"Calcium Carbonate 500 MG",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":382},{"trials":360,"activeCount":103},[],{"trials":362,"activeCount":103},[],{"trials":364,"activeCount":103},[],{"trials":366,"activeCount":103},[],{"trials":368,"activeCount":184,"soonestReadout":373},[369],{"nctId":370,"briefTitle":371,"status":214,"phases":372,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":380},"NCT06580782","Calcium Carbonate to Augment Labor Contractions",[94],"2025-12","2024-11-18",60,[377,378,379],"Labor Dystocia","Labor Induction","Labor Augmentation",[357,381],"Standard Dose Synthetic Pitocin",{"trials":383,"activeCount":103},[],{"intervention":381,"totalTrials":184,"cells":385},{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":394,"NA":400},{"trials":387,"activeCount":103},[],{"trials":389,"activeCount":103},[],{"trials":391,"activeCount":103},[],{"trials":393,"activeCount":103},[],{"trials":395,"activeCount":184,"soonestReadout":373},[396],{"nctId":370,"briefTitle":371,"status":214,"phases":397,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":398,"interventions":399},[94],[377,378,379],[357,381],{"trials":401,"activeCount":103},[],{"intervention":403,"totalTrials":184,"cells":404},"L-Phenylalanine 500 mg Veg Capsule product",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":429},{"trials":406,"activeCount":103},[],{"trials":408,"activeCount":103},[],{"trials":410,"activeCount":103},[],{"trials":412,"activeCount":103},[],{"trials":414,"activeCount":184,"soonestReadout":419},[415],{"nctId":416,"briefTitle":417,"status":214,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":22,"conditions":422,"interventions":428},"NCT06433310","Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study",[94],"2027-12-17","2027-12-31","2024-10-17",[423,424,425,426,427],"Gut Microbiome","Gut Health","Dietary Supplement","L-Phenylalanine","Phenylpropionic Acid",[403],{"trials":430,"activeCount":103},[],{"intervention":432,"totalTrials":184,"cells":433},"Beta-blockers",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":455},{"trials":435,"activeCount":103},[],{"trials":437,"activeCount":103},[],{"trials":439,"activeCount":103},[],{"trials":441,"activeCount":103},[],{"trials":443,"activeCount":184,"soonestReadout":448},[444],{"nctId":445,"briefTitle":446,"status":115,"phases":447,"primaryCompletion":448,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":454},"NCT07298993","Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)",[94],"2029-04","2026-02-02",240,[120,452,453],"HFpEF","HFpEF - Heart Failure With Preserved Ejection Fraction",[432],{"trials":456,"activeCount":103},[],{"intervention":458,"totalTrials":184,"cells":459},"Tirzepatide",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":482},{"trials":461,"activeCount":103},[],{"trials":463,"activeCount":103},[],{"trials":465,"activeCount":103},[],{"trials":467,"activeCount":103},[],{"trials":469,"activeCount":184,"soonestReadout":475},[470],{"nctId":471,"briefTitle":472,"status":473,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},"NCT07257484","Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors","NOT_YET_RECRUITING",[94],"2027-10-06","2027-12-30","2026-04-06",30,[480,21],"Obesity (Disorder)",[458],{"trials":483,"activeCount":103},[],{"intervention":485,"totalTrials":141,"cells":486},"Ketorolac",{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":505,"PHASE3":507,"PHASE4":524,"NA":536},{"trials":488,"activeCount":103},[],{"trials":490,"activeCount":103},[491],{"nctId":492,"briefTitle":493,"status":494,"phases":495,"primaryCompletion":496,"completion":497,"start":498,"enrollment":103,"conditions":499,"interventions":503},"NCT04353505","Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache","WITHDRAWN",[91],"2022-06","2023-06","2020-10",[500,501,502],"Chronic Migraine","Cluster Headache","Trigeminal Neuralgia",[485,504],"Dexamethasone",{"trials":506,"activeCount":103},[],{"trials":508,"activeCount":184,"soonestReadout":513},[509],{"nctId":510,"briefTitle":511,"status":214,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":522},"NCT06994442","Optimizing Pain Treatment in Children On Mechanical Ventilation",[93],"2029-07-31","2029-08-31","2025-12-29",644,[518,519,520,521],"Mechanical Ventilation","Pediatric Acute Respiratory Failure","Analgesics, Opioid","Sedation and Analgesia",[523,485],"Acetaminophen",{"trials":525,"activeCount":103},[526],{"nctId":527,"briefTitle":528,"status":156,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT00161577","Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery",[94],"2006-06","2004-01",25,[534],"Pain Management Following Cardiopulmonary Bypass Surgery",[485],{"trials":537,"activeCount":103},[],{"intervention":539,"totalTrials":184,"cells":540},"Ticagrelor 90 MG",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":561,"NA":563},{"trials":542,"activeCount":103},[],{"trials":544,"activeCount":103},[],{"trials":546,"activeCount":103},[],{"trials":548,"activeCount":184,"soonestReadout":553},[549],{"nctId":550,"briefTitle":551,"status":214,"phases":552,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":559},"NCT05997693","One-Month DAPT in CABG Patients",[93],"2027-01","2031-01","2024-08-15",700,[558],"Chronic Coronary Disease",[539,560],"Low-dose aspirin",{"trials":562,"activeCount":103},[],{"trials":564,"activeCount":103},[],{"intervention":560,"totalTrials":184,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":579,"NA":581},{"trials":568,"activeCount":103},[],{"trials":570,"activeCount":103},[],{"trials":572,"activeCount":103},[],{"trials":574,"activeCount":184,"soonestReadout":553},[575],{"nctId":550,"briefTitle":551,"status":214,"phases":576,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":577,"interventions":578},[93],[558],[539,560],{"trials":580,"activeCount":103},[],{"trials":582,"activeCount":103},[],{"intervention":584,"totalTrials":184,"cells":585},"9 valent human papillomavirus vaccine",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":606,"NA":608},{"trials":587,"activeCount":103},[],{"trials":589,"activeCount":103},[],{"trials":591,"activeCount":103},[],{"trials":593,"activeCount":184,"soonestReadout":598},[594],{"nctId":595,"briefTitle":596,"status":241,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":556,"conditions":601,"interventions":605},"NCT04255849","Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV",[93],"2026-05-01","2026-07-01","2021-02-23",[602,603,604],"HPV Positive Oropharyngeal Squamous Cell Carcinoma","HIV-1-infection","HPV Infection",[584],{"trials":607,"activeCount":103},[],{"trials":609,"activeCount":103},[],{"intervention":611,"totalTrials":184,"cells":612},"Bone Marrow Aspirate Concentrate",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":619,"PHASE4":635,"NA":637},{"trials":614,"activeCount":103},[],{"trials":616,"activeCount":103},[],{"trials":618,"activeCount":103},[],{"trials":620,"activeCount":184,"soonestReadout":625},[621],{"nctId":622,"briefTitle":623,"status":473,"phases":624,"primaryCompletion":625,"completion":626,"start":627,"enrollment":22,"conditions":628,"interventions":633},"NCT07536399","Biologic Augmentation of TMJ Arthroscopy Using BMAC",[93],"2027-12","2028-06","2026-04",[629,630,631,632],"TMJ - Oral &Maxillofacial Surgery","Oral and Maxillofacial Conditions","TMJ Pain","TMJ Arthralgia",[611,634],"Corticosteroid",{"trials":636,"activeCount":103},[],{"trials":638,"activeCount":103},[],{"intervention":634,"totalTrials":184,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":653,"NA":655},{"trials":642,"activeCount":103},[],{"trials":644,"activeCount":103},[],{"trials":646,"activeCount":103},[],{"trials":648,"activeCount":184,"soonestReadout":625},[649],{"nctId":622,"briefTitle":623,"status":473,"phases":650,"primaryCompletion":625,"completion":626,"start":627,"enrollment":22,"conditions":651,"interventions":652},[93],[629,630,631,632],[611,634],{"trials":654,"activeCount":103},[],{"trials":656,"activeCount":103},[],{"intervention":523,"totalTrials":184,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":671,"NA":673},{"trials":660,"activeCount":103},[],{"trials":662,"activeCount":103},[],{"trials":664,"activeCount":103},[],{"trials":666,"activeCount":184,"soonestReadout":513},[667],{"nctId":510,"briefTitle":511,"status":214,"phases":668,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":669,"interventions":670},[93],[518,519,520,521],[523,485],{"trials":672,"activeCount":103},[],{"trials":674,"activeCount":103},[],{"intervention":676,"totalTrials":184,"cells":677},"Fluconazole",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":699,"NA":701},{"trials":679,"activeCount":103},[],{"trials":681,"activeCount":103},[],{"trials":683,"activeCount":103},[],{"trials":685,"activeCount":184,"soonestReadout":690},[686],{"nctId":687,"briefTitle":688,"status":214,"phases":689,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":697},"NCT06274554","Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease",[93],"2028-12","2029-12","2024-10-04",120,[695,696],"Crohn's Disease","Inflammatory Bowel Diseases",[676,698],"IL-23 Therapy",{"trials":700,"activeCount":103},[],{"trials":702,"activeCount":103},[],{"intervention":698,"totalTrials":184,"cells":704},{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":717,"NA":719},{"trials":706,"activeCount":103},[],{"trials":708,"activeCount":103},[],{"trials":710,"activeCount":103},[],{"trials":712,"activeCount":184,"soonestReadout":690},[713],{"nctId":687,"briefTitle":688,"status":214,"phases":714,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":715,"interventions":716},[93],[695,696],[676,698],{"trials":718,"activeCount":103},[],{"trials":720,"activeCount":103},[],{"intervention":48,"totalTrials":722,"cells":723},8,{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":738,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":725,"activeCount":103},[],{"trials":727,"activeCount":103},[728],{"nctId":729,"briefTitle":730,"status":494,"phases":731,"primaryCompletion":373,"completion":626,"start":732,"enrollment":103,"conditions":733,"interventions":735},"NCT05894447","Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers",[91],"2023-11",[734],"Urothelial Carcinoma",[736,48,737],"Naptumomab Estafenatox","Obinutuzumab",{"trials":739,"activeCount":178,"soonestReadout":47},[740,750,760,771,783,794,805],{"nctId":741,"briefTitle":742,"status":214,"phases":743,"primaryCompletion":690,"completion":690,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT05583708","Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer",[92],"2023-08-03",18,[747],"Merkel Cell Carcinoma",[48,749],"Lutetium Lu 177 dotatate",{"nctId":45,"briefTitle":46,"status":241,"phases":751,"primaryCompletion":47,"completion":752,"start":753,"enrollment":754,"conditions":755,"interventions":757},[92],"2026-03","2017-03-07",42,[756],"Esophageal Adenocarcinoma",[48,758,759],"Taxol","Carboplatin",{"nctId":761,"briefTitle":762,"status":214,"phases":763,"primaryCompletion":216,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":770},"NCT03449238","Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients",[91,92],"2030-12-31","2018-11-15",41,[768,769],"Metastatic Breast Cancer","Brain Metastases",[48],{"nctId":772,"briefTitle":773,"status":214,"phases":774,"primaryCompletion":775,"completion":776,"start":77,"enrollment":777,"conditions":778,"interventions":781},"NCT06340711","Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma",[92],"2028-04","2030-04",27,[756,779,780],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[782,48],"OBP-301",{"nctId":784,"briefTitle":785,"status":786,"phases":787,"primaryCompletion":788,"completion":789,"start":790,"enrollment":184,"conditions":791,"interventions":793},"NCT04685499","Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease","TERMINATED",[92],"2022-03-08","2022-06-03","2021-05-03",[792],"Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease",[782,48],{"nctId":795,"briefTitle":796,"status":214,"phases":797,"primaryCompletion":798,"completion":691,"start":799,"enrollment":800,"conditions":801,"interventions":802},"NCT04946370","Phase I\u002FII Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer",[91,92],"2027-10","2021-08-12",52,[18],[803,48,804],"225Ac-J591","Androgen receptor inhibitor",{"nctId":806,"briefTitle":807,"status":786,"phases":808,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":815},"NCT03115801","A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers",[92],"2020-10-13","2016-11",6,[813,814],"Metastatic Renal Cell Carcinoma","Metastatic Urothelial Carcinoma",[816,817,48],"Nivolumab","Atezolizumab",{"trials":819,"activeCount":103},[],{"trials":821,"activeCount":103},[],{"trials":823,"activeCount":103},[],{"intervention":504,"totalTrials":825,"cells":826},16,{"EARLY_PHASE1":827,"PHASE1":841,"PHASE2":872,"PHASE3":966,"PHASE4":987,"NA":999},{"trials":828,"activeCount":103},[829],{"nctId":830,"briefTitle":831,"status":494,"phases":832,"primaryCompletion":497,"completion":833,"start":834,"enrollment":103,"conditions":835,"interventions":839},"NCT04984330","Selinexor for Treatment of Light Chain Amyloidosis With Relapsed\u002FRefractory Disease",[90],"2024-06","2021-12",[836,837,838],"Amyloid","Amyloidosis","AL Amyloidosis",[840,504],"Selinexor",{"trials":842,"activeCount":103},[843,853,868],{"nctId":844,"briefTitle":845,"status":786,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":160,"conditions":849,"interventions":850},"NCT02030483","Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma",[91],"2016-07","2014-02",[30],[851,504,852],"Palbociclib","Lenalidomide",{"nctId":854,"briefTitle":855,"status":156,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":863},"NCT02471911","KPT-330 Plus RICE for Relapsed\u002FRefractory Aggressive B-Cell Lymphoma",[91],"2019-10-31","2021-10-14","2015-12-11",22,[862],"Diffuse Large B-Cell Lymphoma",[864,865,866,759,867,504],"KPT-330","Rituximab","Etoposide","Ifosfamide",{"nctId":492,"briefTitle":493,"status":494,"phases":869,"primaryCompletion":496,"completion":497,"start":498,"enrollment":103,"conditions":870,"interventions":871},[91],[500,501,502],[485,504],{"trials":873,"activeCount":141,"soonestReadout":42},[874,889,904,911,921,931,940,951,959],{"nctId":875,"briefTitle":876,"status":156,"phases":877,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":883},"NCT00148317","Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma",[92],"2011-02","2012-11","2005-06",38,[30],[884,885,886,887,888],"Bortezomib","dexamethasone","liposomal doxorubicin","cyclophoshamide","filgrastim",{"nctId":890,"briefTitle":891,"status":786,"phases":892,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":901},"NCT04843579","Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients",[92],"2022-11-30","2022-12-30","2021-12-29",4,[898,899,900],"Myeloma Multiple","Myeloma","Refractory Multiple Myeloma",[840,902,903,504],"Clarithromycin","Pomalidomide",{"nctId":80,"briefTitle":81,"status":241,"phases":905,"primaryCompletion":82,"completion":906,"start":907,"enrollment":37,"conditions":908,"interventions":910},[92],"2027-12-28","2021-10-28",[30,900,909],"Relapse Multiple Myeloma",[83,902,903,504],{"nctId":912,"briefTitle":913,"status":786,"phases":914,"primaryCompletion":915,"completion":915,"start":916,"enrollment":896,"conditions":917,"interventions":918},"NCT01979276","Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel\u002FRef Myeloma",[91,92],"2016-10","2013-11",[30],[919,920,504],"Romidepsin","pomalidomide",{"nctId":922,"briefTitle":923,"status":156,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":929},"NCT01159574","Study of Decadron, Biaxin, and Pomalidomide in Relapsed\u002FRefractory Myeloma",[92],"2015-05-05","2010-08",121,[30],[885,930,903],"clarithromycin",{"nctId":932,"briefTitle":933,"status":241,"phases":934,"primaryCompletion":553,"completion":935,"start":936,"enrollment":28,"conditions":937,"interventions":939},"NCT04270175","Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed\u002FRefractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab",[92],"2028-01","2021-04-14",[836,838,938],"Refractory AL Amyloidosis",[83,903,504],{"nctId":941,"briefTitle":942,"status":156,"phases":943,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":949},"NCT00538733","Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma",[92],"2010-07","2020-09-17","2007-10",26,[30],[950,58,930,885],"thalomid",{"nctId":952,"briefTitle":953,"status":786,"phases":954,"primaryCompletion":955,"completion":955,"start":200,"enrollment":178,"conditions":956,"interventions":957},"NCT00538824","Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma",[92],"2010-09-22",[30],[885,958,58],"thalidomide",{"nctId":40,"briefTitle":41,"status":241,"phases":960,"primaryCompletion":42,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":965},[92],"2027-03-01","2012-04-19",74,[30],[43,504,902,852,504,852],{"trials":967,"activeCount":103},[968,978],{"nctId":969,"briefTitle":970,"status":786,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":977},"NCT02516696","BiRd vs. Rd as Initial Therapy in Multiple Myeloma",[93],"2022-06-22","2022-07-22","2016-02",12,[30],[902,852,504],{"nctId":979,"briefTitle":980,"status":494,"phases":981,"primaryCompletion":982,"start":982,"enrollment":103,"conditions":983,"interventions":985},"NCT02649504","Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia",[93],"2016-12-01",[984],"Immune Thrombocytopenia",[865,504,986],"Mycophenolate mofetil",{"trials":988,"activeCount":103},[989],{"nctId":990,"briefTitle":991,"status":156,"phases":992,"primaryCompletion":993,"completion":994,"start":879,"enrollment":995,"conditions":996,"interventions":998},"NCT01734161","Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections",[94],"2014-09","2015-08",122,[997],"Postoperative Nausea and Vomiting",[504],{"trials":1000,"activeCount":103},[],{"intervention":865,"totalTrials":28,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1026,"PHASE3":1159,"PHASE4":1165,"NA":1167},{"trials":1004,"activeCount":103},[],{"trials":1006,"activeCount":103},[1007,1011],{"nctId":854,"briefTitle":855,"status":156,"phases":1008,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":1009,"interventions":1010},[91],[862],[864,865,866,759,867,504],{"nctId":1012,"briefTitle":1013,"status":156,"phases":1014,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1020},"NCT03036904","Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas",[91],"2021-11-11","2017-02-06",31,[862,1019],"High Grade B-Cell Lymphoma",[1021,865,866,1022,1023,1024,1025],"Venetoclax","Vincristine Sulfate","Cyclophosphamide","Prednisone","Doxorubicin Hydrochloride",{"trials":1027,"activeCount":141,"soonestReadout":72},[1028,1039,1048,1058,1072,1083,1094,1104,1116,1134,1144,1152],{"nctId":1029,"briefTitle":1030,"status":156,"phases":1031,"primaryCompletion":1032,"completion":1033,"start":1034,"enrollment":881,"conditions":1035,"interventions":1037},"NCT01472562","Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma",[92],"2014-04","2023-07-30","2011-07-29",[1036],"Mantle Cell Lymphoma",[58,1038],"rituximab",{"nctId":1040,"briefTitle":1041,"status":494,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":103,"conditions":1045,"interventions":1047},"NCT00251277","Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura",[91,92],"2009-04","2005-11",[1046],"Thrombotic Thrombocytopenic Purpura",[865],{"nctId":1049,"briefTitle":1050,"status":786,"phases":1051,"primaryCompletion":1052,"completion":1032,"start":1053,"enrollment":896,"conditions":1054,"interventions":1056},"NCT01779167","Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia",[92],"2013-10","2012-06",[1055],"Waldenstrom Macroglobulinemia",[1057,852,865],"Thalidomide",{"nctId":1059,"briefTitle":1060,"status":156,"phases":1061,"primaryCompletion":1062,"completion":974,"start":1063,"enrollment":31,"conditions":1064,"interventions":1066},"NCT01004991","Phase I\u002FII Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma",[91,92],"2013-09","2010-01",[1065],"Diffuse Large B Cell Lymphoma",[1038,1067,1068,1069,1070,1071],"cyclophosphamide","vincristine","doxorubicin","prednisone","azacytidine",{"nctId":1073,"briefTitle":1074,"status":156,"phases":1075,"primaryCompletion":1076,"completion":916,"start":1077,"enrollment":37,"conditions":1078,"interventions":1080},"NCT00401817","Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma",[92],"2011-07","2007-11",[1079],"Untreated Mantle Cell Lymphoma",[1081,865,1082],"Bevacizumab","CHOP",{"nctId":70,"briefTitle":71,"status":241,"phases":1084,"primaryCompletion":72,"completion":775,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1089},[92],"2012-10-16",270,[1088],"Hematologic Malignancies",[73,1090,1091,865,1092,1093],"Melphalan","anti-thymocyte globulin","Mycophenolate Mofetil","Tacrolimus",{"nctId":1095,"briefTitle":1096,"status":156,"phases":1097,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":28,"conditions":1101,"interventions":1103},"NCT01125176","Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL",[92],"2018-12-20","2020-12-29","2012-03-30",[1102],"Chronic Lymphocytic Leukemia",[958,58,1038],{"nctId":1105,"briefTitle":1106,"status":214,"phases":1107,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":22,"conditions":1111,"interventions":1113},"NCT04679012","Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation",[92],"2026-09","2027-09","2021-09-24",[1112,1102],"Richter Syndrome",[1114,865,866,1024,1023,1115],"Polatuzumab Vedotin","Hydroxydaunomycin",{"nctId":1117,"briefTitle":1118,"status":156,"phases":1119,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1127},"NCT02059239","Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed\u002FRefractory Lymphoma",[91,92],"2019-12-16","2020-06-15","2014-06-04",34,[1125,1126],"Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma",[1128,1129,866,1090,1130,1131,1132,1133,865],"Bendamustine","Carmustine","Cytarabine","Alemtuzumab","Autologous Stem Cell Transplantation","Allogeneic Stem Cell Transplantation",{"nctId":1135,"briefTitle":1136,"status":156,"phases":1137,"primaryCompletion":1138,"completion":1139,"start":1140,"enrollment":532,"conditions":1141,"interventions":1142},"NCT00151281","Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma",[92],"2009-12","2011-04-07","2004-11",[1126],[1143,1057,865],"PEPC",{"nctId":1145,"briefTitle":1146,"status":494,"phases":1147,"start":1148,"enrollment":103,"conditions":1149,"interventions":1151},"NCT00161564","A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone",[92],"2004-02",[1150],"Idiopathic Thrombocytopenic Purpura (ITP)",[865],{"nctId":75,"briefTitle":76,"status":241,"phases":1153,"primaryCompletion":77,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1158},[92],"2028-05-30","2019-10-11",37,[1036],[78,852,865,737],{"trials":1160,"activeCount":103},[1161],{"nctId":979,"briefTitle":980,"status":494,"phases":1162,"primaryCompletion":982,"start":982,"enrollment":103,"conditions":1163,"interventions":1164},[93],[984],[865,504,986],{"trials":1166,"activeCount":103},[],{"trials":1168,"activeCount":103},[],{"intervention":58,"totalTrials":37,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1179,"PHASE3":1225,"PHASE4":1231,"NA":1233},{"trials":1172,"activeCount":103},[],{"trials":1174,"activeCount":103},[1175],{"nctId":844,"briefTitle":845,"status":786,"phases":1176,"primaryCompletion":847,"completion":847,"start":848,"enrollment":160,"conditions":1177,"interventions":1178},[91],[30],[851,504,852],{"trials":1180,"activeCount":141,"soonestReadout":42},[1181,1185,1189,1199,1203,1207,1211,1217,1221],{"nctId":1029,"briefTitle":1030,"status":156,"phases":1182,"primaryCompletion":1032,"completion":1033,"start":1034,"enrollment":881,"conditions":1183,"interventions":1184},[92],[1036],[58,1038],{"nctId":1049,"briefTitle":1050,"status":786,"phases":1186,"primaryCompletion":1052,"completion":1032,"start":1053,"enrollment":896,"conditions":1187,"interventions":1188},[92],[1055],[1057,852,865],{"nctId":1190,"briefTitle":1191,"status":786,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":811,"conditions":1195,"interventions":1197},"NCT00840827","Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes",[92],"2010-12","2008-12",[1196],"Myelodysplastic Syndrome",[58,1198],"cyclosporine A",{"nctId":1095,"briefTitle":1096,"status":156,"phases":1200,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":28,"conditions":1201,"interventions":1202},[92],[1102],[958,58,1038],{"nctId":941,"briefTitle":942,"status":156,"phases":1204,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":1205,"interventions":1206},[92],[30],[950,58,930,885],{"nctId":952,"briefTitle":953,"status":786,"phases":1208,"primaryCompletion":955,"completion":955,"start":200,"enrollment":178,"conditions":1209,"interventions":1210},[92],[30],[885,958,58],{"nctId":55,"briefTitle":56,"status":241,"phases":1212,"primaryCompletion":57,"completion":1213,"start":926,"enrollment":800,"conditions":1214,"interventions":1215},[91,92],"2026-12",[30],[58,1216],"melphalan",{"nctId":40,"briefTitle":41,"status":241,"phases":1218,"primaryCompletion":42,"completion":961,"start":962,"enrollment":963,"conditions":1219,"interventions":1220},[92],[30],[43,504,902,852,504,852],{"nctId":75,"briefTitle":76,"status":241,"phases":1222,"primaryCompletion":77,"completion":1154,"start":1155,"enrollment":1156,"conditions":1223,"interventions":1224},[92],[1036],[78,852,865,737],{"trials":1226,"activeCount":103},[1227],{"nctId":969,"briefTitle":970,"status":786,"phases":1228,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":1229,"interventions":1230},[93],[30],[902,852,504],{"trials":1232,"activeCount":103},[],{"trials":1234,"activeCount":103},[],{"intervention":1090,"totalTrials":1236,"cells":1237},10,{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1282,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1239,"activeCount":103},[],{"trials":1241,"activeCount":103},[1242,1258,1270],{"nctId":1243,"briefTitle":1244,"status":156,"phases":1245,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":31,"conditions":1249,"interventions":1254},"NCT03393611","CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed\u002FRefractory Leukemia or Myelodysplastic Syndrome",[91],"2021-08-30","2021-11-18","2012-11-30",[1250,1251,1252,1253],"Myelodysplastic Syndromes","Leukemia, Myeloid, Acute","Leukemia, Relapsed Adult Acute Myeloid","Myelodysplastic Syndromes, Previously Treated",[1255,73,1090,1256,1257],"CPX-351","Rabbit Anti-Human T-Lymphocyte Globulin","Haplo-Cord Stem Cell Transplantation",{"nctId":1259,"briefTitle":1260,"status":156,"phases":1261,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":975,"conditions":1265,"interventions":1269},"NCT01637766","Intra-arterial Chemotherapy for Spinal Metastases",[91],"2018-04","2018-12","2012-04",[1266,1267,1268],"Spinal Diseases","Spinal Metastases","Spinal Tumors",[1090],{"nctId":1271,"briefTitle":1272,"status":786,"phases":1273,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":184,"conditions":1277,"interventions":1280},"NCT04994977","Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery",[91],"2024-07-23","2025-12-01","2023-05-04",[1278,1279],"Atypical Choroid Plexus Papilloma","Choroid Plexus Carcinoma",[1090,759,1281],"Topotecan",{"trials":1283,"activeCount":141,"soonestReadout":57},[1284,1294,1305,1309,1319,1323,1327],{"nctId":1285,"briefTitle":1286,"status":156,"phases":1287,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1293},"NCT00916058","Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma",[91,92],"2016-03-11","2018-03-01","2009-04-23",57,[30],[1128,1090,1128,1128,1128,1128,1128],{"nctId":1295,"briefTitle":1296,"status":786,"phases":1297,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":99,"conditions":1300,"interventions":1303},"NCT01745913","Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies",[92],"2015-04-29","2012-10-26",[1301,1196,1302,1125,1126],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia",[73,1090,1304],"Rabbit ATG",{"nctId":70,"briefTitle":71,"status":241,"phases":1306,"primaryCompletion":72,"completion":775,"start":1085,"enrollment":1086,"conditions":1307,"interventions":1308},[92],[1088],[73,1090,1091,865,1092,1093],{"nctId":65,"briefTitle":66,"status":241,"phases":1310,"primaryCompletion":67,"completion":1311,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1317},[92],"2027-06","2020-10-07",21,[1315,1316],"Hematologic Malignancy","Bone Marrow Transplant",[68,73,1090,1318],"Anti-thymocyte globulin",{"nctId":1117,"briefTitle":1118,"status":156,"phases":1320,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1321,"interventions":1322},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"nctId":55,"briefTitle":56,"status":241,"phases":1324,"primaryCompletion":57,"completion":1213,"start":926,"enrollment":800,"conditions":1325,"interventions":1326},[91,92],[30],[58,1216],{"nctId":1328,"briefTitle":1329,"status":156,"phases":1330,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":218,"conditions":1334,"interventions":1336},"NCT02497404","Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR",[92],"2020-06-17","2021-06-17","2015-02-13",[1335,1250],"Leukemia, Erythroblastic, Acute",[1337,73,1090,1131],"5-Azacytidine",{"trials":1339,"activeCount":103},[],{"trials":1341,"activeCount":103},[],{"trials":1343,"activeCount":103},[],{"intervention":1024,"totalTrials":1345,"cells":1346},7,{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1389,"PHASE3":1399,"PHASE4":1413,"NA":1415},{"trials":1348,"activeCount":103},[],{"trials":1350,"activeCount":184,"soonestReadout":216},[1351,1364,1368,1377],{"nctId":1352,"briefTitle":1353,"status":214,"phases":1354,"primaryCompletion":216,"completion":1355,"start":1356,"enrollment":532,"conditions":1357,"interventions":1362},"NCT05302271","Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia",[91],"2029-12-31","2022-02-22",[1358,1359,1360,1361],"Friedreich Ataxia","Cardiomyopathies","Cardiac Hypertrophy","Myocardial Fibrosis",[1363,1024],"AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN",{"nctId":1012,"briefTitle":1013,"status":156,"phases":1365,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1366,"interventions":1367},[91],[862,1019],[1021,865,866,1022,1023,1024,1025],{"nctId":1369,"briefTitle":1370,"status":156,"phases":1371,"primaryCompletion":1372,"completion":1263,"start":1373,"enrollment":28,"conditions":1374,"interventions":1375},"NCT00916123","Docetaxel\u002FPrednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer",[91],"2015-12","2009-05",[18],[1376,1024,63,63,63,63,63],"Docetaxel",{"nctId":1378,"briefTitle":1379,"status":156,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":825,"conditions":1384,"interventions":1386},"NCT02913196","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",[91],"2021-06-30","2025-10-15","2016-12-30",[1385],"Prostate Cancer Metastatic",[1387,1388,1376,1024],"Apalutamide","Abiraterone acetate",{"trials":1390,"activeCount":184,"soonestReadout":1108},[1391,1395],{"nctId":1059,"briefTitle":1060,"status":156,"phases":1392,"primaryCompletion":1062,"completion":974,"start":1063,"enrollment":31,"conditions":1393,"interventions":1394},[91,92],[1065],[1038,1067,1068,1069,1070,1071],{"nctId":1105,"briefTitle":1106,"status":214,"phases":1396,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":22,"conditions":1397,"interventions":1398},[92],[1112,1102],[1114,865,866,1024,1023,1115],{"trials":1400,"activeCount":103},[1401],{"nctId":1402,"briefTitle":1403,"status":156,"phases":1404,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1411},"NCT00194987","A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia",[92,93],"2015-06-30","2001-04",102,[1409,1410],"Alloimmune Thrombocytopenia","Fetal Alloimmune Thrombocytopenia",[1412,1070],"IVIG",{"trials":1414,"activeCount":103},[],{"trials":1416,"activeCount":103},[],{"intervention":902,"totalTrials":811,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1445,"PHASE4":1451,"NA":1453},{"trials":1420,"activeCount":103},[],{"trials":1422,"activeCount":103},[],{"trials":1424,"activeCount":99,"soonestReadout":42},[1425,1429,1433,1437,1441],{"nctId":890,"briefTitle":891,"status":786,"phases":1426,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":1427,"interventions":1428},[92],[898,899,900],[840,902,903,504],{"nctId":80,"briefTitle":81,"status":241,"phases":1430,"primaryCompletion":82,"completion":906,"start":907,"enrollment":37,"conditions":1431,"interventions":1432},[92],[30,900,909],[83,902,903,504],{"nctId":922,"briefTitle":923,"status":156,"phases":1434,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":1435,"interventions":1436},[92],[30],[885,930,903],{"nctId":941,"briefTitle":942,"status":156,"phases":1438,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":1439,"interventions":1440},[92],[30],[950,58,930,885],{"nctId":40,"briefTitle":41,"status":241,"phases":1442,"primaryCompletion":42,"completion":961,"start":962,"enrollment":963,"conditions":1443,"interventions":1444},[92],[30],[43,504,902,852,504,852],{"trials":1446,"activeCount":103},[1447],{"nctId":969,"briefTitle":970,"status":786,"phases":1448,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":1449,"interventions":1450},[93],[30],[902,852,504],{"trials":1452,"activeCount":103},[],{"trials":1454,"activeCount":103},[],{"intervention":903,"totalTrials":178,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1458,"activeCount":103},[],{"trials":1460,"activeCount":103},[],{"trials":1462,"activeCount":99,"soonestReadout":82},[1463,1467,1471,1475,1479],{"nctId":890,"briefTitle":891,"status":786,"phases":1464,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":1465,"interventions":1466},[92],[898,899,900],[840,902,903,504],{"nctId":80,"briefTitle":81,"status":241,"phases":1468,"primaryCompletion":82,"completion":906,"start":907,"enrollment":37,"conditions":1469,"interventions":1470},[92],[30,900,909],[83,902,903,504],{"nctId":912,"briefTitle":913,"status":786,"phases":1472,"primaryCompletion":915,"completion":915,"start":916,"enrollment":896,"conditions":1473,"interventions":1474},[91,92],[30],[919,920,504],{"nctId":922,"briefTitle":923,"status":156,"phases":1476,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":1477,"interventions":1478},[92],[30],[885,930,903],{"nctId":932,"briefTitle":933,"status":241,"phases":1480,"primaryCompletion":553,"completion":935,"start":936,"enrollment":28,"conditions":1481,"interventions":1482},[92],[836,838,938],[83,903,504],{"trials":1484,"activeCount":103},[],{"trials":1486,"activeCount":103},[],{"trials":1488,"activeCount":103},[],{"intervention":73,"totalTrials":178,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1499,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1492,"activeCount":103},[],{"trials":1494,"activeCount":103},[1495],{"nctId":1243,"briefTitle":1244,"status":156,"phases":1496,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":31,"conditions":1497,"interventions":1498},[91],[1250,1251,1252,1253],[1255,73,1090,1256,1257],{"trials":1500,"activeCount":99,"soonestReadout":67},[1501,1505,1509,1513],{"nctId":1295,"briefTitle":1296,"status":786,"phases":1502,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":99,"conditions":1503,"interventions":1504},[92],[1301,1196,1302,1125,1126],[73,1090,1304],{"nctId":70,"briefTitle":71,"status":241,"phases":1506,"primaryCompletion":72,"completion":775,"start":1085,"enrollment":1086,"conditions":1507,"interventions":1508},[92],[1088],[73,1090,1091,865,1092,1093],{"nctId":65,"briefTitle":66,"status":241,"phases":1510,"primaryCompletion":67,"completion":1311,"start":1312,"enrollment":1313,"conditions":1511,"interventions":1512},[92],[1315,1316],[68,73,1090,1318],{"nctId":1328,"briefTitle":1329,"status":156,"phases":1514,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":218,"conditions":1515,"interventions":1516},[92],[1335,1250],[1337,73,1090,1131],{"trials":1518,"activeCount":103},[],{"trials":1520,"activeCount":103},[],{"trials":1522,"activeCount":103},[],{"intervention":803,"totalTrials":896,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1535,"PHASE2":1555,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1526,"activeCount":103},[1527],{"nctId":1528,"briefTitle":1529,"status":156,"phases":1530,"primaryCompletion":1531,"completion":82,"start":1532,"enrollment":811,"conditions":1533,"interventions":1534},"NCT04576871","Re-treatment 225Ac-J591 for mCRPC",[90],"2023-08-31","2020-10-29",[18],[803],{"trials":1536,"activeCount":184,"soonestReadout":625},[1537,1545],{"nctId":1538,"briefTitle":1539,"status":241,"phases":1540,"primaryCompletion":625,"completion":691,"start":1381,"enrollment":22,"conditions":1541,"interventions":1542},"NCT04886986","Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer",[91],[18],[803,53,1543,1544],"68Ga-PSMA-11","177Lu-PSMA-I&T",{"nctId":1546,"briefTitle":1547,"status":156,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":1553,"interventions":1554},"NCT03276572","Phase I Trial of 225Ac-J591 in Patients With mCRPC",[91],"2021-01-07","2023-09-01","2017-10-10",32,[18],[803],{"trials":1556,"activeCount":184,"soonestReadout":798},[1557],{"nctId":795,"briefTitle":796,"status":214,"phases":1558,"primaryCompletion":798,"completion":691,"start":799,"enrollment":800,"conditions":1559,"interventions":1560},[91,92],[18],[803,48,804],{"trials":1562,"activeCount":103},[],{"trials":1564,"activeCount":103},[],{"trials":1566,"activeCount":103},[],{"intervention":53,"totalTrials":141,"cells":1568},{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1577,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1570,"activeCount":103},[],{"trials":1572,"activeCount":184,"soonestReadout":625},[1573],{"nctId":1538,"briefTitle":1539,"status":241,"phases":1574,"primaryCompletion":625,"completion":691,"start":1381,"enrollment":22,"conditions":1575,"interventions":1576},[91],[18],[803,53,1543,1544],{"trials":1578,"activeCount":184,"soonestReadout":52},[1579,1587],{"nctId":50,"briefTitle":51,"status":241,"phases":1580,"primaryCompletion":52,"completion":1581,"start":1582,"enrollment":1583,"conditions":1584,"interventions":1585},[91,92],"2026-08","2016-12",50,[18],[53,1586],"68Ga-PSMA-HBED-CC",{"nctId":1588,"briefTitle":1589,"status":786,"phases":1590,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":811,"conditions":1593,"interventions":1594},"NCT03545165","177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC",[91,92],"2020-07-15","2018-04-18",[18],[53,63,1586],{"trials":1596,"activeCount":103},[],{"trials":1598,"activeCount":103},[],{"trials":1600,"activeCount":103},[],{"intervention":737,"totalTrials":141,"cells":1602},{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1611,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1604,"activeCount":103},[],{"trials":1606,"activeCount":103},[1607],{"nctId":729,"briefTitle":730,"status":494,"phases":1608,"primaryCompletion":373,"completion":626,"start":732,"enrollment":103,"conditions":1609,"interventions":1610},[91],[734],[736,48,737],{"trials":1612,"activeCount":99,"soonestReadout":77},[1613,1624],{"nctId":1614,"briefTitle":1615,"status":241,"phases":1616,"primaryCompletion":1617,"completion":625,"start":1618,"enrollment":1583,"conditions":1619,"interventions":1621},"NCT05650723","Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab",[92],"2027-03","2023-05-08",[1620],"Leukemia, Lymphocytic, Chronic, B-Cell",[1622,1623,737],"Zanubrutinib Pill","Venetoclax Pill",{"nctId":75,"briefTitle":76,"status":241,"phases":1625,"primaryCompletion":77,"completion":1154,"start":1155,"enrollment":1156,"conditions":1626,"interventions":1627},[92],[1036],[78,852,865,737],{"trials":1629,"activeCount":103},[],{"trials":1631,"activeCount":103},[],{"trials":1633,"activeCount":103},[],{"intervention":83,"totalTrials":99,"cells":1635},{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1637,"activeCount":103},[],{"trials":1639,"activeCount":103},[],{"trials":1641,"activeCount":99,"soonestReadout":82},[1642,1646],{"nctId":80,"briefTitle":81,"status":241,"phases":1643,"primaryCompletion":82,"completion":906,"start":907,"enrollment":37,"conditions":1644,"interventions":1645},[92],[30,900,909],[83,902,903,504],{"nctId":932,"briefTitle":933,"status":241,"phases":1647,"primaryCompletion":553,"completion":935,"start":936,"enrollment":28,"conditions":1648,"interventions":1649},[92],[836,838,938],[83,903,504],{"trials":1651,"activeCount":103},[],{"trials":1653,"activeCount":103},[],{"trials":1655,"activeCount":103},[],{"intervention":1091,"totalTrials":99,"cells":1657},{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1672,"PHASE4":1674,"NA":1676},{"trials":1659,"activeCount":103},[],{"trials":1661,"activeCount":103},[],{"trials":1663,"activeCount":99,"soonestReadout":67},[1664,1668],{"nctId":70,"briefTitle":71,"status":241,"phases":1665,"primaryCompletion":72,"completion":775,"start":1085,"enrollment":1086,"conditions":1666,"interventions":1667},[92],[1088],[73,1090,1091,865,1092,1093],{"nctId":65,"briefTitle":66,"status":241,"phases":1669,"primaryCompletion":67,"completion":1311,"start":1312,"enrollment":1313,"conditions":1670,"interventions":1671},[92],[1315,1316],[68,73,1090,1318],{"trials":1673,"activeCount":103},[],{"trials":1675,"activeCount":103},[],{"trials":1677,"activeCount":103},[],{"intervention":1679,"totalTrials":99,"cells":1680},"Tazemetostat Pill",{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1695,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1682,"activeCount":103},[],{"trials":1684,"activeCount":184,"soonestReadout":1108},[1685],{"nctId":1686,"briefTitle":1687,"status":214,"phases":1688,"primaryCompletion":1108,"completion":1689,"start":1690,"enrollment":28,"conditions":1691,"interventions":1694},"NCT05934838","A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas",[91],"2031-09","2023-10-04",[1692,1693,1036,1065],"Follicular Lymphoma","B-Cell Lymphoma",[1679],{"trials":1696,"activeCount":184,"soonestReadout":1701},[1697],{"nctId":1698,"briefTitle":1699,"status":241,"phases":1700,"primaryCompletion":1701,"completion":1701,"start":1702,"enrollment":1703,"conditions":1704,"interventions":1705},"NCT05994235","Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma",[92],"2033-10","2023-11-01",23,[1692],[1706,1679],"Mosunetuzumab",{"trials":1708,"activeCount":103},[],{"trials":1710,"activeCount":103},[],{"trials":1712,"activeCount":103},[],{"intervention":1714,"totalTrials":99,"cells":1715},"Botensilimab",{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1717,"activeCount":103},[],{"trials":1719,"activeCount":103},[],{"trials":1721,"activeCount":99,"soonestReadout":1726},[1722,1732],{"nctId":1723,"briefTitle":1724,"status":241,"phases":1725,"primaryCompletion":1726,"completion":117,"start":1727,"enrollment":947,"conditions":1728,"interventions":1730},"NCT05571293","Combination Immunotherapy in Colorectal Cancer",[92],"2024-11-14","2023-03-17",[1729],"Colorectal Neoplasms",[1714,1731],"Balstilimab",{"nctId":1733,"briefTitle":1734,"status":214,"phases":1735,"primaryCompletion":1213,"completion":625,"start":1736,"enrollment":1737,"conditions":1738,"interventions":1742},"NCT06300463","Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases",[92],"2024-03-26",24,[1739,1740,1741],"Colorectal Cancer Metastatic","Liver Metastases","Colorectal Cancer",[1714,1731,1743],"AGEN1423",{"trials":1745,"activeCount":103},[],{"trials":1747,"activeCount":103},[],{"trials":1749,"activeCount":103},[],{"intervention":1731,"totalTrials":99,"cells":1751},{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1753,"activeCount":103},[],{"trials":1755,"activeCount":103},[],{"trials":1757,"activeCount":99,"soonestReadout":1726},[1758,1762],{"nctId":1723,"briefTitle":1724,"status":241,"phases":1759,"primaryCompletion":1726,"completion":117,"start":1727,"enrollment":947,"conditions":1760,"interventions":1761},[92],[1729],[1714,1731],{"nctId":1733,"briefTitle":1734,"status":214,"phases":1763,"primaryCompletion":1213,"completion":625,"start":1736,"enrollment":1737,"conditions":1764,"interventions":1765},[92],[1739,1740,1741],[1714,1731,1743],{"trials":1767,"activeCount":103},[],{"trials":1769,"activeCount":103},[],{"trials":1771,"activeCount":103},[],{"intervention":1093,"totalTrials":141,"cells":1773},{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1784,"PHASE4":1786,"NA":1808},{"trials":1775,"activeCount":103},[],{"trials":1777,"activeCount":103},[],{"trials":1779,"activeCount":184,"soonestReadout":72},[1780],{"nctId":70,"briefTitle":71,"status":241,"phases":1781,"primaryCompletion":72,"completion":775,"start":1085,"enrollment":1086,"conditions":1782,"interventions":1783},[92],[1088],[73,1090,1091,865,1092,1093],{"trials":1785,"activeCount":103},[],{"trials":1787,"activeCount":103},[1788,1798],{"nctId":1789,"briefTitle":1790,"status":156,"phases":1791,"primaryCompletion":1138,"completion":1138,"start":1792,"enrollment":178,"conditions":1793,"interventions":1795},"NCT00629122","Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation",[94],"2008-02",[1794],"Kidney Failure, Chronic",[1093,1796,1093,1797],"Clotrimazole Troche","Nystatin Suspension",{"nctId":1799,"briefTitle":1800,"status":786,"phases":1801,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1123,"conditions":1805,"interventions":1807},"NCT00731874","Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status",[94],"2013-06","2013-07","2008-08",[1806],"Immunosuppression",[1093],{"trials":1809,"activeCount":103},[],{"intervention":1067,"totalTrials":896,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1820,"PHASE3":1830,"PHASE4":1843,"NA":1845},{"trials":1813,"activeCount":103},[],{"trials":1815,"activeCount":103},[1816],{"nctId":1012,"briefTitle":1013,"status":156,"phases":1817,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1818,"interventions":1819},[91],[862,1019],[1021,865,866,1022,1023,1024,1025],{"trials":1821,"activeCount":184,"soonestReadout":1108},[1822,1826],{"nctId":1059,"briefTitle":1060,"status":156,"phases":1823,"primaryCompletion":1062,"completion":974,"start":1063,"enrollment":31,"conditions":1824,"interventions":1825},[91,92],[1065],[1038,1067,1068,1069,1070,1071],{"nctId":1105,"briefTitle":1106,"status":214,"phases":1827,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":22,"conditions":1828,"interventions":1829},[92],[1112,1102],[1114,865,866,1024,1023,1115],{"trials":1831,"activeCount":103},[1832],{"nctId":1833,"briefTitle":1834,"status":156,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":16,"conditions":1838,"interventions":1839},"NCT01146834","Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma",[93],"2019-02-04","2011-03",[30],[1840,1067,1841,1842],"bortezomib","G-CSF","Plerixafor",{"trials":1844,"activeCount":103},[],{"trials":1846,"activeCount":103},[],{"intervention":986,"totalTrials":99,"cells":1848},{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1859,"PHASE4":1865,"NA":1867},{"trials":1850,"activeCount":103},[],{"trials":1852,"activeCount":103},[],{"trials":1854,"activeCount":184,"soonestReadout":72},[1855],{"nctId":70,"briefTitle":71,"status":241,"phases":1856,"primaryCompletion":72,"completion":775,"start":1085,"enrollment":1086,"conditions":1857,"interventions":1858},[92],[1088],[73,1090,1091,865,1092,1093],{"trials":1860,"activeCount":103},[1861],{"nctId":979,"briefTitle":980,"status":494,"phases":1862,"primaryCompletion":982,"start":982,"enrollment":103,"conditions":1863,"interventions":1864},[93],[984],[865,504,986],{"trials":1866,"activeCount":103},[],{"trials":1868,"activeCount":103},[],{"intervention":759,"totalTrials":811,"cells":1870},{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1883,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1872,"activeCount":103},[],{"trials":1874,"activeCount":103},[1875,1879],{"nctId":854,"briefTitle":855,"status":156,"phases":1876,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":1877,"interventions":1878},[91],[862],[864,865,866,759,867,504],{"nctId":1271,"briefTitle":1272,"status":786,"phases":1880,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":184,"conditions":1881,"interventions":1882},[91],[1278,1279],[1090,759,1281],{"trials":1884,"activeCount":184,"soonestReadout":47},[1885,1896,1903,1907],{"nctId":1886,"briefTitle":1887,"status":786,"phases":1888,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":811,"conditions":1891,"interventions":1893},"NCT04951115","A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer",[92],"2024-01-17","2021-07-12",[1892],"Small-cell Lung Cancer",[759,1894,866,1895],"Cisplatin","Durvalumab",{"nctId":1897,"briefTitle":1898,"status":786,"phases":1899,"primaryCompletion":1053,"completion":916,"start":1837,"enrollment":141,"conditions":1900,"interventions":1901},"NCT01558492","Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer",[92],[18],[759,1902],"Paclitaxel",{"nctId":45,"briefTitle":46,"status":241,"phases":1904,"primaryCompletion":47,"completion":752,"start":753,"enrollment":754,"conditions":1905,"interventions":1906},[92],[756],[48,758,759],{"nctId":1908,"briefTitle":1909,"status":156,"phases":1910,"primaryCompletion":1911,"start":1912,"enrollment":1913,"conditions":1914,"interventions":1916},"NCT00066716","Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus",[92],"2007-05","2003-06",39,[1915],"Esophageal Cancer",[1917,1918,1919],"carboplatin","celecoxib","paclitaxel",{"trials":1921,"activeCount":103},[],{"trials":1923,"activeCount":103},[],{"trials":1925,"activeCount":103},[],{"intervention":866,"totalTrials":178,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1940,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1929,"activeCount":103},[],{"trials":1931,"activeCount":103},[1932,1936],{"nctId":854,"briefTitle":855,"status":156,"phases":1933,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":1934,"interventions":1935},[91],[862],[864,865,866,759,867,504],{"nctId":1012,"briefTitle":1013,"status":156,"phases":1937,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1938,"interventions":1939},[91],[862,1019],[1021,865,866,1022,1023,1024,1025],{"trials":1941,"activeCount":184,"soonestReadout":1108},[1942,1946,1950],{"nctId":1886,"briefTitle":1887,"status":786,"phases":1943,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":811,"conditions":1944,"interventions":1945},[92],[1892],[759,1894,866,1895],{"nctId":1105,"briefTitle":1106,"status":214,"phases":1947,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":22,"conditions":1948,"interventions":1949},[92],[1112,1102],[1114,865,866,1024,1023,1115],{"nctId":1117,"briefTitle":1118,"status":156,"phases":1951,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1952,"interventions":1953},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"trials":1955,"activeCount":103},[],{"trials":1957,"activeCount":103},[],{"trials":1959,"activeCount":103},[],{"intervention":63,"totalTrials":896,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1985,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1963,"activeCount":103},[],{"trials":1965,"activeCount":103},[1966,1981],{"nctId":1967,"briefTitle":1968,"status":156,"phases":1969,"primaryCompletion":1970,"completion":1971,"start":1972,"enrollment":22,"conditions":1973,"interventions":1980},"NCT00967577","177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors",[91],"2018-06","2021-12-31","2009-07",[1974,1975,21,1976,1741,1977,1978,1915,1979],"Kidney Cancer","Head and Neck Cancer","Non-small Cell Lung Cancer","Pancreatic Cancer","Ovarian Cancer","Gliomas",[63],{"nctId":1369,"briefTitle":1370,"status":156,"phases":1982,"primaryCompletion":1372,"completion":1263,"start":1373,"enrollment":28,"conditions":1983,"interventions":1984},[91],[18],[1376,1024,63,63,63,63,63],{"trials":1986,"activeCount":184,"soonestReadout":62},[1987,1991],{"nctId":1588,"briefTitle":1589,"status":786,"phases":1988,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":811,"conditions":1989,"interventions":1990},[91,92],[18],[53,63,1586],{"nctId":60,"briefTitle":61,"status":241,"phases":1992,"primaryCompletion":62,"completion":1108,"start":1993,"enrollment":1994,"conditions":1995,"interventions":1996},[92],"2009-06",55,[18],[63,1997,1998,1999],"Ketoconazole","Hydrocortisone","111In-J591",{"trials":2001,"activeCount":103},[],{"trials":2003,"activeCount":103},[],{"trials":2005,"activeCount":103},[],{"intervention":1586,"totalTrials":141,"cells":2007},{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":2009,"activeCount":103},[],{"trials":2011,"activeCount":103},[],{"trials":2013,"activeCount":184,"soonestReadout":52},[2014,2018,2022],{"nctId":50,"briefTitle":51,"status":241,"phases":2015,"primaryCompletion":52,"completion":1581,"start":1582,"enrollment":1583,"conditions":2016,"interventions":2017},[91,92],[18],[53,1586],{"nctId":1588,"briefTitle":1589,"status":786,"phases":2019,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":811,"conditions":2020,"interventions":2021},[91,92],[18],[53,63,1586],{"nctId":2023,"briefTitle":2024,"status":156,"phases":2025,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":22,"conditions":2028,"interventions":2029},"NCT03675451","PSMA Imaging of Localized Prostate Cancer",[92],"2018-06-27","2017-02-08",[18],[2030,1586],"89ZR-DF-IAB2M",{"trials":2032,"activeCount":103},[],{"trials":2034,"activeCount":103},[],{"trials":2036,"activeCount":103},[],{"intervention":78,"totalTrials":99,"cells":2038},{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2043,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2040,"activeCount":103},[],{"trials":2042,"activeCount":103},[],{"trials":2044,"activeCount":184,"soonestReadout":77},[2045,2054],{"nctId":2046,"briefTitle":2047,"status":494,"phases":2048,"primaryCompletion":2049,"completion":243,"start":2050,"enrollment":103,"conditions":2051,"interventions":2053},"NCT04660045","Early Intervention With Acalabrutinib in Patients With High Risk CLL",[92],"2026-01","2022-05",[1102,2052],"CLL\u002FSLL",[78],{"nctId":75,"briefTitle":76,"status":241,"phases":2055,"primaryCompletion":77,"completion":1154,"start":1155,"enrollment":1156,"conditions":2056,"interventions":2057},[92],[1036],[78,852,865,737],{"trials":2059,"activeCount":103},[],{"trials":2061,"activeCount":103},[],{"trials":2063,"activeCount":103},[],{"intervention":782,"totalTrials":99,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2067,"activeCount":103},[],{"trials":2069,"activeCount":103},[],{"trials":2071,"activeCount":184,"soonestReadout":775},[2072,2076],{"nctId":772,"briefTitle":773,"status":214,"phases":2073,"primaryCompletion":775,"completion":776,"start":77,"enrollment":777,"conditions":2074,"interventions":2075},[92],[756,779,780],[782,48],{"nctId":784,"briefTitle":785,"status":786,"phases":2077,"primaryCompletion":788,"completion":789,"start":790,"enrollment":184,"conditions":2078,"interventions":2079},[92],[792],[782,48],{"trials":2081,"activeCount":103},[],{"trials":2083,"activeCount":103},[],{"trials":2085,"activeCount":103},[],{"intervention":2087,"totalTrials":99,"cells":2088},"Letrozole 2.5Mg Tab",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2090,"activeCount":103},[],{"trials":2092,"activeCount":103},[],{"trials":2094,"activeCount":184,"soonestReadout":2107},[2095,2103],{"nctId":2096,"briefTitle":2097,"status":494,"phases":2098,"primaryCompletion":305,"completion":216,"start":2099,"enrollment":103,"conditions":2100,"interventions":2101},"NCT04220476","CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer",[92],"2020-03-04",[21],[2087,2102],"Palbociclib 125mg",{"nctId":2104,"briefTitle":2105,"status":214,"phases":2106,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":1407,"conditions":2110,"interventions":2111},"NCT04563507","Combined Immunotherapies in Metastatic ER+ Breast Cancer",[92],"2027-10-31","2028-10-31","2020-11-12",[21],[2087,2102],{"trials":2113,"activeCount":103},[],{"trials":2115,"activeCount":103},[],{"trials":2117,"activeCount":103},[],{"intervention":2102,"totalTrials":99,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2134,"PHASE4":2136,"NA":2138},{"trials":2121,"activeCount":103},[],{"trials":2123,"activeCount":103},[],{"trials":2125,"activeCount":184,"soonestReadout":2107},[2126,2130],{"nctId":2096,"briefTitle":2097,"status":494,"phases":2127,"primaryCompletion":305,"completion":216,"start":2099,"enrollment":103,"conditions":2128,"interventions":2129},[92],[21],[2087,2102],{"nctId":2104,"briefTitle":2105,"status":214,"phases":2131,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":1407,"conditions":2132,"interventions":2133},[92],[21],[2087,2102],{"trials":2135,"activeCount":103},[],{"trials":2137,"activeCount":103},[],{"trials":2139,"activeCount":103},[],{"intervention":2141,"totalTrials":184,"cells":2142},"Gocovri",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2144,"activeCount":103},[],{"trials":2146,"activeCount":103},[],{"trials":2148,"activeCount":184,"soonestReadout":2153},[2149],{"nctId":2150,"briefTitle":2151,"status":473,"phases":2152,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":1737,"conditions":2155,"interventions":2157},"NCT07125222","Use of Gocovri to Improve Disability Due to Radiation Encephalopathy",[92],"2028-08","2025-09",[2156],"Radiation Encephalopathy",[2141],{"trials":2159,"activeCount":103},[],{"trials":2161,"activeCount":103},[],{"trials":2163,"activeCount":103},[],{"intervention":2165,"totalTrials":184,"cells":2166},"Etrumadenant",{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2168,"activeCount":103},[],{"trials":2170,"activeCount":103},[],{"trials":2172,"activeCount":184,"soonestReadout":1213},[2173],{"nctId":2174,"briefTitle":2175,"status":214,"phases":2176,"primaryCompletion":1213,"completion":2177,"start":2178,"enrollment":2179,"conditions":2180,"interventions":2182},"NCT05024097","A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.",[92],"2030-12","2022-03-31",43,[2181],"Rectal Cancer",[2165,2183,2184],"FOLFOX regimen","Zimberelimab",{"trials":2186,"activeCount":103},[],{"trials":2188,"activeCount":103},[],{"trials":2190,"activeCount":103},[],{"intervention":2183,"totalTrials":184,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":103},[],{"trials":2196,"activeCount":103},[],{"trials":2198,"activeCount":184,"soonestReadout":1213},[2199],{"nctId":2174,"briefTitle":2175,"status":214,"phases":2200,"primaryCompletion":1213,"completion":2177,"start":2178,"enrollment":2179,"conditions":2201,"interventions":2202},[92],[2181],[2165,2183,2184],{"trials":2204,"activeCount":103},[],{"trials":2206,"activeCount":103},[],{"trials":2208,"activeCount":103},[],{"intervention":2184,"totalTrials":184,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":103},[],{"trials":2214,"activeCount":103},[],{"trials":2216,"activeCount":184,"soonestReadout":1213},[2217],{"nctId":2174,"briefTitle":2175,"status":214,"phases":2218,"primaryCompletion":1213,"completion":2177,"start":2178,"enrollment":2179,"conditions":2219,"interventions":2220},[92],[2181],[2165,2183,2184],{"trials":2222,"activeCount":103},[],{"trials":2224,"activeCount":103},[],{"trials":2226,"activeCount":103},[],{"intervention":2228,"totalTrials":184,"cells":2229},"Nivolumab 240 MG",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2231,"activeCount":103},[],{"trials":2233,"activeCount":103},[],{"trials":2235,"activeCount":184,"soonestReadout":2240},[2236],{"nctId":2237,"briefTitle":2238,"status":241,"phases":2239,"primaryCompletion":2240,"completion":243,"start":2241,"enrollment":2242,"conditions":2243,"interventions":2245},"NCT04021108","Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)",[92],"2025-06-11","2019-07-22",80,[2244],"Gastroesophageal Adenocarcinoma",[2228],{"trials":2247,"activeCount":103},[],{"trials":2249,"activeCount":103},[],{"trials":2251,"activeCount":103},[],{"intervention":2253,"totalTrials":184,"cells":2254},"Cemiplimab",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2272,"PHASE4":2274,"NA":2276},{"trials":2256,"activeCount":103},[],{"trials":2258,"activeCount":103},[],{"trials":2260,"activeCount":184,"soonestReadout":1213},[2261],{"nctId":2262,"briefTitle":2263,"status":214,"phases":2264,"primaryCompletion":1213,"completion":2265,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2270},"NCT06623656","Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC",[92],"2032-01","2025-02-21",112,[2269],"Carcinoma, Non-Small-Cell Lung",[2253,2271],"Platinum based chemotherapy",{"trials":2273,"activeCount":103},[],{"trials":2275,"activeCount":103},[],{"trials":2277,"activeCount":103},[],{"intervention":2271,"totalTrials":184,"cells":2279},{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2281,"activeCount":103},[],{"trials":2283,"activeCount":103},[],{"trials":2285,"activeCount":184,"soonestReadout":1213},[2286],{"nctId":2262,"briefTitle":2263,"status":214,"phases":2287,"primaryCompletion":1213,"completion":2265,"start":2266,"enrollment":2267,"conditions":2288,"interventions":2289},[92],[2269],[2253,2271],{"trials":2291,"activeCount":103},[],{"trials":2293,"activeCount":103},[],{"trials":2295,"activeCount":103},[],{"intervention":2297,"totalTrials":184,"cells":2298},"Leronlimab",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2315,"PHASE4":2317,"NA":2319},{"trials":2300,"activeCount":103},[],{"trials":2302,"activeCount":103},[],{"trials":2304,"activeCount":184,"soonestReadout":2309},[2305],{"nctId":2306,"briefTitle":2307,"status":214,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":22,"conditions":2311,"interventions":2314},"NCT07553338","Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease",[92],"2027-11","2026-04-30",[2312,2313],"Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease","Alzheimer's Disease",[2297],{"trials":2316,"activeCount":103},[],{"trials":2318,"activeCount":103},[],{"trials":2320,"activeCount":103},[],{"intervention":749,"totalTrials":184,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2324,"activeCount":103},[],{"trials":2326,"activeCount":103},[],{"trials":2328,"activeCount":184,"soonestReadout":690},[2329],{"nctId":741,"briefTitle":742,"status":214,"phases":2330,"primaryCompletion":690,"completion":690,"start":744,"enrollment":745,"conditions":2331,"interventions":2332},[92],[747],[48,749],{"trials":2334,"activeCount":103},[],{"trials":2336,"activeCount":103},[],{"trials":2338,"activeCount":103},[],{"intervention":1622,"totalTrials":184,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2342,"activeCount":103},[],{"trials":2344,"activeCount":103},[],{"trials":2346,"activeCount":184,"soonestReadout":1617},[2347],{"nctId":1614,"briefTitle":1615,"status":241,"phases":2348,"primaryCompletion":1617,"completion":625,"start":1618,"enrollment":1583,"conditions":2349,"interventions":2350},[92],[1620],[1622,1623,737],{"trials":2352,"activeCount":103},[],{"trials":2354,"activeCount":103},[],{"trials":2356,"activeCount":103},[],{"intervention":1623,"totalTrials":184,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":103},[],{"trials":2362,"activeCount":103},[],{"trials":2364,"activeCount":184,"soonestReadout":1617},[2365],{"nctId":1614,"briefTitle":1615,"status":241,"phases":2366,"primaryCompletion":1617,"completion":625,"start":1618,"enrollment":1583,"conditions":2367,"interventions":2368},[92],[1620],[1622,1623,737],{"trials":2370,"activeCount":103},[],{"trials":2372,"activeCount":103},[],{"trials":2374,"activeCount":103},[],{"intervention":2376,"totalTrials":184,"cells":2377},"NAC 900mg\u002Fday",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2379,"activeCount":103},[],{"trials":2381,"activeCount":103},[],{"trials":2383,"activeCount":184,"soonestReadout":2310},[2384],{"nctId":2385,"briefTitle":2386,"status":214,"phases":2387,"primaryCompletion":2310,"completion":2310,"start":2388,"enrollment":2389,"conditions":2390,"interventions":2393},"NCT04542161","Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome",[92],"2020-09-01",95,[2391,2392],"Chronic Fatigue Syndrome","Myalgic Encephalomyelitis",[2376,2394,2395],"NAC 3600mg\u002Fday","NAC 0mg\u002Fday",{"trials":2397,"activeCount":103},[],{"trials":2399,"activeCount":103},[],{"trials":2401,"activeCount":103},[],{"intervention":2394,"totalTrials":184,"cells":2403},{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2414,"PHASE4":2416,"NA":2418},{"trials":2405,"activeCount":103},[],{"trials":2407,"activeCount":103},[],{"trials":2409,"activeCount":184,"soonestReadout":2310},[2410],{"nctId":2385,"briefTitle":2386,"status":214,"phases":2411,"primaryCompletion":2310,"completion":2310,"start":2388,"enrollment":2389,"conditions":2412,"interventions":2413},[92],[2391,2392],[2376,2394,2395],{"trials":2415,"activeCount":103},[],{"trials":2417,"activeCount":103},[],{"trials":2419,"activeCount":103},[],{"intervention":2395,"totalTrials":184,"cells":2421},{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2432,"PHASE4":2434,"NA":2436},{"trials":2423,"activeCount":103},[],{"trials":2425,"activeCount":103},[],{"trials":2427,"activeCount":184,"soonestReadout":2310},[2428],{"nctId":2385,"briefTitle":2386,"status":214,"phases":2429,"primaryCompletion":2310,"completion":2310,"start":2388,"enrollment":2389,"conditions":2430,"interventions":2431},[92],[2391,2392],[2376,2394,2395],{"trials":2433,"activeCount":103},[],{"trials":2435,"activeCount":103},[],{"trials":2437,"activeCount":103},[],{"intervention":758,"totalTrials":184,"cells":2439},{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2450,"PHASE4":2452,"NA":2454},{"trials":2441,"activeCount":103},[],{"trials":2443,"activeCount":103},[],{"trials":2445,"activeCount":184,"soonestReadout":47},[2446],{"nctId":45,"briefTitle":46,"status":241,"phases":2447,"primaryCompletion":47,"completion":752,"start":753,"enrollment":754,"conditions":2448,"interventions":2449},[92],[756],[48,758,759],{"trials":2451,"activeCount":103},[],{"trials":2453,"activeCount":103},[],{"trials":2455,"activeCount":103},[],{"intervention":2457,"totalTrials":184,"cells":2458},"Fractionated dose of 225Ac-J591",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2474,"PHASE4":2476,"NA":2478},{"trials":2460,"activeCount":103},[],{"trials":2462,"activeCount":103},[],{"trials":2464,"activeCount":184,"soonestReadout":2469},[2465],{"nctId":2466,"briefTitle":2467,"status":241,"phases":2468,"primaryCompletion":2469,"completion":243,"start":2470,"enrollment":375,"conditions":2471,"interventions":2472},"NCT04506567","Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC",[91,92],"2025-06-01","2020-08-18",[18],[2457,2473],"Multiple single doses of 225Ac-J591",{"trials":2475,"activeCount":103},[],{"trials":2477,"activeCount":103},[],{"trials":2479,"activeCount":103},[],{"intervention":2473,"totalTrials":184,"cells":2481},{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2486,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2483,"activeCount":103},[],{"trials":2485,"activeCount":103},[],{"trials":2487,"activeCount":184,"soonestReadout":2469},[2488],{"nctId":2466,"briefTitle":2467,"status":241,"phases":2489,"primaryCompletion":2469,"completion":243,"start":2470,"enrollment":375,"conditions":2490,"interventions":2491},[91,92],[18],[2457,2473],{"trials":2493,"activeCount":103},[],{"trials":2495,"activeCount":103},[],{"trials":2497,"activeCount":103},[],{"intervention":1997,"totalTrials":184,"cells":2499},{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2504,"PHASE3":2510,"PHASE4":2512,"NA":2514},{"trials":2501,"activeCount":103},[],{"trials":2503,"activeCount":103},[],{"trials":2505,"activeCount":184,"soonestReadout":62},[2506],{"nctId":60,"briefTitle":61,"status":241,"phases":2507,"primaryCompletion":62,"completion":1108,"start":1993,"enrollment":1994,"conditions":2508,"interventions":2509},[92],[18],[63,1997,1998,1999],{"trials":2511,"activeCount":103},[],{"trials":2513,"activeCount":103},[],{"trials":2515,"activeCount":103},[],{"intervention":1998,"totalTrials":184,"cells":2517},{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2522,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2519,"activeCount":103},[],{"trials":2521,"activeCount":103},[],{"trials":2523,"activeCount":184,"soonestReadout":62},[2524],{"nctId":60,"briefTitle":61,"status":241,"phases":2525,"primaryCompletion":62,"completion":1108,"start":1993,"enrollment":1994,"conditions":2526,"interventions":2527},[92],[18],[63,1997,1998,1999],{"trials":2529,"activeCount":103},[],{"trials":2531,"activeCount":103},[],{"trials":2533,"activeCount":103},[],{"intervention":1999,"totalTrials":184,"cells":2535},{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2540,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2537,"activeCount":103},[],{"trials":2539,"activeCount":103},[],{"trials":2541,"activeCount":184,"soonestReadout":62},[2542],{"nctId":60,"briefTitle":61,"status":241,"phases":2543,"primaryCompletion":62,"completion":1108,"start":1993,"enrollment":1994,"conditions":2544,"interventions":2545},[92],[18],[63,1997,1998,1999],{"trials":2547,"activeCount":103},[],{"trials":2549,"activeCount":103},[],{"trials":2551,"activeCount":103},[],{"intervention":2553,"totalTrials":184,"cells":2554},"Eligard 22.5Mg Suspension for",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2556,"activeCount":103},[],{"trials":2558,"activeCount":103},[],{"trials":2560,"activeCount":184,"soonestReadout":599},[2561],{"nctId":2562,"briefTitle":2563,"status":241,"phases":2564,"primaryCompletion":599,"completion":599,"start":2565,"enrollment":2566,"conditions":2567,"interventions":2570},"NCT03649724","The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's",[92],"2020-11-27",180,[2568,2569],"Alzheimer Disease","Mild Cognitive Impairment",[2553],{"trials":2572,"activeCount":103},[],{"trials":2574,"activeCount":103},[],{"trials":2576,"activeCount":103},[],{"intervention":2578,"totalTrials":184,"cells":2579},"PSMA PET\u002FMR - Gallium-68 labeled PSMA-HBED-CC",{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2581,"activeCount":103},[],{"trials":2583,"activeCount":103},[],{"trials":2585,"activeCount":184,"soonestReadout":420},[2586],{"nctId":2587,"briefTitle":2588,"status":214,"phases":2589,"primaryCompletion":420,"completion":420,"start":2590,"enrollment":1583,"conditions":2591,"interventions":2592},"NCT04402151","Study of PSMA PET\u002FMR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer",[92],"2020-06-30",[18],[2578],{"trials":2594,"activeCount":103},[],{"trials":2596,"activeCount":103},[],{"trials":2598,"activeCount":103},[],{"intervention":1706,"totalTrials":184,"cells":2600},{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2605,"PHASE3":2611,"PHASE4":2613,"NA":2615},{"trials":2602,"activeCount":103},[],{"trials":2604,"activeCount":103},[],{"trials":2606,"activeCount":184,"soonestReadout":1701},[2607],{"nctId":1698,"briefTitle":1699,"status":241,"phases":2608,"primaryCompletion":1701,"completion":1701,"start":1702,"enrollment":1703,"conditions":2609,"interventions":2610},[92],[1692],[1706,1679],{"trials":2612,"activeCount":103},[],{"trials":2614,"activeCount":103},[],{"trials":2616,"activeCount":103},[],{"intervention":68,"totalTrials":184,"cells":2618},{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2623,"PHASE3":2629,"PHASE4":2631,"NA":2633},{"trials":2620,"activeCount":103},[],{"trials":2622,"activeCount":103},[],{"trials":2624,"activeCount":184,"soonestReadout":67},[2625],{"nctId":65,"briefTitle":66,"status":241,"phases":2626,"primaryCompletion":67,"completion":1311,"start":1312,"enrollment":1313,"conditions":2627,"interventions":2628},[92],[1315,1316],[68,73,1090,1318],{"trials":2630,"activeCount":103},[],{"trials":2632,"activeCount":103},[],{"trials":2634,"activeCount":103},[],{"intervention":2636,"totalTrials":184,"cells":2637},"Pembrolizumab (200mg IV for 30 minutes",{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2642,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2639,"activeCount":103},[],{"trials":2641,"activeCount":103},[],{"trials":2643,"activeCount":184,"soonestReadout":131},[2644],{"nctId":2645,"briefTitle":2646,"status":214,"phases":2647,"primaryCompletion":131,"completion":420,"start":2648,"enrollment":307,"conditions":2649,"interventions":2650},"NCT03804944","Converting HR+ Breast Cancer Into an Individualized Vaccine",[92],"2020-03-17",[21],[2636,2651],"CDX-301",{"trials":2653,"activeCount":103},[],{"trials":2655,"activeCount":103},[],{"trials":2657,"activeCount":103},[],{"intervention":2651,"totalTrials":184,"cells":2659},{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2670,"PHASE4":2672,"NA":2674},{"trials":2661,"activeCount":103},[],{"trials":2663,"activeCount":103},[],{"trials":2665,"activeCount":184,"soonestReadout":131},[2666],{"nctId":2645,"briefTitle":2646,"status":214,"phases":2667,"primaryCompletion":131,"completion":420,"start":2648,"enrollment":307,"conditions":2668,"interventions":2669},[92],[21],[2636,2651],{"trials":2671,"activeCount":103},[],{"trials":2673,"activeCount":103},[],{"trials":2675,"activeCount":103},[],{"intervention":1114,"totalTrials":184,"cells":2677},{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2679,"activeCount":103},[],{"trials":2681,"activeCount":103},[],{"trials":2683,"activeCount":184,"soonestReadout":1108},[2684],{"nctId":1105,"briefTitle":1106,"status":214,"phases":2685,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":22,"conditions":2686,"interventions":2687},[92],[1112,1102],[1114,865,866,1024,1023,1115],{"trials":2689,"activeCount":103},[],{"trials":2691,"activeCount":103},[],{"trials":2693,"activeCount":103},[],{"intervention":1115,"totalTrials":184,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2706,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":103},[],{"trials":2699,"activeCount":103},[],{"trials":2701,"activeCount":184,"soonestReadout":1108},[2702],{"nctId":1105,"briefTitle":1106,"status":214,"phases":2703,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":22,"conditions":2704,"interventions":2705},[92],[1112,1102],[1114,865,866,1024,1023,1115],{"trials":2707,"activeCount":103},[],{"trials":2709,"activeCount":103},[],{"trials":2711,"activeCount":103},[],{"intervention":2713,"totalTrials":184,"cells":2714},"Ga-68- DOTATATE",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2729,"PHASE4":2731,"NA":2733},{"trials":2716,"activeCount":103},[],{"trials":2718,"activeCount":103},[],{"trials":2720,"activeCount":184,"soonestReadout":243},[2721],{"nctId":2722,"briefTitle":2723,"status":473,"phases":2724,"primaryCompletion":243,"completion":1311,"start":243,"enrollment":811,"conditions":2725,"interventions":2727},"NCT04298541","Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC",[92],[2726],"Meningioma",[2713,2728],"Ga-68-DOTATOC",{"trials":2730,"activeCount":103},[],{"trials":2732,"activeCount":103},[],{"trials":2734,"activeCount":103},[],{"intervention":2728,"totalTrials":184,"cells":2736},{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2747,"PHASE4":2749,"NA":2751},{"trials":2738,"activeCount":103},[],{"trials":2740,"activeCount":103},[],{"trials":2742,"activeCount":184,"soonestReadout":243},[2743],{"nctId":2722,"briefTitle":2723,"status":473,"phases":2744,"primaryCompletion":243,"completion":1311,"start":243,"enrollment":811,"conditions":2745,"interventions":2746},[92],[2726],[2713,2728],{"trials":2748,"activeCount":103},[],{"trials":2750,"activeCount":103},[],{"trials":2752,"activeCount":103},[],{"intervention":2754,"totalTrials":184,"cells":2755},"PDS0101",{"EARLY_PHASE1":2756,"PHASE1":2758,"PHASE2":2760,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2757,"activeCount":103},[],{"trials":2759,"activeCount":103},[],{"trials":2761,"activeCount":184,"soonestReadout":2766},[2762],{"nctId":2763,"briefTitle":2764,"status":473,"phases":2765,"primaryCompletion":2766,"completion":2766,"start":2767,"enrollment":777,"conditions":2768,"interventions":2774},"NCT07090174","Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV",[92],"2026-07-31","2025-10-20",[2769,2770,2771,2772,2773],"HPV Associated Cancers","HIV (Human Immunodeficiency Virus)","Anal Cancer","Cervical Cancer","HPV 16 Infection",[2754],{"trials":2776,"activeCount":103},[],{"trials":2778,"activeCount":103},[],{"trials":2780,"activeCount":103},[],{"intervention":804,"totalTrials":184,"cells":2782},{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2793,"PHASE4":2795,"NA":2797},{"trials":2784,"activeCount":103},[],{"trials":2786,"activeCount":103},[],{"trials":2788,"activeCount":184,"soonestReadout":798},[2789],{"nctId":795,"briefTitle":796,"status":214,"phases":2790,"primaryCompletion":798,"completion":691,"start":799,"enrollment":800,"conditions":2791,"interventions":2792},[91,92],[18],[803,48,804],{"trials":2794,"activeCount":103},[],{"trials":2796,"activeCount":103},[],{"trials":2798,"activeCount":103},[],{"intervention":43,"totalTrials":184,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2811,"PHASE4":2813,"NA":2815},{"trials":2802,"activeCount":103},[],{"trials":2804,"activeCount":103},[],{"trials":2806,"activeCount":184,"soonestReadout":42},[2807],{"nctId":40,"briefTitle":41,"status":241,"phases":2808,"primaryCompletion":42,"completion":961,"start":962,"enrollment":963,"conditions":2809,"interventions":2810},[92],[30],[43,504,902,852,504,852],{"trials":2812,"activeCount":103},[],{"trials":2814,"activeCount":103},[],{"trials":2816,"activeCount":103},[],{"intervention":2818,"totalTrials":184,"cells":2819},"Luspatercept",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2821,"activeCount":103},[],{"trials":2823,"activeCount":103},[],{"trials":2825,"activeCount":184,"soonestReadout":175},[2826],{"nctId":2827,"briefTitle":2828,"status":214,"phases":2829,"primaryCompletion":175,"completion":2830,"start":2831,"enrollment":1583,"conditions":2832,"interventions":2838},"NCT06788691","Luspatercept for Clonal Cytopenias of Uncertain Significance",[92],"2028-02","2025-03-25",[2833,2834,2835,2836,2837],"CCUS Clonal Cytopenia of Undetermined Significance","Anemia","Leukopenia","Thrombocytopenia","Neutropenia",[2818],{"trials":2840,"activeCount":103},[],{"trials":2842,"activeCount":103},[],{"trials":2844,"activeCount":103},[],{"intervention":1743,"totalTrials":184,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2848,"activeCount":103},[],{"trials":2850,"activeCount":103},[],{"trials":2852,"activeCount":184,"soonestReadout":1213},[2853],{"nctId":1733,"briefTitle":1734,"status":214,"phases":2854,"primaryCompletion":1213,"completion":625,"start":1736,"enrollment":1737,"conditions":2855,"interventions":2856},[92],[1739,1740,1741],[1714,1731,1743],{"trials":2858,"activeCount":103},[],{"trials":2860,"activeCount":103},[],{"trials":2862,"activeCount":103},[],{"intervention":2864,"totalTrials":141,"cells":2865},"Metformin",{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2867,"activeCount":103},[],{"trials":2869,"activeCount":103},[],{"trials":2871,"activeCount":184,"soonestReadout":243},[2872,2880],{"nctId":2873,"briefTitle":2874,"status":241,"phases":2875,"primaryCompletion":243,"completion":243,"start":2876,"enrollment":745,"conditions":2877,"interventions":2879},"NCT04691960","A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging",[92],"2016-08",[2878],"Glioblastoma",[2864],{"nctId":2881,"briefTitle":2882,"status":2883,"phases":2884,"primaryCompletion":243,"completion":243,"start":2885,"enrollment":2886,"conditions":2887,"interventions":2888},"NCT05183204","Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma","SUSPENDED",[92],"2022-02-14",33,[2878],[2889,2864],"Paxalisib",{"trials":2891,"activeCount":103},[],{"trials":2893,"activeCount":103},[],{"trials":2895,"activeCount":103},[2896],{"nctId":2897,"briefTitle":2898,"status":156,"phases":2899,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":2902,"conditions":2903,"interventions":2906},"NCT03921242","Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease",[],"2023-08-01","2019-08-01",4888,[2904,2905],"Diabetes Mellitus, Type 2","Renal Insufficiency, Chronic",[2864,2907,2908,2909,2910],"Sulfonylurea","DPP-4 inhibitor","SGLT2 inhibitor","GLP1 receptor agonist",{"intervention":2912,"totalTrials":99,"cells":2913},"Doxycycline",{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2918,"PHASE3":2930,"PHASE4":2932,"NA":2934},{"trials":2915,"activeCount":103},[],{"trials":2917,"activeCount":103},[],{"trials":2919,"activeCount":184,"soonestReadout":175},[2920],{"nctId":2921,"briefTitle":2922,"status":241,"phases":2923,"primaryCompletion":175,"completion":175,"start":2924,"enrollment":2925,"conditions":2926,"interventions":2929},"NCT05382208","Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)",[92],"2022-08-22",133,[2927,2928],"Emphysema","HIV",[2912],{"trials":2931,"activeCount":103},[],{"trials":2933,"activeCount":103},[],{"trials":2935,"activeCount":103},[2936],{"nctId":2937,"briefTitle":2938,"status":156,"phases":2939,"primaryCompletion":2940,"completion":2941,"start":2942,"enrollment":2943,"conditions":2944,"interventions":2946},"NCT01744093","Doxycycline for COPD in HIV-Infected Patients",[95],"2017-06-30","2020-12-30","2014-12-08",61,[2928,2945,2927],"Chronic Obstructive Pulmonary Disease (COPD)",[2912],{"intervention":2948,"totalTrials":184,"cells":2949},"E-CEL UVEC",{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2964,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2951,"activeCount":103},[],{"trials":2953,"activeCount":184,"soonestReadout":2958},[2954],{"nctId":2955,"briefTitle":2956,"status":214,"phases":2957,"primaryCompletion":2958,"completion":2959,"start":2960,"enrollment":1913,"conditions":2961,"interventions":2963},"NCT04190862","E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas",[91],"2026-09-30","2032-06-30","2020-01-22",[2962],"Anal Fistula",[2948],{"trials":2965,"activeCount":103},[],{"trials":2967,"activeCount":103},[],{"trials":2969,"activeCount":103},[],{"trials":2971,"activeCount":103},[],{"intervention":1363,"totalTrials":184,"cells":2973},{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2982,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2975,"activeCount":103},[],{"trials":2977,"activeCount":184,"soonestReadout":216},[2978],{"nctId":1352,"briefTitle":1353,"status":214,"phases":2979,"primaryCompletion":216,"completion":1355,"start":1356,"enrollment":532,"conditions":2980,"interventions":2981},[91],[1358,1359,1360,1361],[1363,1024],{"trials":2983,"activeCount":103},[],{"trials":2985,"activeCount":103},[],{"trials":2987,"activeCount":103},[],{"trials":2989,"activeCount":103},[],{"intervention":2991,"totalTrials":184,"cells":2992},"Propranolol Hydrochloride",{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":3006,"PHASE3":3008,"PHASE4":3010,"NA":3012},{"trials":2994,"activeCount":103},[],{"trials":2996,"activeCount":184,"soonestReadout":764},[2997],{"nctId":2998,"briefTitle":2999,"status":214,"phases":3000,"primaryCompletion":764,"completion":764,"start":3001,"enrollment":218,"conditions":3002,"interventions":3005},"NCT04713657","Beta-blocker Administration for Cardiomyocyte Division",[91],"2022-12-16",[3003,3004],"Tetralogy of Fallot","Double Outlet Right Ventricle",[2991],{"trials":3007,"activeCount":103},[],{"trials":3009,"activeCount":103},[],{"trials":3011,"activeCount":103},[],{"trials":3013,"activeCount":103},[],{"intervention":3015,"totalTrials":184,"cells":3016},"TVB-2640",{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3032,"PHASE3":3034,"PHASE4":3036,"NA":3038},{"trials":3018,"activeCount":103},[],{"trials":3020,"activeCount":184,"soonestReadout":3025},[3021],{"nctId":3022,"briefTitle":3023,"status":214,"phases":3024,"primaryCompletion":3025,"completion":3026,"start":3027,"enrollment":478,"conditions":3028,"interventions":3030},"NCT05743621","Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer",[91],"2027-01-25","2029-01-25","2023-11-20",[3029],"Prostatic Neoplasms, Castration-Resistant",[3015,3031],"Enzalutamide",{"trials":3033,"activeCount":103},[],{"trials":3035,"activeCount":103},[],{"trials":3037,"activeCount":103},[],{"trials":3039,"activeCount":103},[],{"intervention":3031,"totalTrials":184,"cells":3041},{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3050,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3043,"activeCount":103},[],{"trials":3045,"activeCount":184,"soonestReadout":3025},[3046],{"nctId":3022,"briefTitle":3023,"status":214,"phases":3047,"primaryCompletion":3025,"completion":3026,"start":3027,"enrollment":478,"conditions":3048,"interventions":3049},[91],[3029],[3015,3031],{"trials":3051,"activeCount":103},[],{"trials":3053,"activeCount":103},[],{"trials":3055,"activeCount":103},[],{"trials":3057,"activeCount":103},[],{"intervention":1543,"totalTrials":184,"cells":3059},{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3061,"activeCount":103},[],{"trials":3063,"activeCount":184,"soonestReadout":625},[3064],{"nctId":1538,"briefTitle":1539,"status":241,"phases":3065,"primaryCompletion":625,"completion":691,"start":1381,"enrollment":22,"conditions":3066,"interventions":3067},[91],[18],[803,53,1543,1544],{"trials":3069,"activeCount":103},[],{"trials":3071,"activeCount":103},[],{"trials":3073,"activeCount":103},[],{"trials":3075,"activeCount":103},[],{"intervention":1544,"totalTrials":184,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3086,"PHASE3":3088,"PHASE4":3090,"NA":3092},{"trials":3079,"activeCount":103},[],{"trials":3081,"activeCount":184,"soonestReadout":625},[3082],{"nctId":1538,"briefTitle":1539,"status":241,"phases":3083,"primaryCompletion":625,"completion":691,"start":1381,"enrollment":22,"conditions":3084,"interventions":3085},[91],[18],[803,53,1543,1544],{"trials":3087,"activeCount":103},[],{"trials":3089,"activeCount":103},[],{"trials":3091,"activeCount":103},[],{"trials":3093,"activeCount":103},[],{"intervention":3095,"totalTrials":184,"cells":3096},"AAV8hAAT",{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3111,"PHASE3":3113,"PHASE4":3115,"NA":3117},{"trials":3098,"activeCount":103},[],{"trials":3100,"activeCount":184,"soonestReadout":3105},[3101],{"nctId":3102,"briefTitle":3103,"status":214,"phases":3104,"primaryCompletion":3105,"completion":3106,"start":3107,"enrollment":825,"conditions":3108,"interventions":3110},"NCT06996756","Gene Therapy for Alpha 1- Antitrypsin Deficiency",[91],"2028-04-30","2032-08-01","2025-02-26",[3109],"Alpha 1-Antitrypsin Deficiency",[3095],{"trials":3112,"activeCount":103},[],{"trials":3114,"activeCount":103},[],{"trials":3116,"activeCount":103},[],{"trials":3118,"activeCount":103},[],{"intervention":3120,"totalTrials":184,"cells":3121},"dAd5GNE Vaccine",{"EARLY_PHASE1":3122,"PHASE1":3124,"PHASE2":3135,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3123,"activeCount":103},[],{"trials":3125,"activeCount":184,"soonestReadout":1213},[3126],{"nctId":3127,"briefTitle":3128,"status":214,"phases":3129,"primaryCompletion":1213,"completion":625,"start":3130,"enrollment":3131,"conditions":3132,"interventions":3134},"NCT02455479","Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals",[91],"2012-06-26",150,[3133],"Cocaine Dependence",[3120],{"trials":3136,"activeCount":103},[],{"trials":3138,"activeCount":103},[],{"trials":3140,"activeCount":103},[],{"trials":3142,"activeCount":103},[],{"intervention":3144,"totalTrials":184,"cells":3145},"E-CEL UVEC cells",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3158,"PHASE3":3160,"PHASE4":3162,"NA":3164},{"trials":3147,"activeCount":103},[],{"trials":3149,"activeCount":184,"soonestReadout":1213},[3150],{"nctId":3151,"briefTitle":3152,"status":214,"phases":3153,"primaryCompletion":1213,"completion":1213,"start":3154,"enrollment":22,"conditions":3155,"interventions":3157},"NCT06456073","E-CEL UVEC Treatment for Anal Fissures",[91],"2024-09-12",[3156],"Chronic Anal Fissure",[3144],{"trials":3159,"activeCount":103},[],{"trials":3161,"activeCount":103},[],{"trials":3163,"activeCount":103},[],{"trials":3165,"activeCount":103},[],{"intervention":88,"totalTrials":184,"cells":3167},{"EARLY_PHASE1":3168,"PHASE1":3176,"PHASE2":3178,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3169,"activeCount":184,"soonestReadout":87},[3170],{"nctId":85,"briefTitle":86,"status":241,"phases":3171,"primaryCompletion":87,"completion":1213,"start":3172,"enrollment":22,"conditions":3173,"interventions":3175},[90],"2019-02-05",[3174],"Bladder Cancer",[88],{"trials":3177,"activeCount":103},[],{"trials":3179,"activeCount":103},[],{"trials":3181,"activeCount":103},[],{"trials":3183,"activeCount":103},[],{"trials":3185,"activeCount":103},[],{"intervention":3187,"totalTrials":184,"cells":3188},"Glycerol Phenylbutyrate 1100 MG\u002FML [Ravicti]",{"EARLY_PHASE1":3189,"PHASE1":3201,"PHASE2":3203,"PHASE3":3205,"PHASE4":3207,"NA":3209},{"trials":3190,"activeCount":184,"soonestReadout":3195},[3191],{"nctId":3192,"briefTitle":3193,"status":241,"phases":3194,"primaryCompletion":3195,"completion":131,"start":3196,"enrollment":1583,"conditions":3197,"interventions":3200},"NCT04937062","Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy",[90],"2026-12-01","2021-03-01",[3198,3199],"STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder","Developmental and Epileptic Encephalopathy",[3187],{"trials":3202,"activeCount":103},[],{"trials":3204,"activeCount":103},[],{"trials":3206,"activeCount":103},[],{"trials":3208,"activeCount":103},[],{"trials":3210,"activeCount":103},[],{"intervention":3212,"totalTrials":184,"cells":3213},"Bupivacaine , epinephrine Dexamethasone",{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3220,"PHASE4":3222,"NA":3224},{"trials":3215,"activeCount":103},[],{"trials":3217,"activeCount":103},[],{"trials":3219,"activeCount":103},[],{"trials":3221,"activeCount":103},[],{"trials":3223,"activeCount":103},[],{"trials":3225,"activeCount":184,"soonestReadout":1617},[3226],{"nctId":3227,"briefTitle":3228,"status":214,"phases":3229,"primaryCompletion":1617,"completion":3230,"start":3231,"enrollment":3232,"conditions":3233,"interventions":3235},"NCT07073209","PENG vs Femoral Block for Hip Fracture Analgesia",[95],"2027-04","2025-07-10",352,[3234],"Hip Fractures",[3212],{"intervention":3237,"totalTrials":184,"cells":3238},"MyRisk Hereditary Cancer Test",{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3243,"PHASE3":3245,"PHASE4":3247,"NA":3249},{"trials":3240,"activeCount":103},[],{"trials":3242,"activeCount":103},[],{"trials":3244,"activeCount":103},[],{"trials":3246,"activeCount":103},[],{"trials":3248,"activeCount":103},[],{"trials":3250,"activeCount":184,"soonestReadout":1311},[3251],{"nctId":3252,"briefTitle":3253,"status":214,"phases":3254,"primaryCompletion":1311,"completion":690,"start":3255,"enrollment":3256,"conditions":3257,"interventions":3259},"NCT07052266","Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening",[95],"2025-09-02",550,[3258],"Hereditary Cancer Syndromes",[3237],{"intervention":3261,"totalTrials":184,"cells":3262},"Hormonal Therapy Agent",{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3269,"PHASE4":3271,"NA":3273},{"trials":3264,"activeCount":103},[],{"trials":3266,"activeCount":103},[],{"trials":3268,"activeCount":103},[],{"trials":3270,"activeCount":103},[],{"trials":3272,"activeCount":103},[],{"trials":3274,"activeCount":184,"soonestReadout":3279},[3275],{"nctId":3276,"briefTitle":3277,"status":473,"phases":3278,"primaryCompletion":3279,"completion":3280,"start":752,"enrollment":3281,"conditions":3282,"interventions":3284},"NCT07032506","Intrauterine Stent Placement Following Hysteroscopic Septum Resection",[95],"2029-09-30","2031-12-31",320,[3283],"Intrauterine Adhesion",[3261,3285],"Oral antibiotics",{"intervention":3285,"totalTrials":184,"cells":3287},{"EARLY_PHASE1":3288,"PHASE1":3290,"PHASE2":3292,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3289,"activeCount":103},[],{"trials":3291,"activeCount":103},[],{"trials":3293,"activeCount":103},[],{"trials":3295,"activeCount":103},[],{"trials":3297,"activeCount":103},[],{"trials":3299,"activeCount":184,"soonestReadout":3279},[3300],{"nctId":3276,"briefTitle":3277,"status":473,"phases":3301,"primaryCompletion":3279,"completion":3280,"start":752,"enrollment":3281,"conditions":3302,"interventions":3303},[95],[3283],[3261,3285],{"intervention":3305,"totalTrials":99,"cells":3306},"Botox",{"EARLY_PHASE1":3307,"PHASE1":3309,"PHASE2":3311,"PHASE3":3313,"PHASE4":3324,"NA":3336},{"trials":3308,"activeCount":103},[],{"trials":3310,"activeCount":103},[],{"trials":3312,"activeCount":103},[],{"trials":3314,"activeCount":103},[3315],{"nctId":3316,"briefTitle":3317,"status":156,"phases":3318,"primaryCompletion":3319,"completion":3320,"start":1993,"enrollment":478,"conditions":3321,"interventions":3323},"NCT01220726","Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction",[93],"2011-06","2012-11-13",[3322],"Overactive Bladder",[3305],{"trials":3325,"activeCount":103},[3326],{"nctId":3327,"briefTitle":3328,"status":786,"phases":3329,"primaryCompletion":3330,"completion":3330,"start":3331,"enrollment":896,"conditions":3332,"interventions":3335},"NCT03367429","The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination",[94],"2019-09-18","2018-06-15",[3333,3334],"Stroke","Muscle Spasticity",[3305],{"trials":3337,"activeCount":103},[],{"intervention":3339,"totalTrials":99,"cells":3340},"Recombinant Human Growth Hormone",{"EARLY_PHASE1":3341,"PHASE1":3343,"PHASE2":3345,"PHASE3":3347,"PHASE4":3349,"NA":3367},{"trials":3342,"activeCount":103},[],{"trials":3344,"activeCount":103},[],{"trials":3346,"activeCount":103},[],{"trials":3348,"activeCount":103},[],{"trials":3350,"activeCount":103},[3351,3358],{"nctId":3352,"briefTitle":3353,"status":786,"phases":3354,"completion":200,"enrollment":28,"conditions":3355,"interventions":3357},"NCT00194961","Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease",[94],[3356],"Chronic Kidney Disease",[3339],{"nctId":3359,"briefTitle":3360,"status":2883,"phases":3361,"completion":3362,"start":3363,"enrollment":1583,"conditions":3364,"interventions":3366},"NCT00194883","Effect of Cytokines on Growth of Children With Chronic Kidney Failure",[94],"2003-05","1997-04",[3365],"Chronic Renal Insufficiency",[3339],{"trials":3368,"activeCount":103},[],{"intervention":3370,"totalTrials":99,"cells":3371},"Rifaximin",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3390,"PHASE4":3392,"NA":3403},{"trials":3373,"activeCount":103},[],{"trials":3375,"activeCount":103},[],{"trials":3377,"activeCount":103},[3378],{"nctId":3379,"briefTitle":3380,"status":3381,"phases":3382,"primaryCompletion":3383,"completion":3383,"start":3384,"enrollment":1583,"conditions":3385,"interventions":3389},"NCT00281502","The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy","UNKNOWN",[92],"2012-12","2005-12",[3386,3387,3388],"Hepatic Encephalopathy","Hepatitis C","Liver Cirrhosis",[3370],{"trials":3391,"activeCount":103},[],{"trials":3393,"activeCount":103},[3394],{"nctId":3395,"briefTitle":3396,"status":494,"phases":3397,"primaryCompletion":1972,"completion":1972,"start":3398,"enrollment":103,"conditions":3399,"interventions":3401},"NCT00748904","Rifaximin Versus Lactulose in Renal Failure",[94],"2008-06",[3388,3400],"Renal Failure",[3370,3402],"Lactulose",{"trials":3404,"activeCount":103},[],{"intervention":3406,"totalTrials":99,"cells":3407},"Saline Placebo",{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3412,"PHASE3":3427,"PHASE4":3429,"NA":3441},{"trials":3409,"activeCount":103},[],{"trials":3411,"activeCount":103},[],{"trials":3413,"activeCount":103},[3414],{"nctId":3415,"briefTitle":3416,"status":156,"phases":3417,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":3420,"conditions":3421,"interventions":3425},"NCT00432991","Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section",[92],"2010-09","2007-02",53,[3422,3423,3424],"Nausea","Vomiting","Cesarean Section",[3426,3406],"Ephedrine [Synonyms: Ephedra, Ephedrinum]",{"trials":3428,"activeCount":103},[],{"trials":3430,"activeCount":103},[3431],{"nctId":3432,"briefTitle":3433,"status":156,"phases":3434,"primaryCompletion":3435,"completion":3436,"start":1802,"enrollment":825,"conditions":3437,"interventions":3439},"NCT01783236","Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery",[94],"2015-02","2015-07",[3438],"Lung Tumor",[3440,3406],"IV Acetaminophen",{"trials":3442,"activeCount":103},[],{"intervention":3444,"totalTrials":99,"cells":3445},"quetiapine",{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3460,"PHASE4":3462,"NA":3474},{"trials":3447,"activeCount":103},[],{"trials":3449,"activeCount":103},[],{"trials":3451,"activeCount":103},[3452],{"nctId":3453,"briefTitle":3454,"status":786,"phases":3455,"primaryCompletion":1582,"completion":1582,"start":3456,"enrollment":811,"conditions":3457,"interventions":3459},"NCT02056171","Efficacy of Quetiapine for Pediatric Delirium",[91,92],"2015-03",[3458],"Delirium",[3444],{"trials":3461,"activeCount":103},[],{"trials":3463,"activeCount":103},[3464],{"nctId":3465,"briefTitle":3466,"status":786,"phases":3467,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":184,"conditions":3470,"interventions":3473},"NCT01244711","Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines",[94],"2011-09","2008-09",[3471,3472],"Major Depression","Generalized Anxiety Disorder",[3444],{"trials":3475,"activeCount":103},[],{"intervention":3477,"totalTrials":99,"cells":3478},"Beclomethasone",{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3504},{"trials":3480,"activeCount":103},[],{"trials":3482,"activeCount":103},[],{"trials":3484,"activeCount":103},[],{"trials":3486,"activeCount":103},[],{"trials":3488,"activeCount":103},[3489,3496],{"nctId":3490,"briefTitle":3491,"status":494,"phases":3492,"primaryCompletion":3493,"completion":3493,"start":878,"enrollment":103,"conditions":3494,"interventions":3495},"NCT00532584","Effect of Steroids on Gene Expression in the Healthy Smokers Lungs",[94],"2011-08",[2945],[3477],{"nctId":3497,"briefTitle":3498,"status":786,"phases":3499,"primaryCompletion":3500,"completion":3500,"start":3501,"enrollment":1737,"conditions":3502,"interventions":3503},"NCT00826748","Effect of Inhaled Steroids on Gene Expression in the Lungs - 2",[94],"2014-12","2010-11",[2945],[3477],{"trials":3505,"activeCount":103},[],{"intervention":3507,"totalTrials":184,"cells":3508},"Exenatide-LAR plus Dapagliflozin placebo",{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3513,"PHASE3":3515,"PHASE4":3517,"NA":3528},{"trials":3510,"activeCount":103},[],{"trials":3512,"activeCount":103},[],{"trials":3514,"activeCount":103},[],{"trials":3516,"activeCount":103},[],{"trials":3518,"activeCount":103},[3519],{"nctId":3520,"briefTitle":3521,"status":494,"phases":3522,"primaryCompletion":1970,"completion":1263,"start":3523,"enrollment":103,"conditions":3524,"interventions":3525},"NCT02811484","Efficacy of Exenatide-LAR and Dapagliflozin in Overweight\u002FObese, Insulin Treated Patients With Type 2 Diabetes",[94],"2016-06",[2904],[3507,3526,3527],"Exenatide-LAR plus Dapagliflozin","Insulin Titration",{"trials":3529,"activeCount":103},[],{"intervention":3526,"totalTrials":184,"cells":3531},{"EARLY_PHASE1":3532,"PHASE1":3534,"PHASE2":3536,"PHASE3":3538,"PHASE4":3540,"NA":3546},{"trials":3533,"activeCount":103},[],{"trials":3535,"activeCount":103},[],{"trials":3537,"activeCount":103},[],{"trials":3539,"activeCount":103},[],{"trials":3541,"activeCount":103},[3542],{"nctId":3520,"briefTitle":3521,"status":494,"phases":3543,"primaryCompletion":1970,"completion":1263,"start":3523,"enrollment":103,"conditions":3544,"interventions":3545},[94],[2904],[3507,3526,3527],{"trials":3547,"activeCount":103},[],{"intervention":3527,"totalTrials":184,"cells":3549},{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3554,"PHASE3":3556,"PHASE4":3558,"NA":3564},{"trials":3551,"activeCount":103},[],{"trials":3553,"activeCount":103},[],{"trials":3555,"activeCount":103},[],{"trials":3557,"activeCount":103},[],{"trials":3559,"activeCount":103},[3560],{"nctId":3520,"briefTitle":3521,"status":494,"phases":3561,"primaryCompletion":1970,"completion":1263,"start":3523,"enrollment":103,"conditions":3562,"interventions":3563},[94],[2904],[3507,3526,3527],{"trials":3565,"activeCount":103},[],{"intervention":3567,"totalTrials":184,"cells":3568},"Propanolol",{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3573,"PHASE3":3575,"PHASE4":3577,"NA":3588},{"trials":3570,"activeCount":103},[],{"trials":3572,"activeCount":103},[],{"trials":3574,"activeCount":103},[],{"trials":3576,"activeCount":103},[],{"trials":3578,"activeCount":103},[3579],{"nctId":3580,"briefTitle":3581,"status":786,"phases":3582,"primaryCompletion":1993,"completion":3583,"start":3584,"enrollment":975,"conditions":3585,"interventions":3587},"NCT00648375","Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder",[94],"2009-09","2003-12",[3586],"Post-Traumatic Stress Disorder",[3567],{"trials":3589,"activeCount":103},[],{"intervention":1796,"totalTrials":184,"cells":3591},{"EARLY_PHASE1":3592,"PHASE1":3594,"PHASE2":3596,"PHASE3":3598,"PHASE4":3600,"NA":3606},{"trials":3593,"activeCount":103},[],{"trials":3595,"activeCount":103},[],{"trials":3597,"activeCount":103},[],{"trials":3599,"activeCount":103},[],{"trials":3601,"activeCount":103},[3602],{"nctId":1789,"briefTitle":1790,"status":156,"phases":3603,"primaryCompletion":1138,"completion":1138,"start":1792,"enrollment":178,"conditions":3604,"interventions":3605},[94],[1794],[1093,1796,1093,1797],{"trials":3607,"activeCount":103},[],{"intervention":1797,"totalTrials":184,"cells":3609},{"EARLY_PHASE1":3610,"PHASE1":3612,"PHASE2":3614,"PHASE3":3616,"PHASE4":3618,"NA":3624},{"trials":3611,"activeCount":103},[],{"trials":3613,"activeCount":103},[],{"trials":3615,"activeCount":103},[],{"trials":3617,"activeCount":103},[],{"trials":3619,"activeCount":103},[3620],{"nctId":1789,"briefTitle":1790,"status":156,"phases":3621,"primaryCompletion":1138,"completion":1138,"start":1792,"enrollment":178,"conditions":3622,"interventions":3623},[94],[1794],[1093,1796,1093,1797],{"trials":3625,"activeCount":103},[],{"intervention":3627,"totalTrials":184,"cells":3628},"Perampanel 6 MG",{"EARLY_PHASE1":3629,"PHASE1":3631,"PHASE2":3633,"PHASE3":3635,"PHASE4":3637,"NA":3648},{"trials":3630,"activeCount":103},[],{"trials":3632,"activeCount":103},[],{"trials":3634,"activeCount":103},[],{"trials":3636,"activeCount":103},[],{"trials":3638,"activeCount":103},[3639],{"nctId":3640,"briefTitle":3641,"status":156,"phases":3642,"primaryCompletion":3643,"completion":3643,"start":3644,"enrollment":975,"conditions":3645,"interventions":3647},"NCT03653741","Effects of Perampanel on Neurophysiology Test Perimeters",[94],"2021-11-29","2018-10-01",[3646],"Healthy",[3627],{"trials":3649,"activeCount":103},[],{"intervention":3651,"totalTrials":184,"cells":3652},"BIC\u002FF\u002FTAF 50Mg-200Mg-25Mg",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3659,"PHASE4":3661,"NA":3673},{"trials":3654,"activeCount":103},[],{"trials":3656,"activeCount":103},[],{"trials":3658,"activeCount":103},[],{"trials":3660,"activeCount":103},[],{"trials":3662,"activeCount":103},[3663],{"nctId":3664,"briefTitle":3665,"status":156,"phases":3666,"primaryCompletion":3667,"completion":3667,"start":3668,"enrollment":22,"conditions":3669,"interventions":3672},"NCT04530630","Switch to Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (BIC\u002FF\u002FTAF) After Renal Transplant",[94],"2024-08-28","2020-11-09",[3670,3671],"HIV Infections","Renal Transplant Rejection",[3651],{"trials":3674,"activeCount":103},[],{"intervention":3676,"totalTrials":184,"cells":3677},"Ethyl chloride skin refrigerant spray",{"EARLY_PHASE1":3678,"PHASE1":3680,"PHASE2":3682,"PHASE3":3684,"PHASE4":3686,"NA":3698},{"trials":3679,"activeCount":103},[],{"trials":3681,"activeCount":103},[],{"trials":3683,"activeCount":103},[],{"trials":3685,"activeCount":103},[],{"trials":3687,"activeCount":103},[3688],{"nctId":3689,"briefTitle":3690,"status":494,"phases":3691,"primaryCompletion":3692,"completion":3693,"start":3694,"enrollment":103,"conditions":3695,"interventions":3697},"NCT04422795","The Evaluation of External Thermomechanical Stimulation for Pain Reduction in Patients Undergoing Nail Injection",[94],"2025-02","2025-07","2024-02",[3696],"Nail Diseases",[3676],{"trials":3699,"activeCount":103},[],{"intervention":3701,"totalTrials":184,"cells":3702},"Daptomycin",{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3707,"PHASE3":3709,"PHASE4":3711,"NA":3722},{"trials":3704,"activeCount":103},[],{"trials":3706,"activeCount":103},[],{"trials":3708,"activeCount":103},[],{"trials":3710,"activeCount":103},[],{"trials":3712,"activeCount":103},[3713],{"nctId":3714,"briefTitle":3715,"status":786,"phases":3716,"primaryCompletion":3717,"completion":3717,"start":3718,"enrollment":811,"conditions":3719,"interventions":3721},"NCT00401960","Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.",[94],"2008-10","2006-09",[3720],"Endocarditis, Bacterial",[3701],{"trials":3723,"activeCount":103},[],{"intervention":3725,"totalTrials":184,"cells":3726},"Lithium",{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3731,"PHASE3":3733,"PHASE4":3735,"NA":3747},{"trials":3728,"activeCount":103},[],{"trials":3730,"activeCount":103},[],{"trials":3732,"activeCount":103},[],{"trials":3734,"activeCount":103},[],{"trials":3736,"activeCount":103},[3737],{"nctId":3738,"briefTitle":3739,"status":156,"phases":3740,"primaryCompletion":3493,"completion":3493,"start":1044,"enrollment":3741,"conditions":3742,"interventions":3745},"NCT00254488","Treatment of Bipolar Mania in Older Adults",[94],224,[3743,3744],"Bipolar Disorder","Mania",[3725,3746],"Divalproex",{"trials":3748,"activeCount":103},[],{"intervention":3746,"totalTrials":184,"cells":3750},{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3757,"PHASE4":3759,"NA":3765},{"trials":3752,"activeCount":103},[],{"trials":3754,"activeCount":103},[],{"trials":3756,"activeCount":103},[],{"trials":3758,"activeCount":103},[],{"trials":3760,"activeCount":103},[3761],{"nctId":3738,"briefTitle":3739,"status":156,"phases":3762,"primaryCompletion":3493,"completion":3493,"start":1044,"enrollment":3741,"conditions":3763,"interventions":3764},[94],[3743,3744],[3725,3746],{"trials":3766,"activeCount":103},[],{"intervention":3768,"totalTrials":184,"cells":3769},"Toviaz",{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3776,"PHASE4":3778,"NA":3789},{"trials":3771,"activeCount":103},[],{"trials":3773,"activeCount":103},[],{"trials":3775,"activeCount":103},[],{"trials":3777,"activeCount":103},[],{"trials":3779,"activeCount":103},[3780],{"nctId":3781,"briefTitle":3782,"status":156,"phases":3783,"primaryCompletion":3784,"completion":3784,"start":1063,"enrollment":3785,"conditions":3786,"interventions":3788},"NCT00605319","An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia",[94],"2013-01",17,[3787],"Bladder Outlet Obstruction",[3768],{"trials":3790,"activeCount":103},[],{"intervention":3792,"totalTrials":184,"cells":3793},"Lexapro",{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3798,"PHASE3":3800,"PHASE4":3802,"NA":3813},{"trials":3795,"activeCount":103},[],{"trials":3797,"activeCount":103},[],{"trials":3799,"activeCount":103},[],{"trials":3801,"activeCount":103},[],{"trials":3803,"activeCount":103},[3804],{"nctId":3805,"briefTitle":3806,"status":786,"phases":3807,"primaryCompletion":3808,"completion":3809,"start":946,"enrollment":947,"conditions":3810,"interventions":3812},"NCT01244724","Lexapro for Major Depression in Patients With Epilepsy",[94],"2011-12","2012-03",[3471,3811],"Epilepsy",[3792],{"trials":3814,"activeCount":103},[],{"intervention":3816,"totalTrials":184,"cells":3817},"Enoxaparin sodium",{"EARLY_PHASE1":3818,"PHASE1":3820,"PHASE2":3822,"PHASE3":3824,"PHASE4":3826,"NA":3840},{"trials":3819,"activeCount":103},[],{"trials":3821,"activeCount":103},[],{"trials":3823,"activeCount":103},[],{"trials":3825,"activeCount":103},[],{"trials":3827,"activeCount":103},[3828],{"nctId":3829,"briefTitle":3830,"status":786,"phases":3831,"primaryCompletion":3832,"completion":3833,"start":809,"enrollment":31,"conditions":3834,"interventions":3836},"NCT04406389","Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)",[94],"2021-04-17","2022-04-21",[3835],"COVID-19",[3816,3837,3838,3839],"Unfractionated heparin","Fondapariniux","Argatroban",{"trials":3841,"activeCount":103},[],{"intervention":3837,"totalTrials":184,"cells":3843},{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3848,"PHASE3":3850,"PHASE4":3852,"NA":3858},{"trials":3845,"activeCount":103},[],{"trials":3847,"activeCount":103},[],{"trials":3849,"activeCount":103},[],{"trials":3851,"activeCount":103},[],{"trials":3853,"activeCount":103},[3854],{"nctId":3829,"briefTitle":3830,"status":786,"phases":3855,"primaryCompletion":3832,"completion":3833,"start":809,"enrollment":31,"conditions":3856,"interventions":3857},[94],[3835],[3816,3837,3838,3839],{"trials":3859,"activeCount":103},[],{"intervention":3838,"totalTrials":184,"cells":3861},{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3868,"PHASE4":3870,"NA":3876},{"trials":3863,"activeCount":103},[],{"trials":3865,"activeCount":103},[],{"trials":3867,"activeCount":103},[],{"trials":3869,"activeCount":103},[],{"trials":3871,"activeCount":103},[3872],{"nctId":3829,"briefTitle":3830,"status":786,"phases":3873,"primaryCompletion":3832,"completion":3833,"start":809,"enrollment":31,"conditions":3874,"interventions":3875},[94],[3835],[3816,3837,3838,3839],{"trials":3877,"activeCount":103},[],{"intervention":3839,"totalTrials":184,"cells":3879},{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3886,"PHASE4":3888,"NA":3894},{"trials":3881,"activeCount":103},[],{"trials":3883,"activeCount":103},[],{"trials":3885,"activeCount":103},[],{"trials":3887,"activeCount":103},[],{"trials":3889,"activeCount":103},[3890],{"nctId":3829,"briefTitle":3830,"status":786,"phases":3891,"primaryCompletion":3832,"completion":3833,"start":809,"enrollment":31,"conditions":3892,"interventions":3893},[94],[3835],[3816,3837,3838,3839],{"trials":3895,"activeCount":103},[],{"intervention":3897,"totalTrials":184,"cells":3898},"erythropoietin, GCSF",{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3903,"PHASE3":3905,"PHASE4":3907,"NA":3917},{"trials":3900,"activeCount":103},[],{"trials":3902,"activeCount":103},[],{"trials":3904,"activeCount":103},[],{"trials":3906,"activeCount":103},[],{"trials":3908,"activeCount":103},[3909],{"nctId":3910,"briefTitle":3911,"status":786,"phases":3912,"primaryCompletion":3384,"completion":3384,"start":3913,"conditions":3914,"interventions":3916},"NCT00194857","Treatment of Anemia and Neutropenia in HIV\u002FHCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin",[94],"2002-02",[2834,2837,3915,3670],"Hepatitis C Virus",[3897],{"trials":3918,"activeCount":103},[],{"intervention":3920,"totalTrials":184,"cells":3921},"Risperidone",{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3926,"PHASE3":3928,"PHASE4":3930,"NA":3941},{"trials":3923,"activeCount":103},[],{"trials":3925,"activeCount":103},[],{"trials":3927,"activeCount":103},[],{"trials":3929,"activeCount":103},[],{"trials":3931,"activeCount":103},[3932],{"nctId":3933,"briefTitle":3934,"status":156,"phases":3935,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":947,"conditions":3938,"interventions":3940},"NCT03323437","Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia",[94],"2023-05-31","2017-09-15",[3939],"Schizophrenia Spectrum and Other Psychotic Disorders",[3920],{"trials":3942,"activeCount":103},[],{"intervention":3944,"totalTrials":184,"cells":3945},"Glecaprevir and Pibrentasvir",{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3950,"PHASE3":3952,"PHASE4":3954,"NA":3964},{"trials":3947,"activeCount":103},[],{"trials":3949,"activeCount":103},[],{"trials":3951,"activeCount":103},[],{"trials":3953,"activeCount":103},[],{"trials":3955,"activeCount":103},[3956],{"nctId":3957,"briefTitle":3958,"status":786,"phases":3959,"primaryCompletion":3960,"completion":3960,"start":3961,"enrollment":722,"conditions":3962,"interventions":3963},"NCT05582681","HCV Test and Treat Utilizing Simplified HCV Patient Education",[94],"2024-11-22","2022-11-11",[3387],[3944],{"trials":3965,"activeCount":103},[],{"intervention":3440,"totalTrials":184,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3974,"PHASE4":3976,"NA":3982},{"trials":3969,"activeCount":103},[],{"trials":3971,"activeCount":103},[],{"trials":3973,"activeCount":103},[],{"trials":3975,"activeCount":103},[],{"trials":3977,"activeCount":103},[3978],{"nctId":3432,"briefTitle":3433,"status":156,"phases":3979,"primaryCompletion":3435,"completion":3436,"start":1802,"enrollment":825,"conditions":3980,"interventions":3981},[94],[3438],[3440,3406],{"trials":3983,"activeCount":103},[],{"intervention":3985,"totalTrials":184,"cells":3986},"Standard Care",{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":3995,"NA":4008},{"trials":3988,"activeCount":103},[],{"trials":3990,"activeCount":103},[],{"trials":3992,"activeCount":103},[],{"trials":3994,"activeCount":103},[],{"trials":3996,"activeCount":103},[3997],{"nctId":3998,"briefTitle":3999,"status":3381,"phases":4000,"primaryCompletion":4001,"completion":926,"start":4002,"enrollment":2242,"conditions":4003,"interventions":4006},"NCT00761098","Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)",[94],"2010-05","2005-05",[4004,4005],"Spontaneous Bacterial Peritonitis","Cirrhosis",[3985,4007],"Experimental",{"trials":4009,"activeCount":103},[],{"intervention":4007,"totalTrials":184,"cells":4011},{"EARLY_PHASE1":4012,"PHASE1":4014,"PHASE2":4016,"PHASE3":4018,"PHASE4":4020,"NA":4026},{"trials":4013,"activeCount":103},[],{"trials":4015,"activeCount":103},[],{"trials":4017,"activeCount":103},[],{"trials":4019,"activeCount":103},[],{"trials":4021,"activeCount":103},[4022],{"nctId":3998,"briefTitle":3999,"status":3381,"phases":4023,"primaryCompletion":4001,"completion":926,"start":4002,"enrollment":2242,"conditions":4024,"interventions":4025},[94],[4004,4005],[3985,4007],{"trials":4027,"activeCount":103},[],{"intervention":4029,"totalTrials":184,"cells":4030},"Supraclavicular Block",{"EARLY_PHASE1":4031,"PHASE1":4033,"PHASE2":4035,"PHASE3":4037,"PHASE4":4039,"NA":4050},{"trials":4032,"activeCount":103},[],{"trials":4034,"activeCount":103},[],{"trials":4036,"activeCount":103},[],{"trials":4038,"activeCount":103},[],{"trials":4040,"activeCount":103},[4041],{"nctId":4042,"briefTitle":4043,"status":156,"phases":4044,"primaryCompletion":4045,"completion":4045,"start":4046,"enrollment":1737,"conditions":4047,"interventions":4049},"NCT03138577","Dose-Response Relationships for Hemidiaphragmatic Paresis Following Ultrasound-Guided Supraclavicular Block",[94],"2019-07-30","2018-02-12",[4048],"Surgery of Right Upper Extremity",[4029],{"trials":4051,"activeCount":103},[],{"intervention":4053,"totalTrials":184,"cells":4054},"Triamcinolone Acetonide 2.5 mg\u002FmL",{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4061,"PHASE4":4063,"NA":4077},{"trials":4056,"activeCount":103},[],{"trials":4058,"activeCount":103},[],{"trials":4060,"activeCount":103},[],{"trials":4062,"activeCount":103},[],{"trials":4064,"activeCount":103},[4065],{"nctId":4066,"briefTitle":4067,"status":156,"phases":4068,"primaryCompletion":4069,"completion":4069,"start":4070,"enrollment":37,"conditions":4071,"interventions":4072},"NCT03991936","Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis",[94],"2023-03-29","2020-03-11",[246,3696],[4073,4053,4074,4075,4076],"Placebos","Triamcinolone Acetonide 5.0 mg\u002FmL","Triamcinolone Acetonide 7.5 mg\u002FmL","Triamcinolone Acetonide 10 mg\u002FmL",{"trials":4078,"activeCount":103},[],{"intervention":4074,"totalTrials":184,"cells":4080},{"EARLY_PHASE1":4081,"PHASE1":4083,"PHASE2":4085,"PHASE3":4087,"PHASE4":4089,"NA":4095},{"trials":4082,"activeCount":103},[],{"trials":4084,"activeCount":103},[],{"trials":4086,"activeCount":103},[],{"trials":4088,"activeCount":103},[],{"trials":4090,"activeCount":103},[4091],{"nctId":4066,"briefTitle":4067,"status":156,"phases":4092,"primaryCompletion":4069,"completion":4069,"start":4070,"enrollment":37,"conditions":4093,"interventions":4094},[94],[246,3696],[4073,4053,4074,4075,4076],{"trials":4096,"activeCount":103},[],{"intervention":4075,"totalTrials":184,"cells":4098},{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4105,"PHASE4":4107,"NA":4113},{"trials":4100,"activeCount":103},[],{"trials":4102,"activeCount":103},[],{"trials":4104,"activeCount":103},[],{"trials":4106,"activeCount":103},[],{"trials":4108,"activeCount":103},[4109],{"nctId":4066,"briefTitle":4067,"status":156,"phases":4110,"primaryCompletion":4069,"completion":4069,"start":4070,"enrollment":37,"conditions":4111,"interventions":4112},[94],[246,3696],[4073,4053,4074,4075,4076],{"trials":4114,"activeCount":103},[],{"intervention":4076,"totalTrials":184,"cells":4116},{"EARLY_PHASE1":4117,"PHASE1":4119,"PHASE2":4121,"PHASE3":4123,"PHASE4":4125,"NA":4131},{"trials":4118,"activeCount":103},[],{"trials":4120,"activeCount":103},[],{"trials":4122,"activeCount":103},[],{"trials":4124,"activeCount":103},[],{"trials":4126,"activeCount":103},[4127],{"nctId":4066,"briefTitle":4067,"status":156,"phases":4128,"primaryCompletion":4069,"completion":4069,"start":4070,"enrollment":37,"conditions":4129,"interventions":4130},[94],[246,3696],[4073,4053,4074,4075,4076],{"trials":4132,"activeCount":103},[],{"intervention":3402,"totalTrials":184,"cells":4134},{"EARLY_PHASE1":4135,"PHASE1":4137,"PHASE2":4139,"PHASE3":4141,"PHASE4":4143,"NA":4149},{"trials":4136,"activeCount":103},[],{"trials":4138,"activeCount":103},[],{"trials":4140,"activeCount":103},[],{"trials":4142,"activeCount":103},[],{"trials":4144,"activeCount":103},[4145],{"nctId":3395,"briefTitle":3396,"status":494,"phases":4146,"primaryCompletion":1972,"completion":1972,"start":3398,"enrollment":103,"conditions":4147,"interventions":4148},[94],[3388,3400],[3370,3402],{"trials":4150,"activeCount":103},[],{"intervention":4152,"totalTrials":184,"cells":4153},"Vitamin D drops",{"EARLY_PHASE1":4154,"PHASE1":4156,"PHASE2":4158,"PHASE3":4160,"PHASE4":4162,"NA":4175},{"trials":4155,"activeCount":103},[],{"trials":4157,"activeCount":103},[],{"trials":4159,"activeCount":103},[],{"trials":4161,"activeCount":103},[],{"trials":4163,"activeCount":103},[4164],{"nctId":4165,"briefTitle":4166,"status":3381,"phases":4167,"primaryCompletion":3809,"completion":3809,"start":4168,"enrollment":4169,"conditions":4170,"interventions":4174},"NCT01386736","Vitamin D and Glucose Metabolism in Pediatrics",[94],"2011-04",110,[4171,4172,4173],"Insulin Resistance","Obesity","Vitamin D25 Insufficiency",[4152],{"trials":4176,"activeCount":103},[],{"intervention":4178,"totalTrials":184,"cells":4179},"Letrozole",{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4199},{"trials":4181,"activeCount":103},[],{"trials":4183,"activeCount":103},[],{"trials":4185,"activeCount":103},[],{"trials":4187,"activeCount":103},[],{"trials":4189,"activeCount":103},[4190],{"nctId":4191,"briefTitle":4192,"status":156,"phases":4193,"primaryCompletion":4194,"completion":4195,"start":4196,"enrollment":766,"conditions":4197,"interventions":4198},"NCT01035099","RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF",[94],"2019-07-23","2022-09-30","2009-11",[21,27],[4178,4178],{"trials":4200,"activeCount":103},[],{"intervention":4202,"totalTrials":184,"cells":4203},"Bupivacaine and Fentanyl",{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4223},{"trials":4205,"activeCount":103},[],{"trials":4207,"activeCount":103},[],{"trials":4209,"activeCount":103},[],{"trials":4211,"activeCount":103},[],{"trials":4213,"activeCount":103},[4214],{"nctId":4215,"briefTitle":4216,"status":156,"phases":4217,"primaryCompletion":3718,"completion":3718,"start":4218,"enrollment":4219,"conditions":4220,"interventions":4222},"NCT00151346","Combined Spinal-Epidural Versus Traditional Labor Epidural",[94],"2003-10",127,[4221],"Labour Pain",[4202,4202],{"trials":4224,"activeCount":103},[],{"intervention":4226,"totalTrials":184,"cells":4227},"Liposomal Bupivacaine",{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4232,"PHASE3":4234,"PHASE4":4236,"NA":4247},{"trials":4229,"activeCount":103},[],{"trials":4231,"activeCount":103},[],{"trials":4233,"activeCount":103},[],{"trials":4235,"activeCount":103},[],{"trials":4237,"activeCount":103},[4238],{"nctId":4239,"briefTitle":4240,"status":156,"phases":4241,"primaryCompletion":4242,"completion":4242,"start":1836,"enrollment":1583,"conditions":4243,"interventions":4245},"NCT03802864","Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine",[94],"2020-01-30",[4244],"Male Infertility",[4226,4246],"Standard Bupivacaine",{"trials":4248,"activeCount":103},[],{"intervention":4246,"totalTrials":184,"cells":4250},{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4257,"PHASE4":4259,"NA":4265},{"trials":4252,"activeCount":103},[],{"trials":4254,"activeCount":103},[],{"trials":4256,"activeCount":103},[],{"trials":4258,"activeCount":103},[],{"trials":4260,"activeCount":103},[4261],{"nctId":4239,"briefTitle":4240,"status":156,"phases":4262,"primaryCompletion":4242,"completion":4242,"start":1836,"enrollment":1583,"conditions":4263,"interventions":4264},[94],[4244],[4226,4246],{"trials":4266,"activeCount":103},[],{"intervention":4268,"totalTrials":184,"cells":4269},"HCG",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4276,"PHASE4":4278,"NA":4288},{"trials":4271,"activeCount":103},[],{"trials":4273,"activeCount":103},[],{"trials":4275,"activeCount":103},[],{"trials":4277,"activeCount":103},[],{"trials":4279,"activeCount":103},[4280],{"nctId":4281,"briefTitle":4282,"status":786,"phases":4283,"primaryCompletion":3523,"completion":3523,"start":3784,"enrollment":947,"conditions":4284,"interventions":4285},"NCT01443546","Study of Dual Trigger Ovulation in Oocyte Donors",[94],[27],[4268,4286,4287],"Lupron Trigger","Dual Trigger",{"trials":4289,"activeCount":103},[],{"intervention":4286,"totalTrials":184,"cells":4291},{"EARLY_PHASE1":4292,"PHASE1":4294,"PHASE2":4296,"PHASE3":4298,"PHASE4":4300,"NA":4306},{"trials":4293,"activeCount":103},[],{"trials":4295,"activeCount":103},[],{"trials":4297,"activeCount":103},[],{"trials":4299,"activeCount":103},[],{"trials":4301,"activeCount":103},[4302],{"nctId":4281,"briefTitle":4282,"status":786,"phases":4303,"primaryCompletion":3523,"completion":3523,"start":3784,"enrollment":947,"conditions":4304,"interventions":4305},[94],[27],[4268,4286,4287],{"trials":4307,"activeCount":103},[],{"intervention":4287,"totalTrials":184,"cells":4309},{"EARLY_PHASE1":4310,"PHASE1":4312,"PHASE2":4314,"PHASE3":4316,"PHASE4":4318,"NA":4324},{"trials":4311,"activeCount":103},[],{"trials":4313,"activeCount":103},[],{"trials":4315,"activeCount":103},[],{"trials":4317,"activeCount":103},[],{"trials":4319,"activeCount":103},[4320],{"nctId":4281,"briefTitle":4282,"status":786,"phases":4321,"primaryCompletion":3523,"completion":3523,"start":3784,"enrollment":947,"conditions":4322,"interventions":4323},[94],[27],[4268,4286,4287],{"trials":4325,"activeCount":103},[],{"intervention":4327,"totalTrials":184,"cells":4328},"Sertraline + Olanzapine",{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4350},{"trials":4330,"activeCount":103},[],{"trials":4332,"activeCount":103},[],{"trials":4334,"activeCount":103},[],{"trials":4336,"activeCount":103},[],{"trials":4338,"activeCount":103},[4339],{"nctId":4340,"briefTitle":4341,"status":156,"phases":4342,"primaryCompletion":4343,"completion":4343,"start":4344,"enrollment":4345,"conditions":4346,"interventions":4348},"NCT01427608","Sustaining Remission of Psychotic Depression",[94],"2017-11-30","2011-10",269,[4347],"Psychotic Depression",[4327,4349],"Sertraline + Placebo",{"trials":4351,"activeCount":103},[],{"intervention":4349,"totalTrials":184,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4360,"PHASE4":4362,"NA":4368},{"trials":4355,"activeCount":103},[],{"trials":4357,"activeCount":103},[],{"trials":4359,"activeCount":103},[],{"trials":4361,"activeCount":103},[],{"trials":4363,"activeCount":103},[4364],{"nctId":4340,"briefTitle":4341,"status":156,"phases":4365,"primaryCompletion":4343,"completion":4343,"start":4344,"enrollment":4345,"conditions":4366,"interventions":4367},[94],[4347],[4327,4349],{"trials":4369,"activeCount":103},[],{"intervention":4371,"totalTrials":184,"cells":4372},"escitalopram oxalate antidepressant",{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4377,"PHASE3":4379,"PHASE4":4381,"NA":4391},{"trials":4374,"activeCount":103},[],{"trials":4376,"activeCount":103},[],{"trials":4378,"activeCount":103},[],{"trials":4380,"activeCount":103},[],{"trials":4382,"activeCount":103},[4383],{"nctId":4384,"briefTitle":4385,"status":786,"phases":4386,"completion":4387,"start":1140,"enrollment":22,"conditions":4388,"interventions":4390},"NCT00151294","The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis",[94],"2006-10",[15,4389],"Multiple Sclerosis",[4371],{"trials":4392,"activeCount":103},[],{"intervention":4394,"totalTrials":184,"cells":4395},"Systane Complete",{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4402,"PHASE4":4404,"NA":4414},{"trials":4397,"activeCount":103},[],{"trials":4399,"activeCount":103},[],{"trials":4401,"activeCount":103},[],{"trials":4403,"activeCount":103},[],{"trials":4405,"activeCount":103},[4406],{"nctId":4407,"briefTitle":4408,"status":494,"phases":4409,"primaryCompletion":834,"completion":834,"start":4410,"enrollment":103,"conditions":4411,"interventions":4413},"NCT04230720","Effect of Artificial Tears on Biometry",[94],"2021-04",[4412],"Cataract",[4394],{"trials":4415,"activeCount":103},[],{"intervention":4417,"totalTrials":184,"cells":4418},"Platelet Transfusion",{"EARLY_PHASE1":4419,"PHASE1":4421,"PHASE2":4423,"PHASE3":4425,"PHASE4":4427,"NA":4439},{"trials":4420,"activeCount":103},[],{"trials":4422,"activeCount":103},[],{"trials":4424,"activeCount":103},[],{"trials":4426,"activeCount":103},[],{"trials":4428,"activeCount":103},[4429],{"nctId":4430,"briefTitle":4431,"status":786,"phases":4432,"primaryCompletion":4433,"completion":4434,"start":4435,"enrollment":160,"conditions":4436,"interventions":4438},"NCT05293106","Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial",[94],"2023-09-17","2023-09-27","2022-07-05",[4437],"Cardiopulmonary Bypass Surgery",[4417],{"trials":4440,"activeCount":103},[],{"intervention":4442,"totalTrials":184,"cells":4443},"Esomeprazole",{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4450,"PHASE4":4452,"NA":4463},{"trials":4445,"activeCount":103},[],{"trials":4447,"activeCount":103},[],{"trials":4449,"activeCount":103},[],{"trials":4451,"activeCount":103},[],{"trials":4453,"activeCount":103},[4454],{"nctId":4455,"briefTitle":4456,"status":494,"phases":4457,"primaryCompletion":4458,"completion":1076,"start":201,"enrollment":103,"conditions":4459,"interventions":4462},"NCT00361985","Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery",[94],"2011-01",[4460,4461],"Anastomotic Stricture","Morbid Obesity",[4442,4442],{"trials":4464,"activeCount":103},[],{"intervention":4466,"totalTrials":184,"cells":4467},"Adrenocorticotropic hormone",{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4476,"NA":4486},{"trials":4469,"activeCount":103},[],{"trials":4471,"activeCount":103},[],{"trials":4473,"activeCount":103},[],{"trials":4475,"activeCount":103},[],{"trials":4477,"activeCount":103},[4478],{"nctId":4479,"briefTitle":4480,"status":786,"phases":4481,"primaryCompletion":4482,"completion":4483,"start":3523,"enrollment":28,"conditions":4484,"interventions":4485},"NCT02446886","Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS",[94],"2020-03","2020-06",[4389],[4466],{"trials":4487,"activeCount":103},[],{"intervention":4489,"totalTrials":184,"cells":4490},"Flutamide",{"EARLY_PHASE1":4491,"PHASE1":4493,"PHASE2":4495,"PHASE3":4497,"PHASE4":4499,"NA":4510},{"trials":4492,"activeCount":103},[],{"trials":4494,"activeCount":103},[],{"trials":4496,"activeCount":103},[],{"trials":4498,"activeCount":103},[],{"trials":4500,"activeCount":103},[4501],{"nctId":4502,"briefTitle":4503,"status":156,"phases":4504,"primaryCompletion":3319,"completion":3808,"start":4505,"enrollment":4506,"conditions":4507,"interventions":4509},"NCT00611923","Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder",[94],"2005-02",115,[4508],"Premenstrual Syndrome",[4489],{"trials":4511,"activeCount":103},[],{"intervention":4513,"totalTrials":184,"cells":4514},"lidocaine + epinephrine 1:100,000",{"EARLY_PHASE1":4515,"PHASE1":4517,"PHASE2":4519,"PHASE3":4521,"PHASE4":4523,"NA":4537},{"trials":4516,"activeCount":103},[],{"trials":4518,"activeCount":103},[],{"trials":4520,"activeCount":103},[],{"trials":4522,"activeCount":103},[],{"trials":4524,"activeCount":103},[4525],{"nctId":4526,"briefTitle":4527,"status":156,"phases":4528,"primaryCompletion":4529,"completion":4529,"start":4530,"enrollment":4531,"conditions":4532,"interventions":4534},"NCT05767749","Split Face Study of the Duration of Local Anesthetics",[94],"2023-07-31","2023-03-14",75,[4533],"Anesthetics, Local",[4513,4535,4536],"Ropivacaine 0.5% Injectable Solution","Bupivacaine 0.5% Injectable Solution",{"trials":4538,"activeCount":103},[],{"intervention":4535,"totalTrials":184,"cells":4540},{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4547,"PHASE4":4549,"NA":4555},{"trials":4542,"activeCount":103},[],{"trials":4544,"activeCount":103},[],{"trials":4546,"activeCount":103},[],{"trials":4548,"activeCount":103},[],{"trials":4550,"activeCount":103},[4551],{"nctId":4526,"briefTitle":4527,"status":156,"phases":4552,"primaryCompletion":4529,"completion":4529,"start":4530,"enrollment":4531,"conditions":4553,"interventions":4554},[94],[4533],[4513,4535,4536],{"trials":4556,"activeCount":103},[],{"intervention":4536,"totalTrials":184,"cells":4558},{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4563,"PHASE3":4565,"PHASE4":4567,"NA":4573},{"trials":4560,"activeCount":103},[],{"trials":4562,"activeCount":103},[],{"trials":4564,"activeCount":103},[],{"trials":4566,"activeCount":103},[],{"trials":4568,"activeCount":103},[4569],{"nctId":4526,"briefTitle":4527,"status":156,"phases":4570,"primaryCompletion":4529,"completion":4529,"start":4530,"enrollment":4531,"conditions":4571,"interventions":4572},[94],[4533],[4513,4535,4536],{"trials":4574,"activeCount":103},[],{"intervention":4576,"totalTrials":184,"cells":4577},"Naltrexone HCl 50 MG Oral",{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4582,"PHASE3":4584,"PHASE4":4586,"NA":4597},{"trials":4579,"activeCount":103},[],{"trials":4581,"activeCount":103},[],{"trials":4583,"activeCount":103},[],{"trials":4585,"activeCount":103},[],{"trials":4587,"activeCount":103},[4588],{"nctId":4589,"briefTitle":4590,"status":786,"phases":4591,"primaryCompletion":4592,"completion":4592,"start":4593,"enrollment":160,"conditions":4594,"interventions":4596},"NCT04547985","Naltrexone Treatment for Prolonged Grief Disorder (PGD)",[94],"2023-10-16","2021-01-05",[4595],"Prolonged Grief Disorder",[4576],{"trials":4598,"activeCount":103},[],{"intervention":4600,"totalTrials":184,"cells":4601},"Low-dose Clomiphene",{"EARLY_PHASE1":4602,"PHASE1":4604,"PHASE2":4606,"PHASE3":4608,"PHASE4":4610,"NA":4619},{"trials":4603,"activeCount":103},[],{"trials":4605,"activeCount":103},[],{"trials":4607,"activeCount":103},[],{"trials":4609,"activeCount":103},[],{"trials":4611,"activeCount":103},[4612],{"nctId":4613,"briefTitle":4614,"status":494,"phases":4615,"primaryCompletion":3383,"completion":3383,"start":1264,"enrollment":103,"conditions":4616,"interventions":4617},"NCT01577199","RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders",[94],[27],[4600,4618],"High dose gonadotropins",{"trials":4620,"activeCount":103},[],{"intervention":4618,"totalTrials":184,"cells":4622},{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4627,"PHASE3":4629,"PHASE4":4631,"NA":4637},{"trials":4624,"activeCount":103},[],{"trials":4626,"activeCount":103},[],{"trials":4628,"activeCount":103},[],{"trials":4630,"activeCount":103},[],{"trials":4632,"activeCount":103},[4633],{"nctId":4613,"briefTitle":4614,"status":494,"phases":4634,"primaryCompletion":3383,"completion":3383,"start":1264,"enrollment":103,"conditions":4635,"interventions":4636},[94],[27],[4600,4618],{"trials":4638,"activeCount":103},[],{"intervention":4640,"totalTrials":184,"cells":4641},"Traditional Cryoprecipitate",{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4648,"PHASE4":4650,"NA":4665},{"trials":4643,"activeCount":103},[],{"trials":4645,"activeCount":103},[],{"trials":4647,"activeCount":103},[],{"trials":4649,"activeCount":103},[],{"trials":4651,"activeCount":103},[4652],{"nctId":4653,"briefTitle":4654,"status":156,"phases":4655,"primaryCompletion":4656,"completion":4657,"start":4658,"enrollment":4659,"conditions":4660,"interventions":4663},"NCT05711524","Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding",[94],"2024-10-23","2025-10-03","2023-04-01",208,[4661,4662],"Hypofibrinogenemia","Bleeding",[4640,4664],"Pathogen-Reduced Cryoprecipitate",{"trials":4666,"activeCount":103},[],{"intervention":4664,"totalTrials":184,"cells":4668},{"EARLY_PHASE1":4669,"PHASE1":4671,"PHASE2":4673,"PHASE3":4675,"PHASE4":4677,"NA":4683},{"trials":4670,"activeCount":103},[],{"trials":4672,"activeCount":103},[],{"trials":4674,"activeCount":103},[],{"trials":4676,"activeCount":103},[],{"trials":4678,"activeCount":103},[4679],{"nctId":4653,"briefTitle":4654,"status":156,"phases":4680,"primaryCompletion":4656,"completion":4657,"start":4658,"enrollment":4659,"conditions":4681,"interventions":4682},[94],[4661,4662],[4640,4664],{"trials":4684,"activeCount":103},[],{"intervention":4686,"totalTrials":184,"cells":4687},"Fluoxetine",{"EARLY_PHASE1":4688,"PHASE1":4690,"PHASE2":4692,"PHASE3":4694,"PHASE4":4696,"NA":4708},{"trials":4689,"activeCount":103},[],{"trials":4691,"activeCount":103},[],{"trials":4693,"activeCount":103},[],{"trials":4695,"activeCount":103},[],{"trials":4697,"activeCount":103},[4698],{"nctId":4699,"briefTitle":4700,"status":156,"phases":4701,"primaryCompletion":4702,"completion":3469,"start":4703,"enrollment":4704,"conditions":4705,"interventions":4706},"NCT00611975","Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning",[94],"2008-05","2005-10",83,[3646],[4686,4707],"Bupropion",{"trials":4709,"activeCount":103},[],{"intervention":4707,"totalTrials":184,"cells":4711},{"EARLY_PHASE1":4712,"PHASE1":4714,"PHASE2":4716,"PHASE3":4718,"PHASE4":4720,"NA":4726},{"trials":4713,"activeCount":103},[],{"trials":4715,"activeCount":103},[],{"trials":4717,"activeCount":103},[],{"trials":4719,"activeCount":103},[],{"trials":4721,"activeCount":103},[4722],{"nctId":4699,"briefTitle":4700,"status":156,"phases":4723,"primaryCompletion":4702,"completion":3469,"start":4703,"enrollment":4704,"conditions":4724,"interventions":4725},[94],[3646],[4686,4707],{"trials":4727,"activeCount":103},[],{"intervention":4729,"totalTrials":184,"cells":4730},"Oral contraceptive pill and microdose lupron",{"EARLY_PHASE1":4731,"PHASE1":4733,"PHASE2":4735,"PHASE3":4737,"PHASE4":4739,"NA":4750},{"trials":4732,"activeCount":103},[],{"trials":4734,"activeCount":103},[],{"trials":4736,"activeCount":103},[],{"trials":4738,"activeCount":103},[],{"trials":4740,"activeCount":103},[4741],{"nctId":4742,"briefTitle":4743,"status":494,"phases":4744,"primaryCompletion":3418,"completion":4745,"start":4746,"enrollment":103,"conditions":4747,"interventions":4748},"NCT00826839","Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients",[94],"2012-01","2009-01",[27],[4729,4749],"E2 patch\u002Fantagonist",{"trials":4751,"activeCount":103},[],{"intervention":4749,"totalTrials":184,"cells":4753},{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4760,"PHASE4":4762,"NA":4768},{"trials":4755,"activeCount":103},[],{"trials":4757,"activeCount":103},[],{"trials":4759,"activeCount":103},[],{"trials":4761,"activeCount":103},[],{"trials":4763,"activeCount":103},[4764],{"nctId":4742,"briefTitle":4743,"status":494,"phases":4765,"primaryCompletion":3418,"completion":4745,"start":4746,"enrollment":103,"conditions":4766,"interventions":4767},[94],[27],[4729,4749],{"trials":4769,"activeCount":103},[],{"intervention":4771,"totalTrials":184,"cells":4772},"Hydrocodone 5Mg\u002FAcetaminophen 325Mg Tab",{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4779,"PHASE4":4781,"NA":4795},{"trials":4774,"activeCount":103},[],{"trials":4776,"activeCount":103},[],{"trials":4778,"activeCount":103},[],{"trials":4780,"activeCount":103},[],{"trials":4782,"activeCount":103},[4783],{"nctId":4784,"briefTitle":4785,"status":156,"phases":4786,"primaryCompletion":4787,"completion":4788,"start":4789,"enrollment":22,"conditions":4790,"interventions":4792},"NCT05544734","Hydrocodone Compared to Acetaminophen and Ibuprofen for Post-nail Procedure Analgesia",[94],"2023-05-15","2023-06-01","2022-11-10",[3696,4791],"Nail Abnormality",[4771,4793,4794],"Acetaminophen 1000mg","Ibuprofen 400 mg",{"trials":4796,"activeCount":103},[],{"intervention":4793,"totalTrials":184,"cells":4798},{"EARLY_PHASE1":4799,"PHASE1":4801,"PHASE2":4803,"PHASE3":4805,"PHASE4":4807,"NA":4813},{"trials":4800,"activeCount":103},[],{"trials":4802,"activeCount":103},[],{"trials":4804,"activeCount":103},[],{"trials":4806,"activeCount":103},[],{"trials":4808,"activeCount":103},[4809],{"nctId":4784,"briefTitle":4785,"status":156,"phases":4810,"primaryCompletion":4787,"completion":4788,"start":4789,"enrollment":22,"conditions":4811,"interventions":4812},[94],[3696,4791],[4771,4793,4794],{"trials":4814,"activeCount":103},[],{"intervention":4794,"totalTrials":184,"cells":4816},{"EARLY_PHASE1":4817,"PHASE1":4819,"PHASE2":4821,"PHASE3":4823,"PHASE4":4825,"NA":4831},{"trials":4818,"activeCount":103},[],{"trials":4820,"activeCount":103},[],{"trials":4822,"activeCount":103},[],{"trials":4824,"activeCount":103},[],{"trials":4826,"activeCount":103},[4827],{"nctId":4784,"briefTitle":4785,"status":156,"phases":4828,"primaryCompletion":4787,"completion":4788,"start":4789,"enrollment":22,"conditions":4829,"interventions":4830},[94],[3696,4791],[4771,4793,4794],{"trials":4832,"activeCount":103},[],{"intervention":4834,"totalTrials":184,"cells":4835},"Global vs. G-TL vs Cornell's C3 vs Cornell's C1\u002FC2 media",{"EARLY_PHASE1":4836,"PHASE1":4838,"PHASE2":4840,"PHASE3":4842,"PHASE4":4844,"NA":4854},{"trials":4837,"activeCount":103},[],{"trials":4839,"activeCount":103},[],{"trials":4841,"activeCount":103},[],{"trials":4843,"activeCount":103},[],{"trials":4845,"activeCount":103},[4846],{"nctId":4847,"briefTitle":4848,"status":494,"phases":4849,"primaryCompletion":4850,"completion":4850,"start":4851,"enrollment":103,"conditions":4852,"interventions":4853},"NCT03687697","Comparison of Global, G-TL, & Cornell Media",[94],"2018-05-01","2018-04-01",[27],[4834],{"trials":4855,"activeCount":103},[],{"intervention":4857,"totalTrials":184,"cells":4858},"Metformin Extended Release Oral",{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4863,"PHASE3":4865,"PHASE4":4867,"NA":4880},{"trials":4860,"activeCount":103},[],{"trials":4862,"activeCount":103},[],{"trials":4864,"activeCount":103},[],{"trials":4866,"activeCount":103},[],{"trials":4868,"activeCount":103},[4869],{"nctId":4870,"briefTitle":4871,"status":156,"phases":4872,"primaryCompletion":4873,"completion":4874,"start":4875,"enrollment":34,"conditions":4876,"interventions":4879},"NCT03467763","Trial of an Intervention to Improve Metformin Persistence and Adherence",[94],"2020-02-01","2020-08-01","2018-02-09",[4877,4878],"Metformin Adverse Reaction","Tolerance",[4857],{"trials":4881,"activeCount":103},[],{"intervention":4883,"totalTrials":184,"cells":4884},"intravenous acetaminophen",{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4891,"PHASE4":4893,"NA":4903},{"trials":4886,"activeCount":103},[],{"trials":4888,"activeCount":103},[],{"trials":4890,"activeCount":103},[],{"trials":4892,"activeCount":103},[],{"trials":4894,"activeCount":103},[4895],{"nctId":4896,"briefTitle":4897,"status":156,"phases":4898,"primaryCompletion":4899,"completion":4899,"start":974,"enrollment":4900,"conditions":4901,"interventions":4902},"NCT02452320","Prospective, Double Blind, Placebo Control, Bariatric IV Ace",[94],"2017-01",136,[4172],[4883],{"trials":4904,"activeCount":103},[],{"intervention":4906,"totalTrials":184,"cells":4907},"Medication Only",{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4912,"PHASE3":4914,"PHASE4":4916,"NA":4928},{"trials":4909,"activeCount":103},[],{"trials":4911,"activeCount":103},[],{"trials":4913,"activeCount":103},[],{"trials":4915,"activeCount":103},[],{"trials":4917,"activeCount":103},[4918],{"nctId":4919,"briefTitle":4920,"status":156,"phases":4921,"primaryCompletion":4922,"completion":4922,"start":4923,"enrollment":4924,"conditions":4925,"interventions":4927},"NCT00057551","Research Evaluating the Value of Augmenting Medication With Psychotherapy",[94],"2007-03","2003-04",491,[15,4926],"Depressive Disorder",[4906],{"trials":4929,"activeCount":103},[],{"intervention":4931,"totalTrials":184,"cells":4932},"Ergocalciferol",{"EARLY_PHASE1":4933,"PHASE1":4935,"PHASE2":4937,"PHASE3":4939,"PHASE4":4941,"NA":4954},{"trials":4934,"activeCount":103},[],{"trials":4936,"activeCount":103},[],{"trials":4938,"activeCount":103},[],{"trials":4940,"activeCount":103},[],{"trials":4942,"activeCount":103},[4943],{"nctId":4944,"briefTitle":4945,"status":156,"phases":4946,"primaryCompletion":4947,"completion":4947,"start":4948,"enrollment":375,"conditions":4949,"interventions":4952},"NCT00288873","Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity",[94],"2007-07","2006-02",[4950,4951,4172],"Vitamin D Deficiency","Secondary Hyperparathyroidism",[4931,4953],"Cholecalciferol",{"trials":4955,"activeCount":103},[],{"intervention":4953,"totalTrials":184,"cells":4957},{"EARLY_PHASE1":4958,"PHASE1":4960,"PHASE2":4962,"PHASE3":4964,"PHASE4":4966,"NA":4972},{"trials":4959,"activeCount":103},[],{"trials":4961,"activeCount":103},[],{"trials":4963,"activeCount":103},[],{"trials":4965,"activeCount":103},[],{"trials":4967,"activeCount":103},[4968],{"nctId":4944,"briefTitle":4945,"status":156,"phases":4969,"primaryCompletion":4947,"completion":4947,"start":4948,"enrollment":375,"conditions":4970,"interventions":4971},[94],[4950,4951,4172],[4931,4953],{"trials":4973,"activeCount":103},[],{"intervention":4975,"totalTrials":184,"cells":4976},"Propofol",{"EARLY_PHASE1":4977,"PHASE1":4979,"PHASE2":4981,"PHASE3":4983,"PHASE4":4985,"NA":4994},{"trials":4978,"activeCount":103},[],{"trials":4980,"activeCount":103},[],{"trials":4982,"activeCount":103},[],{"trials":4984,"activeCount":103},[],{"trials":4986,"activeCount":103},[4987],{"nctId":4988,"briefTitle":4989,"status":786,"phases":4990,"primaryCompletion":916,"completion":916,"start":4922,"enrollment":375,"conditions":4991,"interventions":4992},"NCT00504894","Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes",[94],[3646],[4975,4993],"Thiopental",{"trials":4995,"activeCount":103},[],{"intervention":4993,"totalTrials":184,"cells":4997},{"EARLY_PHASE1":4998,"PHASE1":5000,"PHASE2":5002,"PHASE3":5004,"PHASE4":5006,"NA":5012},{"trials":4999,"activeCount":103},[],{"trials":5001,"activeCount":103},[],{"trials":5003,"activeCount":103},[],{"trials":5005,"activeCount":103},[],{"trials":5007,"activeCount":103},[5008],{"nctId":4988,"briefTitle":4989,"status":786,"phases":5009,"primaryCompletion":916,"completion":916,"start":4922,"enrollment":375,"conditions":5010,"interventions":5011},[94],[3646],[4975,4993],{"trials":5013,"activeCount":103},[],{"intervention":5015,"totalTrials":184,"cells":5016},"Lifitegrast 5% Ophthalmic Solution",{"EARLY_PHASE1":5017,"PHASE1":5019,"PHASE2":5021,"PHASE3":5023,"PHASE4":5025,"NA":5036},{"trials":5018,"activeCount":103},[],{"trials":5020,"activeCount":103},[],{"trials":5022,"activeCount":103},[],{"trials":5024,"activeCount":103},[],{"trials":5026,"activeCount":103},[5027],{"nctId":5028,"briefTitle":5029,"status":494,"phases":5030,"primaryCompletion":1971,"completion":1971,"start":3196,"enrollment":103,"conditions":5031,"interventions":5035},"NCT03952481","Effect of Lifitegrast 5% on Tear Film Markers",[94],[5032,5033,5034],"Dry Eye","Dry Eye Syndromes","Dry Eyes Chronic",[5015],{"trials":5037,"activeCount":103},[],{"intervention":5039,"totalTrials":184,"cells":5040},"Metoprolol",{"EARLY_PHASE1":5041,"PHASE1":5043,"PHASE2":5045,"PHASE3":5047,"PHASE4":5049,"NA":5059},{"trials":5042,"activeCount":103},[],{"trials":5044,"activeCount":103},[],{"trials":5046,"activeCount":103},[],{"trials":5048,"activeCount":103},[],{"trials":5050,"activeCount":103},[5051],{"nctId":5052,"briefTitle":5053,"status":156,"phases":5054,"primaryCompletion":4458,"completion":4458,"start":5055,"enrollment":1156,"conditions":5056,"interventions":5057},"NCT00999102","Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life",[94],"2009-10",[24],[5039,5058],"Nebivolol",{"trials":5060,"activeCount":103},[],{"intervention":5058,"totalTrials":184,"cells":5062},{"EARLY_PHASE1":5063,"PHASE1":5065,"PHASE2":5067,"PHASE3":5069,"PHASE4":5071,"NA":5077},{"trials":5064,"activeCount":103},[],{"trials":5066,"activeCount":103},[],{"trials":5068,"activeCount":103},[],{"trials":5070,"activeCount":103},[],{"trials":5072,"activeCount":103},[5073],{"nctId":5052,"briefTitle":5053,"status":156,"phases":5074,"primaryCompletion":4458,"completion":4458,"start":5055,"enrollment":1156,"conditions":5075,"interventions":5076},[94],[24],[5039,5058],{"trials":5078,"activeCount":103},[],{"intervention":5080,"totalTrials":184,"cells":5081},"potassium citrate",{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5086,"PHASE3":5088,"PHASE4":5090,"NA":5101},{"trials":5083,"activeCount":103},[],{"trials":5085,"activeCount":103},[],{"trials":5087,"activeCount":103},[],{"trials":5089,"activeCount":103},[],{"trials":5091,"activeCount":103},[5092],{"nctId":5093,"briefTitle":5094,"status":156,"phases":5095,"primaryCompletion":4168,"completion":4168,"start":5096,"enrollment":4704,"conditions":5097,"interventions":5100},"NCT00357331","The Effects of Potassium Citrate on Bone Metabolism",[94],"2006-08",[5098,5099],"Bone Diseases, Metabolic","Osteoporosis, Postmenopausal",[5080],{"trials":5102,"activeCount":103},[],{"intervention":5104,"totalTrials":184,"cells":5105},"Ceftolozane \u002F Tazobactam",{"EARLY_PHASE1":5106,"PHASE1":5108,"PHASE2":5110,"PHASE3":5112,"PHASE4":5114,"NA":5128},{"trials":5107,"activeCount":103},[],{"trials":5109,"activeCount":103},[],{"trials":5111,"activeCount":103},[],{"trials":5113,"activeCount":103},[],{"trials":5115,"activeCount":103},[5116],{"nctId":5117,"briefTitle":5118,"status":786,"phases":5119,"primaryCompletion":5120,"completion":5120,"start":5121,"enrollment":3785,"conditions":5122,"interventions":5127},"NCT04673175","Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation",[94],"2025-03-16","2023-01-10",[5123,1315,5124,5125,5126],"Pneumonia","Pseudomonas Aeruginosa Infection","Bacteremia","Hematopoietic Stem Cell Transplant (HSCT)",[5104],{"trials":5129,"activeCount":103},[],{"intervention":5131,"totalTrials":184,"cells":5132},"Vitamin D3",{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5137,"PHASE3":5139,"PHASE4":5141,"NA":5151},{"trials":5134,"activeCount":103},[],{"trials":5136,"activeCount":103},[],{"trials":5138,"activeCount":103},[],{"trials":5140,"activeCount":103},[],{"trials":5142,"activeCount":103},[5143],{"nctId":5144,"briefTitle":5145,"status":3381,"phases":5146,"primaryCompletion":5147,"completion":3500,"start":3319,"enrollment":218,"conditions":5148,"interventions":5150},"NCT01323608","The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study",[94],"2014-06",[5149],"Thalassemia Major",[5131],{"trials":5152,"activeCount":103},[],{"intervention":5154,"totalTrials":184,"cells":5155},"sildenafil",{"EARLY_PHASE1":5156,"PHASE1":5158,"PHASE2":5160,"PHASE3":5162,"PHASE4":5164,"NA":5175},{"trials":5157,"activeCount":103},[],{"trials":5159,"activeCount":103},[],{"trials":5161,"activeCount":103},[],{"trials":5163,"activeCount":103},[],{"trials":5165,"activeCount":103},[5166],{"nctId":5167,"briefTitle":5168,"status":156,"phases":5169,"primaryCompletion":5170,"completion":5170,"start":5171,"enrollment":722,"conditions":5172,"interventions":5174},"NCT00194909","An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)",[94],"2006-07","2004-08",[5173],"Diabetic Neuropathy",[5154],{"trials":5176,"activeCount":103},[],{"intervention":1840,"totalTrials":141,"cells":5178},{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5193,"PHASE3":5199,"PHASE4":5205,"NA":5207},{"trials":5180,"activeCount":103},[],{"trials":5182,"activeCount":103},[5183],{"nctId":5184,"briefTitle":5185,"status":786,"phases":5186,"primaryCompletion":5187,"completion":5188,"start":5189,"enrollment":22,"conditions":5190,"interventions":5191},"NCT01111188","Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma",[91],"2013-02-26","2019-04-12","2010-08-23",[1036],[5192,1840],"PD 0332991",{"trials":5194,"activeCount":103},[5195],{"nctId":875,"briefTitle":876,"status":156,"phases":5196,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":5197,"interventions":5198},[92],[30],[884,885,886,887,888],{"trials":5200,"activeCount":103},[5201],{"nctId":1833,"briefTitle":1834,"status":156,"phases":5202,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":16,"conditions":5203,"interventions":5204},[93],[30],[1840,1067,1841,1842],{"trials":5206,"activeCount":103},[],{"trials":5208,"activeCount":103},[],{"intervention":1842,"totalTrials":141,"cells":5210},{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5236,"PHASE3":5238,"PHASE4":5244,"NA":5246},{"trials":5212,"activeCount":103},[],{"trials":5214,"activeCount":103},[5215,5227],{"nctId":5216,"briefTitle":5217,"status":156,"phases":5218,"primaryCompletion":5219,"completion":5219,"start":5220,"enrollment":5221,"conditions":5222,"interventions":5224},"NCT01352650","Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)",[91],"2016-12-27","2011-06-17",71,[5223],"Acute Myeloid Leukemia",[5225,5226],"plerixafor","decitabine",{"nctId":5228,"briefTitle":5229,"status":786,"phases":5230,"primaryCompletion":5231,"completion":5231,"start":5232,"enrollment":99,"conditions":5233,"interventions":5235},"NCT03277209","To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",[91],"2019-12-30","2017-07-25",[5234],"Pancreas Cancer",[1842],{"trials":5237,"activeCount":103},[],{"trials":5239,"activeCount":103},[5240],{"nctId":1833,"briefTitle":1834,"status":156,"phases":5241,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":16,"conditions":5242,"interventions":5243},[93],[30],[1840,1067,1841,1842],{"trials":5245,"activeCount":103},[],{"trials":5247,"activeCount":103},[],{"intervention":5249,"totalTrials":184,"cells":5250},"rimonabant",{"EARLY_PHASE1":5251,"PHASE1":5253,"PHASE2":5255,"PHASE3":5257,"PHASE4":5267,"NA":5269},{"trials":5252,"activeCount":103},[],{"trials":5254,"activeCount":103},[],{"trials":5256,"activeCount":103},[],{"trials":5258,"activeCount":103},[5259],{"nctId":5260,"briefTitle":5261,"status":786,"phases":5262,"primaryCompletion":4746,"completion":4746,"start":5263,"enrollment":1236,"conditions":5264,"interventions":5266},"NCT00603109","Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome",[93],"2007-08",[5265],"Prader-willi Syndrome",[5249],{"trials":5268,"activeCount":103},[],{"trials":5270,"activeCount":103},[],{"intervention":1412,"totalTrials":184,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5279,"PHASE4":5285,"NA":5287},{"trials":5274,"activeCount":103},[],{"trials":5276,"activeCount":103},[],{"trials":5278,"activeCount":103},[],{"trials":5280,"activeCount":103},[5281],{"nctId":1402,"briefTitle":1403,"status":156,"phases":5282,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":1407,"conditions":5283,"interventions":5284},[92,93],[1409,1410],[1412,1070],{"trials":5286,"activeCount":103},[],{"trials":5288,"activeCount":103},[],{"intervention":5290,"totalTrials":184,"cells":5291},"glutamine",{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5296,"PHASE3":5298,"PHASE4":5308,"NA":5310},{"trials":5293,"activeCount":103},[],{"trials":5295,"activeCount":103},[],{"trials":5297,"activeCount":103},[],{"trials":5299,"activeCount":103},[5300],{"nctId":5301,"briefTitle":5302,"status":156,"phases":5303,"primaryCompletion":5304,"completion":5304,"start":3584,"enrollment":478,"conditions":5305,"interventions":5307},"NCT00195013","Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy",[93],"2014-05",[5306,21],"Peripheral Neuropathy",[5290],{"trials":5309,"activeCount":103},[],{"trials":5311,"activeCount":103},[],{"intervention":5313,"totalTrials":184,"cells":5314},"Baloxavir Marboxil",{"EARLY_PHASE1":5315,"PHASE1":5317,"PHASE2":5319,"PHASE3":5321,"PHASE4":5332,"NA":5334},{"trials":5316,"activeCount":103},[],{"trials":5318,"activeCount":103},[],{"trials":5320,"activeCount":103},[],{"trials":5322,"activeCount":103},[5323],{"nctId":5324,"briefTitle":5325,"status":786,"phases":5326,"primaryCompletion":1889,"completion":118,"start":5327,"enrollment":99,"conditions":5328,"interventions":5330},"NCT05170009","Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza",[92,93],"2022-04-22",[5329],"Influenza",[5313,5331],"Oseltamivir",{"trials":5333,"activeCount":103},[],{"trials":5335,"activeCount":103},[],{"intervention":5331,"totalTrials":184,"cells":5337},{"EARLY_PHASE1":5338,"PHASE1":5340,"PHASE2":5342,"PHASE3":5344,"PHASE4":5350,"NA":5352},{"trials":5339,"activeCount":103},[],{"trials":5341,"activeCount":103},[],{"trials":5343,"activeCount":103},[],{"trials":5345,"activeCount":103},[5346],{"nctId":5324,"briefTitle":5325,"status":786,"phases":5347,"primaryCompletion":1889,"completion":118,"start":5327,"enrollment":99,"conditions":5348,"interventions":5349},[92,93],[5329],[5313,5331],{"trials":5351,"activeCount":103},[],{"trials":5353,"activeCount":103},[],{"intervention":5355,"totalTrials":184,"cells":5356},"Rituxan, Cyclophosphamide, Vincristine, Prednisone",{"EARLY_PHASE1":5357,"PHASE1":5359,"PHASE2":5361,"PHASE3":5363,"PHASE4":5374,"NA":5376},{"trials":5358,"activeCount":103},[],{"trials":5360,"activeCount":103},[],{"trials":5362,"activeCount":103},[],{"trials":5364,"activeCount":103},[5365],{"nctId":5366,"briefTitle":5367,"status":156,"phases":5368,"primaryCompletion":1792,"completion":1792,"start":5369,"enrollment":3785,"conditions":5370,"interventions":5372},"NCT00774202","Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",[92,93],"2003-11",[5371],"Immune Thrombocytopenic Purpura",[5355,5373],"Higher Dose of Rituximab",{"trials":5375,"activeCount":103},[],{"trials":5377,"activeCount":103},[],{"intervention":5373,"totalTrials":184,"cells":5379},{"EARLY_PHASE1":5380,"PHASE1":5382,"PHASE2":5384,"PHASE3":5386,"PHASE4":5392,"NA":5394},{"trials":5381,"activeCount":103},[],{"trials":5383,"activeCount":103},[],{"trials":5385,"activeCount":103},[],{"trials":5387,"activeCount":103},[5388],{"nctId":5366,"briefTitle":5367,"status":156,"phases":5389,"primaryCompletion":1792,"completion":1792,"start":5369,"enrollment":3785,"conditions":5390,"interventions":5391},[92,93],[5371],[5355,5373],{"trials":5393,"activeCount":103},[],{"trials":5395,"activeCount":103},[],{"intervention":5397,"totalTrials":184,"cells":5398},"DCS (D-Cycloserine ) + Prolonged Imaginal Exposure",{"EARLY_PHASE1":5399,"PHASE1":5401,"PHASE2":5403,"PHASE3":5405,"PHASE4":5418,"NA":5420},{"trials":5400,"activeCount":103},[],{"trials":5402,"activeCount":103},[],{"trials":5404,"activeCount":103},[],{"trials":5406,"activeCount":103},[5407],{"nctId":5408,"briefTitle":5409,"status":156,"phases":5410,"primaryCompletion":5411,"completion":5411,"start":5412,"enrollment":5413,"conditions":5414,"interventions":5416},"NCT01352637","Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer",[93],"2018-09","2011-05",192,[5415],"Post Traumatic Stress Disorder",[5397,5417],"DCS (D-Cycloserine ) + Virtual Reality Exposure",{"trials":5419,"activeCount":103},[],{"trials":5421,"activeCount":103},[],{"intervention":5417,"totalTrials":184,"cells":5423},{"EARLY_PHASE1":5424,"PHASE1":5426,"PHASE2":5428,"PHASE3":5430,"PHASE4":5436,"NA":5438},{"trials":5425,"activeCount":103},[],{"trials":5427,"activeCount":103},[],{"trials":5429,"activeCount":103},[],{"trials":5431,"activeCount":103},[5432],{"nctId":5408,"briefTitle":5409,"status":156,"phases":5433,"primaryCompletion":5411,"completion":5411,"start":5412,"enrollment":5413,"conditions":5434,"interventions":5435},[93],[5415],[5397,5417],{"trials":5437,"activeCount":103},[],{"trials":5439,"activeCount":103},[],{"intervention":5441,"totalTrials":184,"cells":5442},"Antimicrobial therapy: Co-trimoxazole or Doxycycline",{"EARLY_PHASE1":5443,"PHASE1":5445,"PHASE2":5447,"PHASE3":5449,"PHASE4":5461,"NA":5463},{"trials":5444,"activeCount":103},[],{"trials":5446,"activeCount":103},[],{"trials":5448,"activeCount":103},[],{"trials":5450,"activeCount":103},[5451],{"nctId":5452,"briefTitle":5453,"status":786,"phases":5454,"primaryCompletion":5455,"completion":5455,"start":5456,"enrollment":5457,"conditions":5458,"interventions":5460},"NCT02759120","CleanUP IPF for the Pulmonary Trials Cooperative",[93],"2020-03-16","2017-03-22",513,[5459],"Idiopathic Pulmonary Fibrosis",[5441],{"trials":5462,"activeCount":103},[],{"trials":5464,"activeCount":103},[],{"intervention":5466,"totalTrials":184,"cells":5467},"Coenzyme Q10 with vitamin E",{"EARLY_PHASE1":5468,"PHASE1":5470,"PHASE2":5472,"PHASE3":5474,"PHASE4":5484,"NA":5486},{"trials":5469,"activeCount":103},[],{"trials":5471,"activeCount":103},[],{"trials":5473,"activeCount":103},[],{"trials":5475,"activeCount":103},[5476],{"nctId":5477,"briefTitle":5478,"status":786,"phases":5479,"primaryCompletion":3493,"completion":3493,"start":1194,"enrollment":5480,"conditions":5481,"interventions":5483},"NCT00740714","Effects of Coenzyme Q10 (CoQ) in Parkinson Disease",[93],600,[5482],"Parkinson Disease",[5466],{"trials":5485,"activeCount":103},[],{"trials":5487,"activeCount":103},[],{"intervention":5489,"totalTrials":184,"cells":5490},"Olanzapine",{"EARLY_PHASE1":5491,"PHASE1":5493,"PHASE2":5495,"PHASE3":5497,"PHASE4":5509,"NA":5511},{"trials":5492,"activeCount":103},[],{"trials":5494,"activeCount":103},[],{"trials":5496,"activeCount":103},[],{"trials":5498,"activeCount":103},[5499],{"nctId":5500,"briefTitle":5501,"status":156,"phases":5502,"primaryCompletion":3398,"completion":3398,"start":5503,"enrollment":5504,"conditions":5505,"interventions":5507},"NCT00056472","Study of Pharmacotherapy of Psychotic Depression",[93],"2003-01",259,[5506],"Major Depressive Disorder With Psychotic Features",[5489,5508],"Sertraline",{"trials":5510,"activeCount":103},[],{"trials":5512,"activeCount":103},[],{"intervention":5508,"totalTrials":184,"cells":5514},{"EARLY_PHASE1":5515,"PHASE1":5517,"PHASE2":5519,"PHASE3":5521,"PHASE4":5527,"NA":5529},{"trials":5516,"activeCount":103},[],{"trials":5518,"activeCount":103},[],{"trials":5520,"activeCount":103},[],{"trials":5522,"activeCount":103},[5523],{"nctId":5500,"briefTitle":5501,"status":156,"phases":5524,"primaryCompletion":3398,"completion":3398,"start":5503,"enrollment":5504,"conditions":5525,"interventions":5526},[93],[5506],[5489,5508],{"trials":5528,"activeCount":103},[],{"trials":5530,"activeCount":103},[],{"intervention":5532,"totalTrials":184,"cells":5533},"acetylsalicylic acid",{"EARLY_PHASE1":5534,"PHASE1":5536,"PHASE2":5538,"PHASE3":5540,"PHASE4":5553,"NA":5555},{"trials":5535,"activeCount":103},[],{"trials":5537,"activeCount":103},[],{"trials":5539,"activeCount":103},[],{"trials":5541,"activeCount":103},[5542],{"nctId":5543,"briefTitle":5544,"status":156,"phases":5545,"primaryCompletion":5546,"completion":5547,"start":5548,"enrollment":5549,"conditions":5550,"interventions":5552},"NCT04070573","Low Doses of Aspirin in the Prevention of Preeclampsia",[93],"2024-03-04","2025-01-23","2019-10-21",400,[5551],"Preeclampsia",[5532],{"trials":5554,"activeCount":103},[],{"trials":5556,"activeCount":103},[],{"intervention":1841,"totalTrials":184,"cells":5558},{"EARLY_PHASE1":5559,"PHASE1":5561,"PHASE2":5563,"PHASE3":5565,"PHASE4":5571,"NA":5573},{"trials":5560,"activeCount":103},[],{"trials":5562,"activeCount":103},[],{"trials":5564,"activeCount":103},[],{"trials":5566,"activeCount":103},[5567],{"nctId":1833,"briefTitle":1834,"status":156,"phases":5568,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":16,"conditions":5569,"interventions":5570},[93],[30],[1840,1067,1841,1842],{"trials":5572,"activeCount":103},[],{"trials":5574,"activeCount":103},[],{"intervention":5576,"totalTrials":184,"cells":5577},"Botulinum toxin type A",{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5582,"PHASE3":5584,"PHASE4":5600,"NA":5602},{"trials":5579,"activeCount":103},[],{"trials":5581,"activeCount":103},[],{"trials":5583,"activeCount":103},[],{"trials":5585,"activeCount":103},[5586],{"nctId":5587,"briefTitle":5588,"status":156,"phases":5589,"primaryCompletion":5590,"completion":5590,"start":5591,"enrollment":4531,"conditions":5592,"interventions":5598},"NCT03223298","Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles",[93],"2020-03-13","2018-08-31",[5593,5594,5595,5596,5597],"Pain, Head","Pain Syndrome","Temporomandibular Disorder","Myofascial Pain Syndrome","Myofascial Pain",[5576,5599],"0.9% Sodium Chloride",{"trials":5601,"activeCount":103},[],{"trials":5603,"activeCount":103},[],{"intervention":5599,"totalTrials":184,"cells":5605},{"EARLY_PHASE1":5606,"PHASE1":5608,"PHASE2":5610,"PHASE3":5612,"PHASE4":5618,"NA":5620},{"trials":5607,"activeCount":103},[],{"trials":5609,"activeCount":103},[],{"trials":5611,"activeCount":103},[],{"trials":5613,"activeCount":103},[5614],{"nctId":5587,"briefTitle":5588,"status":156,"phases":5615,"primaryCompletion":5590,"completion":5590,"start":5591,"enrollment":4531,"conditions":5616,"interventions":5617},[93],[5593,5594,5595,5596,5597],[5576,5599],{"trials":5619,"activeCount":103},[],{"trials":5621,"activeCount":103},[],{"intervention":5623,"totalTrials":184,"cells":5624},"Ribavirin, PEG-Intron",{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5631,"PHASE4":5641,"NA":5643},{"trials":5626,"activeCount":103},[],{"trials":5628,"activeCount":103},[],{"trials":5630,"activeCount":103},[],{"trials":5632,"activeCount":103},[5633],{"nctId":5634,"briefTitle":5635,"status":156,"phases":5636,"enrollment":5637,"conditions":5638,"interventions":5640},"NCT00299936","Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects",[93],5000,[5639],"Chronic Hepatitis C",[5623],{"trials":5642,"activeCount":103},[],{"trials":5644,"activeCount":103},[],{"intervention":5646,"totalTrials":184,"cells":5647},"Gabapentin",{"EARLY_PHASE1":5648,"PHASE1":5650,"PHASE2":5652,"PHASE3":5654,"PHASE4":5665,"NA":5667},{"trials":5649,"activeCount":103},[],{"trials":5651,"activeCount":103},[],{"trials":5653,"activeCount":103},[],{"trials":5655,"activeCount":103},[5656],{"nctId":5657,"briefTitle":5658,"status":156,"phases":5659,"primaryCompletion":5660,"completion":3001,"start":5661,"enrollment":963,"conditions":5662,"interventions":5664},"NCT04230980","Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery",[93],"2022-11-28","2020-07-28",[5663],"Non-obstructive Azoospermia",[5646],{"trials":5666,"activeCount":103},[],{"trials":5668,"activeCount":103},[],{"intervention":1130,"totalTrials":178,"cells":5670},{"EARLY_PHASE1":5671,"PHASE1":5684,"PHASE2":5686,"PHASE3":5723,"PHASE4":5725,"NA":5727},{"trials":5672,"activeCount":103},[5673],{"nctId":5674,"briefTitle":5675,"status":156,"phases":5676,"primaryCompletion":1138,"completion":5677,"start":5678,"enrollment":1313,"conditions":5679,"interventions":5681},"NCT00572065","Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis",[90],"2010-02-08","2008-02-29",[5680],"Myelofibrosis",[5682,5683],"arsenic trioxide","cytarabine",{"trials":5685,"activeCount":103},[],{"trials":5687,"activeCount":103},[5688,5696,5708,5712],{"nctId":5689,"briefTitle":5690,"status":156,"phases":5691,"primaryCompletion":5692,"completion":1792,"start":3362,"enrollment":2179,"conditions":5693,"interventions":5694},"NCT00195000","Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS",[92],"2006-05",[5223,1196],[5695,1130],"Mylotarg",{"nctId":5697,"briefTitle":5698,"status":786,"phases":5699,"primaryCompletion":5700,"completion":5701,"start":5702,"enrollment":34,"conditions":5703,"interventions":5705},"NCT02532010","Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML",[92],"2016-02-09","2017-10-24","2015-06-15",[5704],"Acute Myeloid Leukemia (AML)",[5706,5707,1130],"Pacritinib","Decitabine",{"nctId":1117,"briefTitle":1118,"status":156,"phases":5709,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":5710,"interventions":5711},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"nctId":5713,"briefTitle":5714,"status":156,"phases":5715,"primaryCompletion":5716,"completion":5717,"start":5718,"enrollment":5719,"conditions":5720,"interventions":5721},"NCT00195104","Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML",[91,92],"2006-03-17","2006-06-20","2003-09-17",87,[1196],[5722,1130],"Arsenic Trioxide",{"trials":5724,"activeCount":103},[],{"trials":5726,"activeCount":103},[],{"trials":5728,"activeCount":103},[],{"intervention":1255,"totalTrials":896,"cells":5730},{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5758,"PHASE3":5769,"PHASE4":5771,"NA":5773},{"trials":5732,"activeCount":103},[],{"trials":5734,"activeCount":103},[5735,5745,5749],{"nctId":5736,"briefTitle":5737,"status":786,"phases":5738,"primaryCompletion":5739,"completion":5740,"start":5741,"enrollment":37,"conditions":5742,"interventions":5743},"NCT03878927","CPX-351+GO in Subjects 55 Years Old, or Older, With AML",[91],"2022-08-15","2022-09-01","2019-08-23",[5223],[1255,5744],"Gemtuzumab Ozogamicin",{"nctId":1243,"briefTitle":1244,"status":156,"phases":5746,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":31,"conditions":5747,"interventions":5748},[91],[1250,1251,1252,1253],[1255,73,1090,1256,1257],{"nctId":5750,"briefTitle":5751,"status":156,"phases":5752,"primaryCompletion":5753,"completion":5754,"start":5755,"enrollment":16,"conditions":5756,"interventions":5757},"NCT00875693","A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)",[91],"2014-06-30","2017-12-27","2009-06-02",[1301,1196],[1255],{"trials":5759,"activeCount":103},[5760],{"nctId":5761,"briefTitle":5762,"status":156,"phases":5763,"primaryCompletion":5764,"completion":5765,"start":5766,"enrollment":478,"conditions":5767,"interventions":5768},"NCT03335267","Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia",[92],"2018-12-19","2020-05-29","2017-10-19",[1251],[1255],{"trials":5770,"activeCount":103},[],{"trials":5772,"activeCount":103},[],{"trials":5774,"activeCount":103},[],{"intervention":1057,"totalTrials":896,"cells":5776},{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5799,"PHASE4":5801,"NA":5803},{"trials":5778,"activeCount":103},[],{"trials":5780,"activeCount":103},[],{"trials":5782,"activeCount":103},[5783,5787,5791,5795],{"nctId":1049,"briefTitle":1050,"status":786,"phases":5784,"primaryCompletion":1052,"completion":1032,"start":1053,"enrollment":896,"conditions":5785,"interventions":5786},[92],[1055],[1057,852,865],{"nctId":1095,"briefTitle":1096,"status":156,"phases":5788,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":28,"conditions":5789,"interventions":5790},[92],[1102],[958,58,1038],{"nctId":1135,"briefTitle":1136,"status":156,"phases":5792,"primaryCompletion":1138,"completion":1139,"start":1140,"enrollment":532,"conditions":5793,"interventions":5794},[92],[1126],[1143,1057,865],{"nctId":952,"briefTitle":953,"status":786,"phases":5796,"primaryCompletion":955,"completion":955,"start":200,"enrollment":178,"conditions":5797,"interventions":5798},[92],[30],[885,958,58],{"trials":5800,"activeCount":103},[],{"trials":5802,"activeCount":103},[],{"trials":5804,"activeCount":103},[],{"intervention":5226,"totalTrials":141,"cells":5806},{"EARLY_PHASE1":5807,"PHASE1":5809,"PHASE2":5821,"PHASE3":5827,"PHASE4":5829,"NA":5831},{"trials":5808,"activeCount":103},[],{"trials":5810,"activeCount":103},[5811,5815],{"nctId":5216,"briefTitle":5217,"status":156,"phases":5812,"primaryCompletion":5219,"completion":5219,"start":5220,"enrollment":5221,"conditions":5813,"interventions":5814},[91],[5223],[5225,5226],{"nctId":5816,"briefTitle":5817,"status":156,"phases":5818,"primaryCompletion":1138,"completion":1138,"start":4947,"enrollment":478,"conditions":5819,"interventions":5820},"NCT00538876","Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML",[91],[5223],[5226],{"trials":5822,"activeCount":103},[5823],{"nctId":5697,"briefTitle":5698,"status":786,"phases":5824,"primaryCompletion":5700,"completion":5701,"start":5702,"enrollment":34,"conditions":5825,"interventions":5826},[92],[5704],[5706,5707,1130],{"trials":5828,"activeCount":103},[],{"trials":5830,"activeCount":103},[],{"trials":5832,"activeCount":103},[],{"intervention":1895,"totalTrials":141,"cells":5834},{"EARLY_PHASE1":5835,"PHASE1":5837,"PHASE2":5839,"PHASE3":5865,"PHASE4":5867,"NA":5869},{"trials":5836,"activeCount":103},[],{"trials":5838,"activeCount":103},[],{"trials":5840,"activeCount":103},[5841,5845,5854],{"nctId":1886,"briefTitle":1887,"status":786,"phases":5842,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":811,"conditions":5843,"interventions":5844},[92],[1892],[759,1894,866,1895],{"nctId":5846,"briefTitle":5847,"status":156,"phases":5848,"primaryCompletion":5849,"completion":5850,"start":5851,"enrollment":375,"conditions":5852,"interventions":5853},"NCT02904954","Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer",[92],"2020-09-16","2022-10-04","2016-12-02",[2269],[1895],{"nctId":5855,"briefTitle":5856,"status":494,"phases":5857,"primaryCompletion":5858,"completion":5859,"start":5860,"enrollment":103,"conditions":5861,"interventions":5863},"NCT06994299","A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable\u002FAdvanced Hepatocellular Carcinoma",[92],"2027-07-01","2028-07-01","2025-10-01",[5862],"Hepatocellular Carcinoma (HCC)",[5864,1895],"Tremelimumab",{"trials":5866,"activeCount":103},[],{"trials":5868,"activeCount":103},[],{"trials":5870,"activeCount":103},[],{"intervention":5872,"totalTrials":141,"cells":5873},"Ribavirin",{"EARLY_PHASE1":5874,"PHASE1":5884,"PHASE2":5897,"PHASE3":5907,"PHASE4":5909,"NA":5911},{"trials":5875,"activeCount":103},[5876],{"nctId":5877,"briefTitle":5878,"status":786,"phases":5879,"primaryCompletion":5880,"completion":5880,"start":5881,"enrollment":141,"conditions":5882,"interventions":5883},"NCT03585725","A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma",[90],"2020-07-22","2018-09-26",[1692,1036],[5872],{"trials":5885,"activeCount":103},[5886],{"nctId":5887,"briefTitle":5888,"status":786,"phases":5889,"primaryCompletion":5170,"completion":5096,"start":5890,"enrollment":745,"conditions":5891,"interventions":5892},"NCT00277758","Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN\u002FRBV In Chronic Hepatitis C Virus Genotype I",[91],"2004-03",[3387],[5893,5872,5894,5895,5896],"Interleukin 2","Pegylated Interferon Alpha","Inteleukin-2","Ribavirin + Pegylated interferon-alpha",{"trials":5898,"activeCount":103},[5899],{"nctId":5900,"briefTitle":5901,"status":156,"phases":5902,"primaryCompletion":3383,"completion":3383,"start":1373,"enrollment":28,"conditions":5903,"interventions":5904},"NCT00892697","Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)",[92],[3387],[5905,5906,5872],"Telaprevir","Peginterferon alfa-2a",{"trials":5908,"activeCount":103},[],{"trials":5910,"activeCount":103},[],{"trials":5912,"activeCount":103},[],{"intervention":840,"totalTrials":99,"cells":5914},{"EARLY_PHASE1":5915,"PHASE1":5921,"PHASE2":5923,"PHASE3":5929,"PHASE4":5931,"NA":5933},{"trials":5916,"activeCount":103},[5917],{"nctId":830,"briefTitle":831,"status":494,"phases":5918,"primaryCompletion":497,"completion":833,"start":834,"enrollment":103,"conditions":5919,"interventions":5920},[90],[836,837,838],[840,504],{"trials":5922,"activeCount":103},[],{"trials":5924,"activeCount":103},[5925],{"nctId":890,"briefTitle":891,"status":786,"phases":5926,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":5927,"interventions":5928},[92],[898,899,900],[840,902,903,504],{"trials":5930,"activeCount":103},[],{"trials":5932,"activeCount":103},[],{"trials":5934,"activeCount":103},[],{"intervention":1281,"totalTrials":99,"cells":5936},{"EARLY_PHASE1":5937,"PHASE1":5939,"PHASE2":5945,"PHASE3":5954,"PHASE4":5956,"NA":5958},{"trials":5938,"activeCount":103},[],{"trials":5940,"activeCount":103},[5941],{"nctId":1271,"briefTitle":1272,"status":786,"phases":5942,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":184,"conditions":5943,"interventions":5944},[91],[1278,1279],[1090,759,1281],{"trials":5946,"activeCount":103},[5947],{"nctId":5948,"briefTitle":5949,"status":786,"phases":5950,"completion":5096,"start":5951,"enrollment":1552,"conditions":5952,"interventions":5953},"NCT00194935","Weekly Topotecan Therapy in Patients With Ovarian Cancer",[92],"2003-02",[1978],[1281],{"trials":5955,"activeCount":103},[],{"trials":5957,"activeCount":103},[],{"trials":5959,"activeCount":103},[],{"intervention":1128,"totalTrials":99,"cells":5961},{"EARLY_PHASE1":5962,"PHASE1":5964,"PHASE2":5966,"PHASE3":5976,"PHASE4":5978,"NA":5980},{"trials":5963,"activeCount":103},[],{"trials":5965,"activeCount":103},[],{"trials":5967,"activeCount":103},[5968,5972],{"nctId":1285,"briefTitle":1286,"status":156,"phases":5969,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":5970,"interventions":5971},[91,92],[30],[1128,1090,1128,1128,1128,1128,1128],{"nctId":1117,"briefTitle":1118,"status":156,"phases":5973,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":5974,"interventions":5975},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"trials":5977,"activeCount":103},[],{"trials":5979,"activeCount":103},[],{"trials":5981,"activeCount":103},[],{"intervention":1894,"totalTrials":99,"cells":5983},{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":5988,"PHASE3":6003,"PHASE4":6005,"NA":6007},{"trials":5985,"activeCount":103},[],{"trials":5987,"activeCount":103},[],{"trials":5989,"activeCount":103},[5990,5994],{"nctId":1886,"briefTitle":1887,"status":786,"phases":5991,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":811,"conditions":5992,"interventions":5993},[92],[1892],[759,1894,866,1895],{"nctId":5995,"briefTitle":5996,"status":786,"phases":5997,"completion":3718,"start":5998,"enrollment":5999,"conditions":6000,"interventions":6001},"NCT00195078","Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer",[91,92],"2004-04",29,[1975],[6002,1894],"ZD1839",{"trials":6004,"activeCount":103},[],{"trials":6006,"activeCount":103},[],{"trials":6008,"activeCount":103},[],{"intervention":1071,"totalTrials":99,"cells":6010},{"EARLY_PHASE1":6011,"PHASE1":6013,"PHASE2":6015,"PHASE3":6031,"PHASE4":6033,"NA":6035},{"trials":6012,"activeCount":103},[],{"trials":6014,"activeCount":103},[],{"trials":6016,"activeCount":103},[6017,6021],{"nctId":1059,"briefTitle":1060,"status":156,"phases":6018,"primaryCompletion":1062,"completion":974,"start":1063,"enrollment":31,"conditions":6019,"interventions":6020},[91,92],[1065],[1038,1067,1068,1069,1070,1071],{"nctId":6022,"briefTitle":6023,"status":156,"phases":6024,"primaryCompletion":6025,"completion":6026,"start":3418,"enrollment":3785,"conditions":6027,"interventions":6029},"NCT01120834","Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)",[91,92],"2013-04","2016-10-20",[6028],"Lymphoma",[1071,6030],"vorinostat",{"trials":6032,"activeCount":103},[],{"trials":6034,"activeCount":103},[],{"trials":6036,"activeCount":103},[],{"intervention":816,"totalTrials":99,"cells":6038},{"EARLY_PHASE1":6039,"PHASE1":6041,"PHASE2":6043,"PHASE3":6059,"PHASE4":6061,"NA":6063},{"trials":6040,"activeCount":103},[],{"trials":6042,"activeCount":103},[],{"trials":6044,"activeCount":103},[6045,6055],{"nctId":6046,"briefTitle":6047,"status":786,"phases":6048,"primaryCompletion":6049,"completion":6049,"start":6050,"enrollment":28,"conditions":6051,"interventions":6053},"NCT03168464","Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)",[91,92],"2022-03-11","2017-10-09",[6052],"Non Small Cell Lung Cancer Metastatic",[6054,816],"Ipilimumab",{"nctId":806,"briefTitle":807,"status":786,"phases":6056,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":6057,"interventions":6058},[92],[813,814],[816,817,48],{"trials":6060,"activeCount":103},[],{"trials":6062,"activeCount":103},[],{"trials":6064,"activeCount":103},[],{"intervention":1081,"totalTrials":99,"cells":6066},{"EARLY_PHASE1":6067,"PHASE1":6069,"PHASE2":6071,"PHASE3":6086,"PHASE4":6088,"NA":6090},{"trials":6068,"activeCount":103},[],{"trials":6070,"activeCount":103},[],{"trials":6072,"activeCount":103},[6073,6077],{"nctId":1073,"briefTitle":1074,"status":156,"phases":6074,"primaryCompletion":1076,"completion":916,"start":1077,"enrollment":37,"conditions":6075,"interventions":6076},[92],[1079],[1081,865,1082],{"nctId":6078,"briefTitle":6079,"status":494,"phases":6080,"primaryCompletion":6081,"completion":974,"start":944,"enrollment":103,"conditions":6082,"interventions":6085},"NCT01314066","Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)",[92],"2015-11",[6083,6084],"Severe Sepsis","Acute Respiratory Distress Syndrome",[1081],{"trials":6087,"activeCount":103},[],{"trials":6089,"activeCount":103},[],{"trials":6091,"activeCount":103},[],{"intervention":6093,"totalTrials":99,"cells":6094},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":6095,"PHASE1":6097,"PHASE2":6109,"PHASE3":6120,"PHASE4":6122,"NA":6124},{"trials":6096,"activeCount":103},[],{"trials":6098,"activeCount":103},[6099],{"nctId":6100,"briefTitle":6101,"status":156,"phases":6102,"primaryCompletion":6103,"completion":6104,"start":6105,"enrollment":22,"conditions":6106,"interventions":6108},"NCT02516384","Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)",[91],"2016-12-31","2017-01-31","2016-10-01",[6107],"Ulcerative Colitis",[6093],{"trials":6110,"activeCount":103},[6111],{"nctId":6112,"briefTitle":6113,"status":156,"phases":6114,"primaryCompletion":6115,"completion":6116,"start":6117,"enrollment":777,"conditions":6118,"interventions":6119},"NCT03998488","Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis",[92],"2023-06-09","2024-04-12","2020-01-31",[6107,696],[6093],{"trials":6121,"activeCount":103},[],{"trials":6123,"activeCount":103},[],{"trials":6125,"activeCount":103},[],{"intervention":1902,"totalTrials":99,"cells":6127},{"EARLY_PHASE1":6128,"PHASE1":6130,"PHASE2":6132,"PHASE3":6142,"PHASE4":6144,"NA":6146},{"trials":6129,"activeCount":103},[],{"trials":6131,"activeCount":103},[],{"trials":6133,"activeCount":103},[6134,6138],{"nctId":1897,"briefTitle":1898,"status":786,"phases":6135,"primaryCompletion":1053,"completion":916,"start":1837,"enrollment":141,"conditions":6136,"interventions":6137},[92],[18],[759,1902],{"nctId":1908,"briefTitle":1909,"status":156,"phases":6139,"primaryCompletion":1911,"start":1912,"enrollment":1913,"conditions":6140,"interventions":6141},[92],[1915],[1917,1918,1919],{"trials":6143,"activeCount":103},[],{"trials":6145,"activeCount":103},[],{"trials":6147,"activeCount":103},[],{"intervention":6149,"totalTrials":99,"cells":6150},"Eltrombopag",{"EARLY_PHASE1":6151,"PHASE1":6153,"PHASE2":6155,"PHASE3":6175,"PHASE4":6177,"NA":6179},{"trials":6152,"activeCount":103},[],{"trials":6154,"activeCount":103},[],{"trials":6156,"activeCount":103},[6157,6165],{"nctId":6158,"briefTitle":6159,"status":156,"phases":6160,"primaryCompletion":6161,"completion":6161,"start":4746,"enrollment":22,"conditions":6162,"interventions":6163},"NCT00902018","Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)",[92],"2015-09-07",[984],[6149,6164],"Romiplostim",{"nctId":6166,"briefTitle":6167,"status":156,"phases":6168,"primaryCompletion":6169,"completion":6170,"start":6171,"enrollment":9,"conditions":6172,"interventions":6174},"NCT01880047","Safety and Efficacy of Eltrombopag at Escalated Doses",[92],"2017-02-15","2017-10-16","2013-02",[984,6173],"Platelet Disorder",[6149],{"trials":6176,"activeCount":103},[],{"trials":6178,"activeCount":103},[],{"trials":6180,"activeCount":103},[],{"intervention":6182,"totalTrials":99,"cells":6183},"Dasatinib",{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6209,"PHASE4":6211,"NA":6213},{"trials":6185,"activeCount":103},[],{"trials":6187,"activeCount":103},[],{"trials":6189,"activeCount":103},[6190,6200],{"nctId":6191,"briefTitle":6192,"status":786,"phases":6193,"primaryCompletion":6194,"completion":6195,"start":6196,"enrollment":1236,"conditions":6197,"interventions":6199},"NCT00538980","Dasatinib in Polycythemia Vera",[92],"2010-08-25","2010-08-27","2007-04-30",[6198],"Polycythemia Vera",[6182],{"nctId":6201,"briefTitle":6202,"status":786,"phases":6203,"primaryCompletion":1193,"completion":6204,"start":1993,"enrollment":99,"conditions":6205,"interventions":6207},"NCT00918463","A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",[92],"2011-05-23",[6206],"Diffuse Large B-cell Lymphoma",[6208],"dasatinib",{"trials":6210,"activeCount":103},[],{"trials":6212,"activeCount":103},[],{"trials":6214,"activeCount":103},[],{"intervention":5682,"totalTrials":99,"cells":6216},{"EARLY_PHASE1":6217,"PHASE1":6223,"PHASE2":6225,"PHASE3":6231,"PHASE4":6233,"NA":6235},{"trials":6218,"activeCount":103},[6219],{"nctId":5674,"briefTitle":5675,"status":156,"phases":6220,"primaryCompletion":1138,"completion":5677,"start":5678,"enrollment":1313,"conditions":6221,"interventions":6222},[90],[5680],[5682,5683],{"trials":6224,"activeCount":103},[],{"trials":6226,"activeCount":103},[6227],{"nctId":5713,"briefTitle":5714,"status":156,"phases":6228,"primaryCompletion":5716,"completion":5717,"start":5718,"enrollment":5719,"conditions":6229,"interventions":6230},[91,92],[1196],[5722,1130],{"trials":6232,"activeCount":103},[],{"trials":6234,"activeCount":103},[],{"trials":6236,"activeCount":103},[],{"intervention":5906,"totalTrials":99,"cells":6238},{"EARLY_PHASE1":6239,"PHASE1":6241,"PHASE2":6243,"PHASE3":6256,"PHASE4":6258,"NA":6260},{"trials":6240,"activeCount":103},[],{"trials":6242,"activeCount":103},[],{"trials":6244,"activeCount":103},[6245,6249],{"nctId":5900,"briefTitle":5901,"status":156,"phases":6246,"primaryCompletion":3383,"completion":3383,"start":1373,"enrollment":28,"conditions":6247,"interventions":6248},[92],[3387],[5905,5906,5872],{"nctId":6250,"briefTitle":6251,"status":786,"phases":6252,"primaryCompletion":6253,"completion":6253,"start":3784,"enrollment":722,"conditions":6254,"interventions":6255},"NCT01758588","Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis",[92],"2017-06",[5680],[5906],{"trials":6257,"activeCount":103},[],{"trials":6259,"activeCount":103},[],{"trials":6261,"activeCount":103},[],{"intervention":1131,"totalTrials":99,"cells":6263},{"EARLY_PHASE1":6264,"PHASE1":6266,"PHASE2":6268,"PHASE3":6278,"PHASE4":6280,"NA":6282},{"trials":6265,"activeCount":103},[],{"trials":6267,"activeCount":103},[],{"trials":6269,"activeCount":103},[6270,6274],{"nctId":1117,"briefTitle":1118,"status":156,"phases":6271,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":6272,"interventions":6273},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"nctId":1328,"briefTitle":1329,"status":156,"phases":6275,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":218,"conditions":6276,"interventions":6277},[92],[1335,1250],[1337,73,1090,1131],{"trials":6279,"activeCount":103},[],{"trials":6281,"activeCount":103},[],{"trials":6283,"activeCount":103},[],{"intervention":6285,"totalTrials":99,"cells":6286},"Oxaliplatin",{"EARLY_PHASE1":6287,"PHASE1":6289,"PHASE2":6302,"PHASE3":6316,"PHASE4":6318,"NA":6320},{"trials":6288,"activeCount":103},[],{"trials":6290,"activeCount":103},[6291],{"nctId":6292,"briefTitle":6293,"status":156,"phases":6294,"primaryCompletion":6295,"completion":5411,"start":3319,"enrollment":975,"conditions":6296,"interventions":6298},"NCT01386346","Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer",[91],"2014-08",[1915,6297],"Malignant Neoplasm of Cardio-esophageal Junction of Stomach",[6299,6285,6300,6301],"Azacitidine","Epirubicin","Capecitabine",{"trials":6303,"activeCount":103},[6304],{"nctId":6305,"briefTitle":6306,"status":494,"phases":6307,"primaryCompletion":974,"completion":6308,"start":848,"enrollment":103,"conditions":6309,"interventions":6312},"NCT02046538","Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer",[92],"2018-02",[6310,6311],"Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum",[6313,6285,6314,6315],"Leucovorin","5-FU","Irinotecan",{"trials":6317,"activeCount":103},[],{"trials":6319,"activeCount":103},[],{"trials":6321,"activeCount":103},[],{"intervention":6301,"totalTrials":99,"cells":6323},{"EARLY_PHASE1":6324,"PHASE1":6326,"PHASE2":6332,"PHASE3":6345,"PHASE4":6347,"NA":6349},{"trials":6325,"activeCount":103},[],{"trials":6327,"activeCount":103},[6328],{"nctId":6292,"briefTitle":6293,"status":156,"phases":6329,"primaryCompletion":6295,"completion":5411,"start":3319,"enrollment":975,"conditions":6330,"interventions":6331},[91],[1915,6297],[6299,6285,6300,6301],{"trials":6333,"activeCount":103},[6334],{"nctId":6335,"briefTitle":6336,"status":786,"phases":6337,"primaryCompletion":6338,"completion":6339,"start":6340,"enrollment":184,"conditions":6341,"interventions":6343},"NCT03930771","Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas",[92],"2021-08-19","2021-10-01","2019-05-21",[6342],"Recurrent Pituitary Adenomas",[6301,6344],"Temozolomide",{"trials":6346,"activeCount":103},[],{"trials":6348,"activeCount":103},[],{"trials":6350,"activeCount":103},[],{"intervention":6352,"totalTrials":184,"cells":6353},"CC-486 Administration",{"EARLY_PHASE1":6354,"PHASE1":6356,"PHASE2":6358,"PHASE3":6371,"PHASE4":6373,"NA":6375},{"trials":6355,"activeCount":103},[],{"trials":6357,"activeCount":103},[],{"trials":6359,"activeCount":103},[6360],{"nctId":6361,"briefTitle":6362,"status":156,"phases":6363,"primaryCompletion":6364,"completion":6365,"start":6366,"enrollment":1313,"conditions":6367,"interventions":6369},"NCT03542266","CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma",[92],"2020-03-25","2022-07-25","2018-06-01",[6368],"Previously Untreated Peripheral T-cell Lymphoma",[6352,6370],"CHOP Administration",{"trials":6372,"activeCount":103},[],{"trials":6374,"activeCount":103},[],{"trials":6376,"activeCount":103},[],{"intervention":6370,"totalTrials":184,"cells":6378},{"EARLY_PHASE1":6379,"PHASE1":6381,"PHASE2":6383,"PHASE3":6389,"PHASE4":6391,"NA":6393},{"trials":6380,"activeCount":103},[],{"trials":6382,"activeCount":103},[],{"trials":6384,"activeCount":103},[6385],{"nctId":6361,"briefTitle":6362,"status":156,"phases":6386,"primaryCompletion":6364,"completion":6365,"start":6366,"enrollment":1313,"conditions":6387,"interventions":6388},[92],[6368],[6352,6370],{"trials":6390,"activeCount":103},[],{"trials":6392,"activeCount":103},[],{"trials":6394,"activeCount":103},[],{"intervention":6396,"totalTrials":184,"cells":6397},"Cabazitaxel",{"EARLY_PHASE1":6398,"PHASE1":6400,"PHASE2":6402,"PHASE3":6412,"PHASE4":6414,"NA":6416},{"trials":6399,"activeCount":103},[],{"trials":6401,"activeCount":103},[],{"trials":6403,"activeCount":103},[6404],{"nctId":6405,"briefTitle":6406,"status":156,"phases":6407,"primaryCompletion":847,"completion":6253,"start":3383,"enrollment":6408,"conditions":6409,"interventions":6411},"NCT01757171","Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma",[92],85,[779,2244,6410],"Distal Esophageal Adenocarcinoma",[6396],{"trials":6413,"activeCount":103},[],{"trials":6415,"activeCount":103},[],{"trials":6417,"activeCount":103},[],{"intervention":886,"totalTrials":184,"cells":6419},{"EARLY_PHASE1":6420,"PHASE1":6422,"PHASE2":6424,"PHASE3":6430,"PHASE4":6432,"NA":6434},{"trials":6421,"activeCount":103},[],{"trials":6423,"activeCount":103},[],{"trials":6425,"activeCount":103},[6426],{"nctId":875,"briefTitle":876,"status":156,"phases":6427,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":6428,"interventions":6429},[92],[30],[884,885,886,887,888],{"trials":6431,"activeCount":103},[],{"trials":6433,"activeCount":103},[],{"trials":6435,"activeCount":103},[],{"intervention":887,"totalTrials":184,"cells":6437},{"EARLY_PHASE1":6438,"PHASE1":6440,"PHASE2":6442,"PHASE3":6448,"PHASE4":6450,"NA":6452},{"trials":6439,"activeCount":103},[],{"trials":6441,"activeCount":103},[],{"trials":6443,"activeCount":103},[6444],{"nctId":875,"briefTitle":876,"status":156,"phases":6445,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":6446,"interventions":6447},[92],[30],[884,885,886,887,888],{"trials":6449,"activeCount":103},[],{"trials":6451,"activeCount":103},[],{"trials":6453,"activeCount":103},[],{"intervention":888,"totalTrials":184,"cells":6455},{"EARLY_PHASE1":6456,"PHASE1":6458,"PHASE2":6460,"PHASE3":6466,"PHASE4":6468,"NA":6470},{"trials":6457,"activeCount":103},[],{"trials":6459,"activeCount":103},[],{"trials":6461,"activeCount":103},[6462],{"nctId":875,"briefTitle":876,"status":156,"phases":6463,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":6464,"interventions":6465},[92],[30],[884,885,886,887,888],{"trials":6467,"activeCount":103},[],{"trials":6469,"activeCount":103},[],{"trials":6471,"activeCount":103},[],{"intervention":6473,"totalTrials":184,"cells":6474},"AdVEGF-All6A+",{"EARLY_PHASE1":6475,"PHASE1":6477,"PHASE2":6479,"PHASE3":6491,"PHASE4":6493,"NA":6495},{"trials":6476,"activeCount":103},[],{"trials":6478,"activeCount":103},[],{"trials":6480,"activeCount":103},[6481],{"nctId":6482,"briefTitle":6483,"status":494,"phases":6484,"primaryCompletion":6485,"completion":6485,"start":6486,"enrollment":103,"conditions":6487,"interventions":6489},"NCT01757223","Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery",[91,92],"2030-10","2020-12",[6488],"Coronary Artery Disease",[6473,6490],"AdNull",{"trials":6492,"activeCount":103},[],{"trials":6494,"activeCount":103},[],{"trials":6496,"activeCount":103},[],{"intervention":6490,"totalTrials":184,"cells":6498},{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6509,"PHASE4":6511,"NA":6513},{"trials":6500,"activeCount":103},[],{"trials":6502,"activeCount":103},[],{"trials":6504,"activeCount":103},[6505],{"nctId":6482,"briefTitle":6483,"status":494,"phases":6506,"primaryCompletion":6485,"completion":6485,"start":6486,"enrollment":103,"conditions":6507,"interventions":6508},[91,92],[6488],[6473,6490],{"trials":6510,"activeCount":103},[],{"trials":6512,"activeCount":103},[],{"trials":6514,"activeCount":103},[],{"intervention":6516,"totalTrials":184,"cells":6517},"Ubiquinol",{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6531,"PHASE4":6533,"NA":6535},{"trials":6519,"activeCount":103},[],{"trials":6521,"activeCount":103},[],{"trials":6523,"activeCount":103},[6524],{"nctId":6525,"briefTitle":6526,"status":156,"phases":6527,"primaryCompletion":6103,"completion":6103,"start":6528,"enrollment":37,"conditions":6529,"interventions":6530},"NCT03061513","Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers",[92],"2012-02-28",[5482],[6516],{"trials":6532,"activeCount":103},[],{"trials":6534,"activeCount":103},[],{"trials":6536,"activeCount":103},[],{"intervention":6538,"totalTrials":184,"cells":6539},"recombinant interferon alfa",{"EARLY_PHASE1":6540,"PHASE1":6542,"PHASE2":6544,"PHASE3":6554,"PHASE4":6556,"NA":6558},{"trials":6541,"activeCount":103},[],{"trials":6543,"activeCount":103},[],{"trials":6545,"activeCount":103},[6546],{"nctId":6547,"briefTitle":6548,"status":156,"phases":6549,"primaryCompletion":4702,"completion":4702,"start":6550,"enrollment":947,"conditions":6551,"interventions":6552},"NCT00003656","Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer",[92],"1999-01",[1974],[6538,6553],"tretinoin liposome",{"trials":6555,"activeCount":103},[],{"trials":6557,"activeCount":103},[],{"trials":6559,"activeCount":103},[],{"intervention":6553,"totalTrials":184,"cells":6561},{"EARLY_PHASE1":6562,"PHASE1":6564,"PHASE2":6566,"PHASE3":6572,"PHASE4":6574,"NA":6576},{"trials":6563,"activeCount":103},[],{"trials":6565,"activeCount":103},[],{"trials":6567,"activeCount":103},[6568],{"nctId":6547,"briefTitle":6548,"status":156,"phases":6569,"primaryCompletion":4702,"completion":4702,"start":6550,"enrollment":947,"conditions":6570,"interventions":6571},[92],[1974],[6538,6553],{"trials":6573,"activeCount":103},[],{"trials":6575,"activeCount":103},[],{"trials":6577,"activeCount":103},[],{"intervention":6579,"totalTrials":184,"cells":6580},"Nilotinib",{"EARLY_PHASE1":6581,"PHASE1":6583,"PHASE2":6585,"PHASE3":6596,"PHASE4":6598,"NA":6600},{"trials":6582,"activeCount":103},[],{"trials":6584,"activeCount":103},[],{"trials":6586,"activeCount":103},[6587],{"nctId":6588,"briefTitle":6589,"status":156,"phases":6590,"primaryCompletion":6591,"completion":6591,"start":6592,"enrollment":825,"conditions":6593,"interventions":6595},"NCT02353728","Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy",[92],"2021-02","2015-01",[6594],"Chronic Myeloid Leukemia",[6579],{"trials":6597,"activeCount":103},[],{"trials":6599,"activeCount":103},[],{"trials":6601,"activeCount":103},[],{"intervention":6603,"totalTrials":184,"cells":6604},"aldesleukin",{"EARLY_PHASE1":6605,"PHASE1":6607,"PHASE2":6609,"PHASE3":6620,"PHASE4":6622,"NA":6624},{"trials":6606,"activeCount":103},[],{"trials":6608,"activeCount":103},[],{"trials":6610,"activeCount":103},[6611],{"nctId":6612,"briefTitle":6613,"status":2883,"phases":6614,"start":6615,"conditions":6616,"interventions":6618},"NCT00003067","Biological Therapy in Treating Patients With Primary or Advanced Glioma",[92],"1997-07",[6617],"Brain and Central Nervous System Tumors",[6603,6619],"lymphokine-activated killer cells",{"trials":6621,"activeCount":103},[],{"trials":6623,"activeCount":103},[],{"trials":6625,"activeCount":103},[],{"intervention":6619,"totalTrials":184,"cells":6627},{"EARLY_PHASE1":6628,"PHASE1":6630,"PHASE2":6632,"PHASE3":6638,"PHASE4":6640,"NA":6642},{"trials":6629,"activeCount":103},[],{"trials":6631,"activeCount":103},[],{"trials":6633,"activeCount":103},[6634],{"nctId":6612,"briefTitle":6613,"status":2883,"phases":6635,"start":6615,"conditions":6636,"interventions":6637},[92],[6617],[6603,6619],{"trials":6639,"activeCount":103},[],{"trials":6641,"activeCount":103},[],{"trials":6643,"activeCount":103},[],{"intervention":6645,"totalTrials":184,"cells":6646},"Clomiphene citrate",{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6664,"PHASE4":6666,"NA":6668},{"trials":6648,"activeCount":103},[],{"trials":6650,"activeCount":103},[],{"trials":6652,"activeCount":103},[6653],{"nctId":6654,"briefTitle":6655,"status":156,"phases":6656,"primaryCompletion":6657,"completion":6658,"start":6659,"enrollment":34,"conditions":6660,"interventions":6663},"NCT01880086","Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration",[92],"2016-03","2017-11","2013-08",[6661,6662,4244],"Hypogonadism","Opioid-Related Disorders",[6645],{"trials":6665,"activeCount":103},[],{"trials":6667,"activeCount":103},[],{"trials":6669,"activeCount":103},[],{"intervention":6671,"totalTrials":184,"cells":6672},"Vosaroxin",{"EARLY_PHASE1":6673,"PHASE1":6675,"PHASE2":6677,"PHASE3":6687,"PHASE4":6689,"NA":6691},{"trials":6674,"activeCount":103},[],{"trials":6676,"activeCount":103},[],{"trials":6678,"activeCount":103},[6679],{"nctId":6680,"briefTitle":6681,"status":156,"phases":6682,"primaryCompletion":6683,"completion":6683,"start":6684,"enrollment":1236,"conditions":6685,"interventions":6686},"NCT01980056","Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy",[91,92],"2015-01-19","2013-10-25",[1196],[6671],{"trials":6688,"activeCount":103},[],{"trials":6690,"activeCount":103},[],{"trials":6692,"activeCount":103},[],{"intervention":6694,"totalTrials":184,"cells":6695},"Ibrutinib",{"EARLY_PHASE1":6696,"PHASE1":6698,"PHASE2":6700,"PHASE3":6717,"PHASE4":6719,"NA":6721},{"trials":6697,"activeCount":103},[],{"trials":6699,"activeCount":103},[],{"trials":6701,"activeCount":103},[6702],{"nctId":6703,"briefTitle":6704,"status":786,"phases":6705,"primaryCompletion":6706,"completion":809,"start":6707,"enrollment":184,"conditions":6708,"interventions":6715},"NCT03679624","Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia",[92],"2020-09-15","2020-07-30",[1055,6709,6710,6711,6712,6713,6714],"Waldenstrom's Disease","Waldenström; Hypergammaglobulinemia","Waldenstrom's Macroglobulinemia Recurrent","Waldenstrom's Macroglobulinemia of Lymph Nodes","Waldenstrom's Macroglobulinaemia, Without Mention of Remission","Waldenstrom's Macroglobulinemia Refractory",[6694,6716],"Daratumumab",{"trials":6718,"activeCount":103},[],{"trials":6720,"activeCount":103},[],{"trials":6722,"activeCount":103},[],{"intervention":6716,"totalTrials":184,"cells":6724},{"EARLY_PHASE1":6725,"PHASE1":6727,"PHASE2":6729,"PHASE3":6735,"PHASE4":6737,"NA":6739},{"trials":6726,"activeCount":103},[],{"trials":6728,"activeCount":103},[],{"trials":6730,"activeCount":103},[6731],{"nctId":6703,"briefTitle":6704,"status":786,"phases":6732,"primaryCompletion":6706,"completion":809,"start":6707,"enrollment":184,"conditions":6733,"interventions":6734},[92],[1055,6709,6710,6711,6712,6713,6714],[6694,6716],{"trials":6736,"activeCount":103},[],{"trials":6738,"activeCount":103},[],{"trials":6740,"activeCount":103},[],{"intervention":6742,"totalTrials":184,"cells":6743},"Bortezomib, CHOP, Rituximab",{"EARLY_PHASE1":6744,"PHASE1":6746,"PHASE2":6748,"PHASE3":6759,"PHASE4":6761,"NA":6763},{"trials":6745,"activeCount":103},[],{"trials":6747,"activeCount":103},[],{"trials":6749,"activeCount":103},[6750],{"nctId":6751,"briefTitle":6752,"status":156,"phases":6753,"primaryCompletion":6754,"completion":6755,"start":531,"enrollment":6756,"conditions":6757,"interventions":6758},"NCT00151320","Phase I\u002FII Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL",[91,92],"2010-04","2013-04-24",76,[1126],[6742],{"trials":6760,"activeCount":103},[],{"trials":6762,"activeCount":103},[],{"trials":6764,"activeCount":103},[],{"intervention":6766,"totalTrials":184,"cells":6767},"SGI-110",{"EARLY_PHASE1":6768,"PHASE1":6770,"PHASE2":6772,"PHASE3":6783,"PHASE4":6785,"NA":6787},{"trials":6769,"activeCount":103},[],{"trials":6771,"activeCount":103},[],{"trials":6773,"activeCount":103},[6774],{"nctId":6775,"briefTitle":6776,"status":156,"phases":6777,"primaryCompletion":6778,"completion":6778,"start":6779,"enrollment":860,"conditions":6780,"interventions":6782},"NCT03075826","A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms",[92],"2021-03-31","2016-03-15",[6781],"Myeloproliferative Neoplasms",[6766],{"trials":6784,"activeCount":103},[],{"trials":6786,"activeCount":103},[],{"trials":6788,"activeCount":103},[],{"intervention":6790,"totalTrials":184,"cells":6791},"AAVrh.10CUCLN2",{"EARLY_PHASE1":6792,"PHASE1":6794,"PHASE2":6796,"PHASE3":6808,"PHASE4":6810,"NA":6812},{"trials":6793,"activeCount":103},[],{"trials":6795,"activeCount":103},[],{"trials":6797,"activeCount":103},[6798],{"nctId":6799,"briefTitle":6800,"status":156,"phases":6801,"primaryCompletion":6802,"completion":2027,"start":6803,"enrollment":722,"conditions":6804,"interventions":6807},"NCT01414985","AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis",[91,92],"2015-11-30","2010-04-15",[6805,6806],"Late Infantile Neuronal Ceroid Lipofuscinosis","Batten Disease",[6790],{"trials":6809,"activeCount":103},[],{"trials":6811,"activeCount":103},[],{"trials":6813,"activeCount":103},[],{"intervention":6815,"totalTrials":184,"cells":6816},"68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron",{"EARLY_PHASE1":6817,"PHASE1":6819,"PHASE2":6821,"PHASE3":6831,"PHASE4":6833,"NA":6835},{"trials":6818,"activeCount":103},[],{"trials":6820,"activeCount":103},[],{"trials":6822,"activeCount":103},[6823],{"nctId":6824,"briefTitle":6825,"status":156,"phases":6826,"primaryCompletion":1381,"completion":1381,"start":6827,"enrollment":825,"conditions":6828,"interventions":6830},"NCT04685811","Evaluation of PSMA Antagonist Produced by Two Different Methods",[91,92],"2020-12-09",[6829],"Metastatic Prostate Adenocarcinoma",[6815],{"trials":6832,"activeCount":103},[],{"trials":6834,"activeCount":103},[],{"trials":6836,"activeCount":103},[],{"intervention":5695,"totalTrials":184,"cells":6838},{"EARLY_PHASE1":6839,"PHASE1":6841,"PHASE2":6843,"PHASE3":6849,"PHASE4":6851,"NA":6853},{"trials":6840,"activeCount":103},[],{"trials":6842,"activeCount":103},[],{"trials":6844,"activeCount":103},[6845],{"nctId":5689,"briefTitle":5690,"status":156,"phases":6846,"primaryCompletion":5692,"completion":1792,"start":3362,"enrollment":2179,"conditions":6847,"interventions":6848},[92],[5223,1196],[5695,1130],{"trials":6850,"activeCount":103},[],{"trials":6852,"activeCount":103},[],{"trials":6854,"activeCount":103},[],{"intervention":6856,"totalTrials":184,"cells":6857},"PET\u002FMRI with Gallium-68 labeled PSMA-HBED-CC",{"EARLY_PHASE1":6858,"PHASE1":6860,"PHASE2":6862,"PHASE3":6875,"PHASE4":6877,"NA":6879},{"trials":6859,"activeCount":103},[],{"trials":6861,"activeCount":103},[],{"trials":6863,"activeCount":103},[6864],{"nctId":6865,"briefTitle":6866,"status":786,"phases":6867,"primaryCompletion":6868,"completion":6868,"start":6869,"enrollment":6870,"conditions":6871,"interventions":6872},"NCT03439033","Comparison Study of PET\u002FCT or PET\u002FMRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer",[92],"2021-05-05","2018-04-03",273,[18],[6856,6873,6874],"Multiple PET\u002FMRI with Gallium-68 labeled PSMA-HBED-CC","PET\u002FCT with Gallium-68 labeled PSMA-HBED-CC",{"trials":6876,"activeCount":103},[],{"trials":6878,"activeCount":103},[],{"trials":6880,"activeCount":103},[],{"intervention":6873,"totalTrials":184,"cells":6882},{"EARLY_PHASE1":6883,"PHASE1":6885,"PHASE2":6887,"PHASE3":6893,"PHASE4":6895,"NA":6897},{"trials":6884,"activeCount":103},[],{"trials":6886,"activeCount":103},[],{"trials":6888,"activeCount":103},[6889],{"nctId":6865,"briefTitle":6866,"status":786,"phases":6890,"primaryCompletion":6868,"completion":6868,"start":6869,"enrollment":6870,"conditions":6891,"interventions":6892},[92],[18],[6856,6873,6874],{"trials":6894,"activeCount":103},[],{"trials":6896,"activeCount":103},[],{"trials":6898,"activeCount":103},[],{"intervention":6874,"totalTrials":184,"cells":6900},{"EARLY_PHASE1":6901,"PHASE1":6903,"PHASE2":6905,"PHASE3":6911,"PHASE4":6913,"NA":6915},{"trials":6902,"activeCount":103},[],{"trials":6904,"activeCount":103},[],{"trials":6906,"activeCount":103},[6907],{"nctId":6865,"briefTitle":6866,"status":786,"phases":6908,"primaryCompletion":6868,"completion":6868,"start":6869,"enrollment":6870,"conditions":6909,"interventions":6910},[92],[18],[6856,6873,6874],{"trials":6912,"activeCount":103},[],{"trials":6914,"activeCount":103},[],{"trials":6916,"activeCount":103},[],{"intervention":6918,"totalTrials":184,"cells":6919},"Vactosertib",{"EARLY_PHASE1":6920,"PHASE1":6922,"PHASE2":6924,"PHASE3":6935,"PHASE4":6937,"NA":6939},{"trials":6921,"activeCount":103},[],{"trials":6923,"activeCount":103},[],{"trials":6925,"activeCount":103},[6926],{"nctId":6927,"briefTitle":6928,"status":786,"phases":6929,"primaryCompletion":6930,"completion":6930,"start":6931,"enrollment":99,"conditions":6932,"interventions":6934},"NCT04103645","Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients",[92],"2024-07-10","2019-11-22",[6933],"Myeloproliferative Neoplasm",[6918,6918,6918,6918,6918],{"trials":6936,"activeCount":103},[],{"trials":6938,"activeCount":103},[],{"trials":6940,"activeCount":103},[],{"intervention":6942,"totalTrials":184,"cells":6943},"Tarceva",{"EARLY_PHASE1":6944,"PHASE1":6946,"PHASE2":6948,"PHASE3":6958,"PHASE4":6960,"NA":6962},{"trials":6945,"activeCount":103},[],{"trials":6947,"activeCount":103},[],{"trials":6949,"activeCount":103},[6950],{"nctId":6951,"briefTitle":6952,"status":156,"phases":6953,"primaryCompletion":6954,"completion":3493,"start":4387,"enrollment":860,"conditions":6955,"interventions":6957},"NCT00385996","Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I\u002FII Non-Small Cell Lung Cancer",[92],"2008-11",[6956],"Carcinoma, Non-small Cell Lung",[6942],{"trials":6959,"activeCount":103},[],{"trials":6961,"activeCount":103},[],{"trials":6963,"activeCount":103},[],{"intervention":1068,"totalTrials":184,"cells":6965},{"EARLY_PHASE1":6966,"PHASE1":6968,"PHASE2":6970,"PHASE3":6976,"PHASE4":6978,"NA":6980},{"trials":6967,"activeCount":103},[],{"trials":6969,"activeCount":103},[],{"trials":6971,"activeCount":103},[6972],{"nctId":1059,"briefTitle":1060,"status":156,"phases":6973,"primaryCompletion":1062,"completion":974,"start":1063,"enrollment":31,"conditions":6974,"interventions":6975},[91,92],[1065],[1038,1067,1068,1069,1070,1071],{"trials":6977,"activeCount":103},[],{"trials":6979,"activeCount":103},[],{"trials":6981,"activeCount":103},[],{"intervention":1069,"totalTrials":184,"cells":6983},{"EARLY_PHASE1":6984,"PHASE1":6986,"PHASE2":6988,"PHASE3":6994,"PHASE4":6996,"NA":6998},{"trials":6985,"activeCount":103},[],{"trials":6987,"activeCount":103},[],{"trials":6989,"activeCount":103},[6990],{"nctId":1059,"briefTitle":1060,"status":156,"phases":6991,"primaryCompletion":1062,"completion":974,"start":1063,"enrollment":31,"conditions":6992,"interventions":6993},[91,92],[1065],[1038,1067,1068,1069,1070,1071],{"trials":6995,"activeCount":103},[],{"trials":6997,"activeCount":103},[],{"trials":6999,"activeCount":103},[],{"intervention":7001,"totalTrials":184,"cells":7002},"Toclizumab",{"EARLY_PHASE1":7003,"PHASE1":7005,"PHASE2":7007,"PHASE3":7018,"PHASE4":7020,"NA":7022},{"trials":7004,"activeCount":103},[],{"trials":7006,"activeCount":103},[],{"trials":7008,"activeCount":103},[7009],{"nctId":7010,"briefTitle":7011,"status":786,"phases":7012,"primaryCompletion":7013,"completion":7013,"start":7014,"enrollment":99,"conditions":7015,"interventions":7017},"NCT01757197","Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)",[92],"2014-06-17","2013-11-07",[7016],"Glucocorticosteroid Refractory Acute GVHD",[7001],{"trials":7019,"activeCount":103},[],{"trials":7021,"activeCount":103},[],{"trials":7023,"activeCount":103},[],{"intervention":7025,"totalTrials":184,"cells":7026},"Nivolumab 240mg",{"EARLY_PHASE1":7027,"PHASE1":7029,"PHASE2":7031,"PHASE3":7042,"PHASE4":7044,"NA":7046},{"trials":7028,"activeCount":103},[],{"trials":7030,"activeCount":103},[],{"trials":7032,"activeCount":103},[7033],{"nctId":7034,"briefTitle":7035,"status":786,"phases":7036,"primaryCompletion":7037,"completion":7038,"start":7039,"enrollment":811,"conditions":7040,"interventions":7041},"NCT03634800","Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)",[92],"2020-01-09","2020-01-16","2018-10-23",[30],[7025],{"trials":7043,"activeCount":103},[],{"trials":7045,"activeCount":103},[],{"trials":7047,"activeCount":103},[],{"intervention":6054,"totalTrials":184,"cells":7049},{"EARLY_PHASE1":7050,"PHASE1":7052,"PHASE2":7054,"PHASE3":7060,"PHASE4":7062,"NA":7064},{"trials":7051,"activeCount":103},[],{"trials":7053,"activeCount":103},[],{"trials":7055,"activeCount":103},[7056],{"nctId":6046,"briefTitle":6047,"status":786,"phases":7057,"primaryCompletion":6049,"completion":6049,"start":6050,"enrollment":28,"conditions":7058,"interventions":7059},[91,92],[6052],[6054,816],{"trials":7061,"activeCount":103},[],{"trials":7063,"activeCount":103},[],{"trials":7065,"activeCount":103},[],{"intervention":7067,"totalTrials":184,"cells":7068},"Promacta",{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7073,"PHASE3":7083,"PHASE4":7085,"NA":7087},{"trials":7070,"activeCount":103},[],{"trials":7072,"activeCount":103},[],{"trials":7074,"activeCount":103},[7075],{"nctId":7076,"briefTitle":7077,"status":786,"phases":7078,"primaryCompletion":7079,"completion":2940,"start":1993,"enrollment":1737,"conditions":7080,"interventions":7082},"NCT00909363","Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients",[92],"2017-05-15",[7081,2836,4662],"Wiskott-Aldrich Syndrome",[7067],{"trials":7084,"activeCount":103},[],{"trials":7086,"activeCount":103},[],{"trials":7088,"activeCount":103},[],{"intervention":6002,"totalTrials":184,"cells":7090},{"EARLY_PHASE1":7091,"PHASE1":7093,"PHASE2":7095,"PHASE3":7101,"PHASE4":7103,"NA":7105},{"trials":7092,"activeCount":103},[],{"trials":7094,"activeCount":103},[],{"trials":7096,"activeCount":103},[7097],{"nctId":5995,"briefTitle":5996,"status":786,"phases":7098,"completion":3718,"start":5998,"enrollment":5999,"conditions":7099,"interventions":7100},[91,92],[1975],[6002,1894],{"trials":7102,"activeCount":103},[],{"trials":7104,"activeCount":103},[],{"trials":7106,"activeCount":103},[],{"intervention":7108,"totalTrials":184,"cells":7109},"ORG 34517",{"EARLY_PHASE1":7110,"PHASE1":7112,"PHASE2":7114,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7111,"activeCount":103},[],{"trials":7113,"activeCount":103},[],{"trials":7115,"activeCount":103},[7116],{"nctId":7117,"briefTitle":7118,"status":156,"phases":7119,"primaryCompletion":1044,"completion":1044,"start":7120,"enrollment":532,"conditions":7121,"interventions":7124},"NCT00226278","Safety Study of ORG 34517 for Major Depression With Psychotic Features",[92],"2004-09",[7122,7123],"Major Depressive Disorder","Psychotic Disorders",[7108],{"trials":7126,"activeCount":103},[],{"trials":7128,"activeCount":103},[],{"trials":7130,"activeCount":103},[],{"intervention":7132,"totalTrials":184,"cells":7133},"Fresolimumab",{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7138,"PHASE3":7146,"PHASE4":7148,"NA":7150},{"trials":7135,"activeCount":103},[],{"trials":7137,"activeCount":103},[],{"trials":7139,"activeCount":103},[7140],{"nctId":7141,"briefTitle":7142,"status":156,"phases":7143,"primaryCompletion":5147,"completion":5147,"start":1076,"enrollment":1703,"conditions":7144,"interventions":7145},"NCT01401062","Fresolimumab and Radiotherapy in Metastatic Breast Cancer",[92],[768],[7132],{"trials":7147,"activeCount":103},[],{"trials":7149,"activeCount":103},[],{"trials":7151,"activeCount":103},[],{"intervention":1198,"totalTrials":184,"cells":7153},{"EARLY_PHASE1":7154,"PHASE1":7156,"PHASE2":7158,"PHASE3":7164,"PHASE4":7166,"NA":7168},{"trials":7155,"activeCount":103},[],{"trials":7157,"activeCount":103},[],{"trials":7159,"activeCount":103},[7160],{"nctId":1190,"briefTitle":1191,"status":786,"phases":7161,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":811,"conditions":7162,"interventions":7163},[92],[1196],[58,1198],{"trials":7165,"activeCount":103},[],{"trials":7167,"activeCount":103},[],{"trials":7169,"activeCount":103},[],{"intervention":7171,"totalTrials":184,"cells":7172},"haplo-identical cells",{"EARLY_PHASE1":7173,"PHASE1":7175,"PHASE2":7177,"PHASE3":7188,"PHASE4":7190,"NA":7192},{"trials":7174,"activeCount":103},[],{"trials":7176,"activeCount":103},[],{"trials":7178,"activeCount":103},[7179],{"nctId":7180,"briefTitle":7181,"status":786,"phases":7182,"primaryCompletion":7183,"completion":7183,"start":7184,"enrollment":2179,"conditions":7185,"interventions":7186},"NCT02508324","IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia",[92],"2022-06-24","2015-09-10",[5223,1196],[7171,7187],"umbilical cord blood unit",{"trials":7189,"activeCount":103},[],{"trials":7191,"activeCount":103},[],{"trials":7193,"activeCount":103},[],{"intervention":7187,"totalTrials":184,"cells":7195},{"EARLY_PHASE1":7196,"PHASE1":7198,"PHASE2":7200,"PHASE3":7206,"PHASE4":7208,"NA":7210},{"trials":7197,"activeCount":103},[],{"trials":7199,"activeCount":103},[],{"trials":7201,"activeCount":103},[7202],{"nctId":7180,"briefTitle":7181,"status":786,"phases":7203,"primaryCompletion":7183,"completion":7183,"start":7184,"enrollment":2179,"conditions":7204,"interventions":7205},[92],[5223,1196],[7171,7187],{"trials":7207,"activeCount":103},[],{"trials":7209,"activeCount":103},[],{"trials":7211,"activeCount":103},[],{"intervention":1082,"totalTrials":184,"cells":7213},{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7218,"PHASE3":7224,"PHASE4":7226,"NA":7228},{"trials":7215,"activeCount":103},[],{"trials":7217,"activeCount":103},[],{"trials":7219,"activeCount":103},[7220],{"nctId":1073,"briefTitle":1074,"status":156,"phases":7221,"primaryCompletion":1076,"completion":916,"start":1077,"enrollment":37,"conditions":7222,"interventions":7223},[92],[1079],[1081,865,1082],{"trials":7225,"activeCount":103},[],{"trials":7227,"activeCount":103},[],{"trials":7229,"activeCount":103},[],{"intervention":7231,"totalTrials":184,"cells":7232},"Deferoxamine",{"EARLY_PHASE1":7233,"PHASE1":7235,"PHASE2":7237,"PHASE3":7247,"PHASE4":7249,"NA":7251},{"trials":7234,"activeCount":103},[],{"trials":7236,"activeCount":103},[],{"trials":7238,"activeCount":103},[7239],{"nctId":7240,"briefTitle":7241,"status":3381,"phases":7242,"primaryCompletion":3583,"completion":1138,"start":1804,"enrollment":811,"conditions":7243,"interventions":7245},"NCT00738413","Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both",[91,92],[7244],"Thalassemia",[7231,7246],"Deferasirox",{"trials":7248,"activeCount":103},[],{"trials":7250,"activeCount":103},[],{"trials":7252,"activeCount":103},[],{"intervention":7246,"totalTrials":184,"cells":7254},{"EARLY_PHASE1":7255,"PHASE1":7257,"PHASE2":7259,"PHASE3":7265,"PHASE4":7267,"NA":7269},{"trials":7256,"activeCount":103},[],{"trials":7258,"activeCount":103},[],{"trials":7260,"activeCount":103},[7261],{"nctId":7240,"briefTitle":7241,"status":3381,"phases":7262,"primaryCompletion":3583,"completion":1138,"start":1804,"enrollment":811,"conditions":7263,"interventions":7264},[91,92],[7244],[7231,7246],{"trials":7266,"activeCount":103},[],{"trials":7268,"activeCount":103},[],{"trials":7270,"activeCount":103},[],{"intervention":6164,"totalTrials":184,"cells":7272},{"EARLY_PHASE1":7273,"PHASE1":7275,"PHASE2":7277,"PHASE3":7283,"PHASE4":7285,"NA":7287},{"trials":7274,"activeCount":103},[],{"trials":7276,"activeCount":103},[],{"trials":7278,"activeCount":103},[7279],{"nctId":6158,"briefTitle":6159,"status":156,"phases":7280,"primaryCompletion":6161,"completion":6161,"start":4746,"enrollment":22,"conditions":7281,"interventions":7282},[92],[984],[6149,6164],{"trials":7284,"activeCount":103},[],{"trials":7286,"activeCount":103},[],{"trials":7288,"activeCount":103},[],{"intervention":1304,"totalTrials":184,"cells":7290},{"EARLY_PHASE1":7291,"PHASE1":7293,"PHASE2":7295,"PHASE3":7301,"PHASE4":7303,"NA":7305},{"trials":7292,"activeCount":103},[],{"trials":7294,"activeCount":103},[],{"trials":7296,"activeCount":103},[7297],{"nctId":1295,"briefTitle":1296,"status":786,"phases":7298,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":99,"conditions":7299,"interventions":7300},[92],[1301,1196,1302,1125,1126],[73,1090,1304],{"trials":7302,"activeCount":103},[],{"trials":7304,"activeCount":103},[],{"trials":7306,"activeCount":103},[],{"intervention":3426,"totalTrials":184,"cells":7308},{"EARLY_PHASE1":7309,"PHASE1":7311,"PHASE2":7313,"PHASE3":7319,"PHASE4":7321,"NA":7323},{"trials":7310,"activeCount":103},[],{"trials":7312,"activeCount":103},[],{"trials":7314,"activeCount":103},[7315],{"nctId":3415,"briefTitle":3416,"status":156,"phases":7316,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":3420,"conditions":7317,"interventions":7318},[92],[3422,3423,3424],[3426,3406],{"trials":7320,"activeCount":103},[],{"trials":7322,"activeCount":103},[],{"trials":7324,"activeCount":103},[],{"intervention":7326,"totalTrials":184,"cells":7327},"Rimegepant",{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7332,"PHASE3":7343,"PHASE4":7345,"NA":7347},{"trials":7329,"activeCount":103},[],{"trials":7331,"activeCount":103},[],{"trials":7333,"activeCount":103},[7334],{"nctId":7335,"briefTitle":7336,"status":156,"phases":7337,"primaryCompletion":7338,"completion":374,"start":7339,"enrollment":766,"conditions":7340,"interventions":7342},"NCT04629950","Rimegepant in Moderate Plaque-type Psoriasis",[92],"2024-08-20","2021-01-19",[7341],"Psoriasis",[7326],{"trials":7344,"activeCount":103},[],{"trials":7346,"activeCount":103},[],{"trials":7348,"activeCount":103},[],{"intervention":7350,"totalTrials":184,"cells":7351},"alpha-lipoic acid and L-acetyl carnitine",{"EARLY_PHASE1":7352,"PHASE1":7354,"PHASE2":7356,"PHASE3":7368,"PHASE4":7370,"NA":7372},{"trials":7353,"activeCount":103},[],{"trials":7355,"activeCount":103},[],{"trials":7357,"activeCount":103},[7358],{"nctId":7359,"briefTitle":7360,"status":156,"phases":7361,"primaryCompletion":7362,"completion":7363,"start":7364,"enrollment":37,"conditions":7365,"interventions":7367},"NCT01537549","Alpha-lipoic Acid\u002FL-acetyl Carnitine for Progressive Supranuclear Palsy",[91,92],"2013-09-24","2015-04-07","2010-09-14",[7366],"Progressive Supranuclear Palsy",[7350],{"trials":7369,"activeCount":103},[],{"trials":7371,"activeCount":103},[],{"trials":7373,"activeCount":103},[],{"intervention":919,"totalTrials":184,"cells":7375},{"EARLY_PHASE1":7376,"PHASE1":7378,"PHASE2":7380,"PHASE3":7386,"PHASE4":7388,"NA":7390},{"trials":7377,"activeCount":103},[],{"trials":7379,"activeCount":103},[],{"trials":7381,"activeCount":103},[7382],{"nctId":912,"briefTitle":913,"status":786,"phases":7383,"primaryCompletion":915,"completion":915,"start":916,"enrollment":896,"conditions":7384,"interventions":7385},[91,92],[30],[919,920,504],{"trials":7387,"activeCount":103},[],{"trials":7389,"activeCount":103},[],{"trials":7391,"activeCount":103},[],{"intervention":7393,"totalTrials":184,"cells":7394},"(11C)PE2I",{"EARLY_PHASE1":7395,"PHASE1":7397,"PHASE2":7399,"PHASE3":7412,"PHASE4":7414,"NA":7416},{"trials":7396,"activeCount":103},[],{"trials":7398,"activeCount":103},[],{"trials":7400,"activeCount":103},[7401],{"nctId":7402,"briefTitle":7403,"status":156,"phases":7404,"primaryCompletion":7405,"completion":7405,"start":7406,"enrollment":7407,"conditions":7408,"interventions":7410},"NCT03675282","Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls",[91,92],"2024-04-23","2018-08-14",82,[5482,7409,3646],"REM Sleep Behavior Disorder",[7393,7411],"Ioflupane",{"trials":7413,"activeCount":103},[],{"trials":7415,"activeCount":103},[],{"trials":7417,"activeCount":103},[],{"intervention":7411,"totalTrials":184,"cells":7419},{"EARLY_PHASE1":7420,"PHASE1":7422,"PHASE2":7424,"PHASE3":7430,"PHASE4":7432,"NA":7434},{"trials":7421,"activeCount":103},[],{"trials":7423,"activeCount":103},[],{"trials":7425,"activeCount":103},[7426],{"nctId":7402,"briefTitle":7403,"status":156,"phases":7427,"primaryCompletion":7405,"completion":7405,"start":7406,"enrollment":7407,"conditions":7428,"interventions":7429},[91,92],[5482,7409,3646],[7393,7411],{"trials":7431,"activeCount":103},[],{"trials":7433,"activeCount":103},[],{"trials":7435,"activeCount":103},[],{"intervention":7437,"totalTrials":184,"cells":7438},"N-acetylcysteine",{"EARLY_PHASE1":7439,"PHASE1":7441,"PHASE2":7443,"PHASE3":7451,"PHASE4":7453,"NA":7455},{"trials":7440,"activeCount":103},[],{"trials":7442,"activeCount":103},[],{"trials":7444,"activeCount":103},[7445],{"nctId":7446,"briefTitle":7447,"status":156,"phases":7448,"primaryCompletion":2876,"completion":2876,"start":4745,"enrollment":1583,"conditions":7449,"interventions":7450},"NCT01470027","N-Acetylcysteine for Neuroprotection in Parkinson's Disease",[91,92],[5482],[7437],{"trials":7452,"activeCount":103},[],{"trials":7454,"activeCount":103},[],{"trials":7456,"activeCount":103},[],{"intervention":2030,"totalTrials":184,"cells":7458},{"EARLY_PHASE1":7459,"PHASE1":7461,"PHASE2":7463,"PHASE3":7469,"PHASE4":7471,"NA":7473},{"trials":7460,"activeCount":103},[],{"trials":7462,"activeCount":103},[],{"trials":7464,"activeCount":103},[7465],{"nctId":2023,"briefTitle":2024,"status":156,"phases":7466,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":22,"conditions":7467,"interventions":7468},[92],[18],[2030,1586],{"trials":7470,"activeCount":103},[],{"trials":7472,"activeCount":103},[],{"trials":7474,"activeCount":103},[],{"intervention":7476,"totalTrials":184,"cells":7477},"Duloxetine",{"EARLY_PHASE1":7478,"PHASE1":7480,"PHASE2":7482,"PHASE3":7493,"PHASE4":7495,"NA":7497},{"trials":7479,"activeCount":103},[],{"trials":7481,"activeCount":103},[],{"trials":7483,"activeCount":103},[7484],{"nctId":7485,"briefTitle":7486,"status":156,"phases":7487,"primaryCompletion":5591,"completion":5591,"start":7488,"enrollment":7489,"conditions":7490,"interventions":7492},"NCT03038867","Impact of Duloxetine on Male Fertility",[92],"2016-12-12",69,[7491,15],"Infertility, Male",[7476],{"trials":7494,"activeCount":103},[],{"trials":7496,"activeCount":103},[],{"trials":7498,"activeCount":103},[],{"intervention":5706,"totalTrials":184,"cells":7500},{"EARLY_PHASE1":7501,"PHASE1":7503,"PHASE2":7505,"PHASE3":7511,"PHASE4":7513,"NA":7515},{"trials":7502,"activeCount":103},[],{"trials":7504,"activeCount":103},[],{"trials":7506,"activeCount":103},[7507],{"nctId":5697,"briefTitle":5698,"status":786,"phases":7508,"primaryCompletion":5700,"completion":5701,"start":5702,"enrollment":34,"conditions":7509,"interventions":7510},[92],[5704],[5706,5707,1130],{"trials":7512,"activeCount":103},[],{"trials":7514,"activeCount":103},[],{"trials":7516,"activeCount":103},[],{"intervention":7518,"totalTrials":184,"cells":7519},"AdcuCD40L",{"EARLY_PHASE1":7520,"PHASE1":7522,"PHASE2":7524,"PHASE3":7533,"PHASE4":7535,"NA":7537},{"trials":7521,"activeCount":103},[],{"trials":7523,"activeCount":103},[],{"trials":7525,"activeCount":103},[7526],{"nctId":7527,"briefTitle":7528,"status":494,"phases":7529,"primaryCompletion":1076,"completion":1076,"start":1076,"enrollment":103,"conditions":7530,"interventions":7532},"NCT00504322","Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma",[91,92],[7531],"Esophageal Neoplasms",[7518],{"trials":7534,"activeCount":103},[],{"trials":7536,"activeCount":103},[],{"trials":7538,"activeCount":103},[],{"intervention":7540,"totalTrials":184,"cells":7541},"Indigo carmine",{"EARLY_PHASE1":7542,"PHASE1":7544,"PHASE2":7546,"PHASE3":7555,"PHASE4":7557,"NA":7559},{"trials":7543,"activeCount":103},[],{"trials":7545,"activeCount":103},[],{"trials":7547,"activeCount":103},[7548],{"nctId":7549,"briefTitle":7550,"status":156,"phases":7551,"primaryCompletion":1032,"completion":993,"start":1264,"enrollment":1236,"conditions":7552,"interventions":7554},"NCT01767415","Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection",[91,92],[7553],"Brain Tumors With Ill-defined Margins",[7540],{"trials":7556,"activeCount":103},[],{"trials":7558,"activeCount":103},[],{"trials":7560,"activeCount":103},[],{"intervention":7562,"totalTrials":184,"cells":7563},"Telomelysin",{"EARLY_PHASE1":7564,"PHASE1":7566,"PHASE2":7568,"PHASE3":7580,"PHASE4":7582,"NA":7584},{"trials":7565,"activeCount":103},[],{"trials":7567,"activeCount":103},[],{"trials":7569,"activeCount":103},[7570],{"nctId":7571,"briefTitle":7572,"status":156,"phases":7573,"primaryCompletion":7574,"completion":7575,"start":7576,"enrollment":3785,"conditions":7577,"interventions":7579},"NCT03921021","Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma",[92],"2023-06-20","2023-07-20","2019-05-09",[7578],"Esophagogastric Adenocarcinoma",[7562],{"trials":7581,"activeCount":103},[],{"trials":7583,"activeCount":103},[],{"trials":7585,"activeCount":103},[],{"intervention":7587,"totalTrials":184,"cells":7588},"Tosedostat",{"EARLY_PHASE1":7589,"PHASE1":7591,"PHASE2":7593,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7590,"activeCount":103},[],{"trials":7592,"activeCount":103},[],{"trials":7594,"activeCount":103},[7595],{"nctId":7596,"briefTitle":7597,"status":156,"phases":7598,"primaryCompletion":7599,"completion":7599,"start":7600,"enrollment":975,"conditions":7601,"interventions":7602},"NCT02452346","Study of Clinical Efficacy and Safety of Tosedostat in MDS",[92],"2017-10-25","2015-03-20",[1196],[7587],{"trials":7604,"activeCount":103},[],{"trials":7606,"activeCount":103},[],{"trials":7608,"activeCount":103},[],{"intervention":7610,"totalTrials":184,"cells":7611},"bortezomib, dexamethasone, ifosfamide",{"EARLY_PHASE1":7612,"PHASE1":7614,"PHASE2":7616,"PHASE3":7626,"PHASE4":7628,"NA":7630},{"trials":7613,"activeCount":103},[],{"trials":7615,"activeCount":103},[],{"trials":7617,"activeCount":103},[7618],{"nctId":7619,"briefTitle":7620,"status":156,"phases":7621,"primaryCompletion":1193,"completion":7622,"start":1911,"enrollment":28,"conditions":7623,"interventions":7624},"NCT00504751","Phase II Study of \"VIPER\" Chemotherapy in Rel\u002FRef DLBCL",[92],"2012-02-17",[1126],[7610,7625],"mesna, cisplatin, etoposide, rituximab",{"trials":7627,"activeCount":103},[],{"trials":7629,"activeCount":103},[],{"trials":7631,"activeCount":103},[],{"intervention":7625,"totalTrials":184,"cells":7633},{"EARLY_PHASE1":7634,"PHASE1":7636,"PHASE2":7638,"PHASE3":7644,"PHASE4":7646,"NA":7648},{"trials":7635,"activeCount":103},[],{"trials":7637,"activeCount":103},[],{"trials":7639,"activeCount":103},[7640],{"nctId":7619,"briefTitle":7620,"status":156,"phases":7641,"primaryCompletion":1193,"completion":7622,"start":1911,"enrollment":28,"conditions":7642,"interventions":7643},[92],[1126],[7610,7625],{"trials":7645,"activeCount":103},[],{"trials":7647,"activeCount":103},[],{"trials":7649,"activeCount":103},[],{"intervention":7651,"totalTrials":184,"cells":7652},"Anakinra",{"EARLY_PHASE1":7653,"PHASE1":7655,"PHASE2":7657,"PHASE3":7670,"PHASE4":7672,"NA":7674},{"trials":7654,"activeCount":103},[],{"trials":7656,"activeCount":103},[],{"trials":7658,"activeCount":103},[7659],{"nctId":7660,"briefTitle":7661,"status":494,"phases":7662,"primaryCompletion":496,"completion":7663,"start":834,"enrollment":103,"conditions":7664,"interventions":7668},"NCT04603742","Anakinra, COVID-19, Cytokine Storm",[92],"2022-09",[7665,7666,7667],"Covid19","Cytokine Storm","Mechanical Ventilation Complication",[7651,7669],"0.9% Saline",{"trials":7671,"activeCount":103},[],{"trials":7673,"activeCount":103},[],{"trials":7675,"activeCount":103},[],{"intervention":7669,"totalTrials":184,"cells":7677},{"EARLY_PHASE1":7678,"PHASE1":7680,"PHASE2":7682,"PHASE3":7688,"PHASE4":7690,"NA":7692},{"trials":7679,"activeCount":103},[],{"trials":7681,"activeCount":103},[],{"trials":7683,"activeCount":103},[7684],{"nctId":7660,"briefTitle":7661,"status":494,"phases":7685,"primaryCompletion":496,"completion":7663,"start":834,"enrollment":103,"conditions":7686,"interventions":7687},[92],[7665,7666,7667],[7651,7669],{"trials":7689,"activeCount":103},[],{"trials":7691,"activeCount":103},[],{"trials":7693,"activeCount":103},[],{"intervention":7695,"totalTrials":184,"cells":7696},"Umbralisib",{"EARLY_PHASE1":7697,"PHASE1":7699,"PHASE2":7701,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7698,"activeCount":103},[],{"trials":7700,"activeCount":103},[],{"trials":7702,"activeCount":103},[7703],{"nctId":7704,"briefTitle":7705,"status":786,"phases":7706,"primaryCompletion":7707,"completion":7708,"start":47,"enrollment":184,"conditions":7709,"interventions":7711},"NCT04149821","Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy",[92],"2022-01-21","2022-06-09",[1102,7710,2052],"CLL Progression",[7695,7712],"Ublituximab",{"trials":7714,"activeCount":103},[],{"trials":7716,"activeCount":103},[],{"trials":7718,"activeCount":103},[],{"intervention":7712,"totalTrials":184,"cells":7720},{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7731,"PHASE4":7733,"NA":7735},{"trials":7722,"activeCount":103},[],{"trials":7724,"activeCount":103},[],{"trials":7726,"activeCount":103},[7727],{"nctId":7704,"briefTitle":7705,"status":786,"phases":7728,"primaryCompletion":7707,"completion":7708,"start":47,"enrollment":184,"conditions":7729,"interventions":7730},[92],[1102,7710,2052],[7695,7712],{"trials":7732,"activeCount":103},[],{"trials":7734,"activeCount":103},[],{"trials":7736,"activeCount":103},[],{"intervention":7738,"totalTrials":184,"cells":7739},"MLN8237",{"EARLY_PHASE1":7740,"PHASE1":7742,"PHASE2":7744,"PHASE3":7756,"PHASE4":7758,"NA":7760},{"trials":7741,"activeCount":103},[],{"trials":7743,"activeCount":103},[],{"trials":7745,"activeCount":103},[7746],{"nctId":7747,"briefTitle":7748,"status":156,"phases":7749,"primaryCompletion":847,"completion":7750,"start":6171,"enrollment":375,"conditions":7751,"interventions":7755},"NCT01799278","A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer",[92],"2017-08",[7752,7753,7754],"Small Cell Prostate Cancer","Neuroendocrine Prostate Cancer","Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers",[7738],{"trials":7757,"activeCount":103},[],{"trials":7759,"activeCount":103},[],{"trials":7761,"activeCount":103},[],{"intervention":7763,"totalTrials":184,"cells":7764},"Clarithromycin, Lenalidomide, Dexamethasone",{"EARLY_PHASE1":7765,"PHASE1":7767,"PHASE2":7769,"PHASE3":7780,"PHASE4":7782,"NA":7784},{"trials":7766,"activeCount":103},[],{"trials":7768,"activeCount":103},[],{"trials":7770,"activeCount":103},[7771],{"nctId":7772,"briefTitle":7773,"status":156,"phases":7774,"primaryCompletion":7775,"completion":7776,"start":7777,"enrollment":1583,"conditions":7778,"interventions":7779},"NCT00151203","Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma",[92],"2007-04","2020-09-29","2004-12",[30],[7763],{"trials":7781,"activeCount":103},[],{"trials":7783,"activeCount":103},[],{"trials":7785,"activeCount":103},[],{"intervention":5864,"totalTrials":184,"cells":7787},{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7792,"PHASE3":7798,"PHASE4":7800,"NA":7802},{"trials":7789,"activeCount":103},[],{"trials":7791,"activeCount":103},[],{"trials":7793,"activeCount":103},[7794],{"nctId":5855,"briefTitle":5856,"status":494,"phases":7795,"primaryCompletion":5858,"completion":5859,"start":5860,"enrollment":103,"conditions":7796,"interventions":7797},[92],[5862],[5864,1895],{"trials":7799,"activeCount":103},[],{"trials":7801,"activeCount":103},[],{"trials":7803,"activeCount":103},[],{"intervention":5905,"totalTrials":184,"cells":7805},{"EARLY_PHASE1":7806,"PHASE1":7808,"PHASE2":7810,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7807,"activeCount":103},[],{"trials":7809,"activeCount":103},[],{"trials":7811,"activeCount":103},[7812],{"nctId":5900,"briefTitle":5901,"status":156,"phases":7813,"primaryCompletion":3383,"completion":3383,"start":1373,"enrollment":28,"conditions":7814,"interventions":7815},[92],[3387],[5905,5906,5872],{"trials":7817,"activeCount":103},[],{"trials":7819,"activeCount":103},[],{"trials":7821,"activeCount":103},[],{"intervention":7823,"totalTrials":184,"cells":7824},"Intravenous Immunoglobulin",{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7829,"PHASE3":7837,"PHASE4":7839,"NA":7841},{"trials":7826,"activeCount":103},[],{"trials":7828,"activeCount":103},[],{"trials":7830,"activeCount":103},[7831],{"nctId":7832,"briefTitle":7833,"status":786,"phases":7834,"primaryCompletion":4746,"completion":6754,"start":4948,"enrollment":1737,"conditions":7835,"interventions":7836},"NCT00299988","Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease",[92],[2313],[7823],{"trials":7838,"activeCount":103},[],{"trials":7840,"activeCount":103},[],{"trials":7842,"activeCount":103},[],{"intervention":7844,"totalTrials":184,"cells":7845},"Cabozantinib",{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7861,"PHASE4":7863,"NA":7865},{"trials":7847,"activeCount":103},[],{"trials":7849,"activeCount":103},[],{"trials":7851,"activeCount":103},[7852],{"nctId":7853,"briefTitle":7854,"status":786,"phases":7855,"primaryCompletion":7856,"completion":7857,"start":7858,"enrollment":896,"conditions":7859,"interventions":7860},"NCT04631744","Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",[92],"2025-05-12","2025-11-09","2021-03-03",[18],[7844],{"trials":7862,"activeCount":103},[],{"trials":7864,"activeCount":103},[],{"trials":7866,"activeCount":103},[],{"intervention":1129,"totalTrials":184,"cells":7868},{"EARLY_PHASE1":7869,"PHASE1":7871,"PHASE2":7873,"PHASE3":7879,"PHASE4":7881,"NA":7883},{"trials":7870,"activeCount":103},[],{"trials":7872,"activeCount":103},[],{"trials":7874,"activeCount":103},[7875],{"nctId":1117,"briefTitle":1118,"status":156,"phases":7876,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":7877,"interventions":7878},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"trials":7880,"activeCount":103},[],{"trials":7882,"activeCount":103},[],{"trials":7884,"activeCount":103},[],{"intervention":1132,"totalTrials":184,"cells":7886},{"EARLY_PHASE1":7887,"PHASE1":7889,"PHASE2":7891,"PHASE3":7897,"PHASE4":7899,"NA":7901},{"trials":7888,"activeCount":103},[],{"trials":7890,"activeCount":103},[],{"trials":7892,"activeCount":103},[7893],{"nctId":1117,"briefTitle":1118,"status":156,"phases":7894,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":7895,"interventions":7896},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"trials":7898,"activeCount":103},[],{"trials":7900,"activeCount":103},[],{"trials":7902,"activeCount":103},[],{"intervention":1133,"totalTrials":184,"cells":7904},{"EARLY_PHASE1":7905,"PHASE1":7907,"PHASE2":7909,"PHASE3":7915,"PHASE4":7917,"NA":7919},{"trials":7906,"activeCount":103},[],{"trials":7908,"activeCount":103},[],{"trials":7910,"activeCount":103},[7911],{"nctId":1117,"briefTitle":1118,"status":156,"phases":7912,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":7913,"interventions":7914},[91,92],[1125,1126],[1128,1129,866,1090,1130,1131,1132,1133,865],{"trials":7916,"activeCount":103},[],{"trials":7918,"activeCount":103},[],{"trials":7920,"activeCount":103},[],{"intervention":950,"totalTrials":184,"cells":7922},{"EARLY_PHASE1":7923,"PHASE1":7925,"PHASE2":7927,"PHASE3":7933,"PHASE4":7935,"NA":7937},{"trials":7924,"activeCount":103},[],{"trials":7926,"activeCount":103},[],{"trials":7928,"activeCount":103},[7929],{"nctId":941,"briefTitle":942,"status":156,"phases":7930,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":7931,"interventions":7932},[92],[30],[950,58,930,885],{"trials":7934,"activeCount":103},[],{"trials":7936,"activeCount":103},[],{"trials":7938,"activeCount":103},[],{"intervention":7940,"totalTrials":184,"cells":7941},"KN046",{"EARLY_PHASE1":7942,"PHASE1":7944,"PHASE2":7946,"PHASE3":7957,"PHASE4":7959,"NA":7961},{"trials":7943,"activeCount":103},[],{"trials":7945,"activeCount":103},[],{"trials":7947,"activeCount":103},[7948],{"nctId":7949,"briefTitle":7950,"status":786,"phases":7951,"primaryCompletion":7952,"completion":7952,"start":7953,"enrollment":896,"conditions":7954,"interventions":7956},"NCT04925947","A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors",[92],"2023-05-05","2021-12-13",[7955],"Thymic Carcinoma",[7940],{"trials":7958,"activeCount":103},[],{"trials":7960,"activeCount":103},[],{"trials":7962,"activeCount":103},[],{"intervention":1143,"totalTrials":184,"cells":7964},{"EARLY_PHASE1":7965,"PHASE1":7967,"PHASE2":7969,"PHASE3":7975,"PHASE4":7977,"NA":7979},{"trials":7966,"activeCount":103},[],{"trials":7968,"activeCount":103},[],{"trials":7970,"activeCount":103},[7971],{"nctId":1135,"briefTitle":1136,"status":156,"phases":7972,"primaryCompletion":1138,"completion":1139,"start":1140,"enrollment":532,"conditions":7973,"interventions":7974},[92],[1126],[1143,1057,865],{"trials":7976,"activeCount":103},[],{"trials":7978,"activeCount":103},[],{"trials":7980,"activeCount":103},[],{"intervention":7982,"totalTrials":184,"cells":7983},"Amlodipine 5mg",{"EARLY_PHASE1":7984,"PHASE1":7986,"PHASE2":7988,"PHASE3":8002,"PHASE4":8004,"NA":8006},{"trials":7985,"activeCount":103},[],{"trials":7987,"activeCount":103},[],{"trials":7989,"activeCount":103},[7990],{"nctId":7991,"briefTitle":7992,"status":156,"phases":7993,"primaryCompletion":7994,"completion":7995,"start":7996,"enrollment":7997,"conditions":7998,"interventions":8001},"NCT04692467","Treatment of Early Hypertension Among Persons Living With HIV in Haiti",[92],"2023-06-30","2023-12-30","2021-02-26",250,[7999,8000],"HIV\u002FAIDS","Pre Hypertension",[7982],{"trials":8003,"activeCount":103},[],{"trials":8005,"activeCount":103},[],{"trials":8007,"activeCount":103},[],{"intervention":8009,"totalTrials":184,"cells":8010},"Rosiglitazone",{"EARLY_PHASE1":8011,"PHASE1":8013,"PHASE2":8015,"PHASE3":8029,"PHASE4":8031,"NA":8033},{"trials":8012,"activeCount":103},[],{"trials":8014,"activeCount":103},[],{"trials":8016,"activeCount":103},[8017],{"nctId":8018,"briefTitle":8019,"status":156,"phases":8020,"primaryCompletion":926,"completion":926,"start":8021,"enrollment":8022,"conditions":8023,"interventions":8027},"NCT00130286","Growth Hormone and\u002For Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance",[91,92],"2005-03",77,[8024,4171,3670,8025,8026],"HIV-Associated Lipodystrophy Syndrome","Metabolic Syndrome X","Body Weight Changes",[8009,8028],"Recombinant human growth hormone + rosiglitazone",{"trials":8030,"activeCount":103},[],{"trials":8032,"activeCount":103},[],{"trials":8034,"activeCount":103},[],{"intervention":8028,"totalTrials":184,"cells":8036},{"EARLY_PHASE1":8037,"PHASE1":8039,"PHASE2":8041,"PHASE3":8047,"PHASE4":8049,"NA":8051},{"trials":8038,"activeCount":103},[],{"trials":8040,"activeCount":103},[],{"trials":8042,"activeCount":103},[8043],{"nctId":8018,"briefTitle":8019,"status":156,"phases":8044,"primaryCompletion":926,"completion":926,"start":8021,"enrollment":8022,"conditions":8045,"interventions":8046},[91,92],[8024,4171,3670,8025,8026],[8009,8028],{"trials":8048,"activeCount":103},[],{"trials":8050,"activeCount":103},[],{"trials":8052,"activeCount":103},[],{"intervention":6030,"totalTrials":184,"cells":8054},{"EARLY_PHASE1":8055,"PHASE1":8057,"PHASE2":8059,"PHASE3":8065,"PHASE4":8067,"NA":8069},{"trials":8056,"activeCount":103},[],{"trials":8058,"activeCount":103},[],{"trials":8060,"activeCount":103},[8061],{"nctId":6022,"briefTitle":6023,"status":156,"phases":8062,"primaryCompletion":6025,"completion":6026,"start":3418,"enrollment":3785,"conditions":8063,"interventions":8064},[91,92],[6028],[1071,6030],{"trials":8066,"activeCount":103},[],{"trials":8068,"activeCount":103},[],{"trials":8070,"activeCount":103},[],{"intervention":8072,"totalTrials":184,"cells":8073},"Study Drug",{"EARLY_PHASE1":8074,"PHASE1":8076,"PHASE2":8078,"PHASE3":8089,"PHASE4":8091,"NA":8093},{"trials":8075,"activeCount":103},[],{"trials":8077,"activeCount":103},[],{"trials":8079,"activeCount":103},[8080],{"nctId":8081,"briefTitle":8082,"status":786,"phases":8083,"primaryCompletion":8084,"completion":8085,"start":8086,"enrollment":141,"conditions":8087,"interventions":8088},"NCT02538471","LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer",[92],"2018-09-04","2019-02-20","2015-08-10",[768],[8072],{"trials":8090,"activeCount":103},[],{"trials":8092,"activeCount":103},[],{"trials":8094,"activeCount":103},[],{"intervention":8096,"totalTrials":184,"cells":8097},"Pyrimethamine",{"EARLY_PHASE1":8098,"PHASE1":8100,"PHASE2":8102,"PHASE3":8112,"PHASE4":8114,"NA":8116},{"trials":8099,"activeCount":103},[],{"trials":8101,"activeCount":103},[],{"trials":8103,"activeCount":103},[8104],{"nctId":8105,"briefTitle":8106,"status":156,"phases":8107,"primaryCompletion":3500,"completion":8108,"start":4196,"enrollment":1552,"conditions":8109,"interventions":8111},"NCT01083667","SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)",[91,92],"2016-05",[8110],"Familial Amyotrophic Lateral Sclerosis",[8096],{"trials":8113,"activeCount":103},[],{"trials":8115,"activeCount":103},[],{"trials":8117,"activeCount":103},[],{"intervention":8119,"totalTrials":184,"cells":8120},"Vitamin C",{"EARLY_PHASE1":8121,"PHASE1":8123,"PHASE2":8125,"PHASE3":8136,"PHASE4":8138,"NA":8140},{"trials":8122,"activeCount":103},[],{"trials":8124,"activeCount":103},[],{"trials":8126,"activeCount":103},[8127],{"nctId":8128,"briefTitle":8129,"status":156,"phases":8130,"primaryCompletion":8131,"completion":8131,"start":8132,"enrollment":2943,"conditions":8133,"interventions":8135},"NCT03146962","High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies",[92],"2023-04-21","2017-03-29",[1741,1977,8134],"Lung Cancer",[8119],{"trials":8137,"activeCount":103},[],{"trials":8139,"activeCount":103},[],{"trials":8141,"activeCount":103},[],{"intervention":8143,"totalTrials":184,"cells":8144},"methyldopa",{"EARLY_PHASE1":8145,"PHASE1":8147,"PHASE2":8149,"PHASE3":8163,"PHASE4":8165,"NA":8167},{"trials":8146,"activeCount":103},[],{"trials":8148,"activeCount":103},[],{"trials":8150,"activeCount":103},[8151],{"nctId":8152,"briefTitle":8153,"status":494,"phases":8154,"primaryCompletion":8021,"completion":8021,"start":8155,"enrollment":103,"conditions":8156,"interventions":8159},"NCT00194974","Treatment Targets for Chronic Hypertension in Pregnancy",[91,92],"2004-07",[8157,24,8158],"Pregnancy Toxemia","Proteinuria",[8143,8160,8161,8162],"labetalol","nifedipine","clonidine",{"trials":8164,"activeCount":103},[],{"trials":8166,"activeCount":103},[],{"trials":8168,"activeCount":103},[],{"intervention":8160,"totalTrials":184,"cells":8170},{"EARLY_PHASE1":8171,"PHASE1":8173,"PHASE2":8175,"PHASE3":8181,"PHASE4":8183,"NA":8185},{"trials":8172,"activeCount":103},[],{"trials":8174,"activeCount":103},[],{"trials":8176,"activeCount":103},[8177],{"nctId":8152,"briefTitle":8153,"status":494,"phases":8178,"primaryCompletion":8021,"completion":8021,"start":8155,"enrollment":103,"conditions":8179,"interventions":8180},[91,92],[8157,24,8158],[8143,8160,8161,8162],{"trials":8182,"activeCount":103},[],{"trials":8184,"activeCount":103},[],{"trials":8186,"activeCount":103},[],{"intervention":8161,"totalTrials":184,"cells":8188},{"EARLY_PHASE1":8189,"PHASE1":8191,"PHASE2":8193,"PHASE3":8199,"PHASE4":8201,"NA":8203},{"trials":8190,"activeCount":103},[],{"trials":8192,"activeCount":103},[],{"trials":8194,"activeCount":103},[8195],{"nctId":8152,"briefTitle":8153,"status":494,"phases":8196,"primaryCompletion":8021,"completion":8021,"start":8155,"enrollment":103,"conditions":8197,"interventions":8198},[91,92],[8157,24,8158],[8143,8160,8161,8162],{"trials":8200,"activeCount":103},[],{"trials":8202,"activeCount":103},[],{"trials":8204,"activeCount":103},[],{"intervention":8162,"totalTrials":184,"cells":8206},{"EARLY_PHASE1":8207,"PHASE1":8209,"PHASE2":8211,"PHASE3":8217,"PHASE4":8219,"NA":8221},{"trials":8208,"activeCount":103},[],{"trials":8210,"activeCount":103},[],{"trials":8212,"activeCount":103},[8213],{"nctId":8152,"briefTitle":8153,"status":494,"phases":8214,"primaryCompletion":8021,"completion":8021,"start":8155,"enrollment":103,"conditions":8215,"interventions":8216},[91,92],[8157,24,8158],[8143,8160,8161,8162],{"trials":8218,"activeCount":103},[],{"trials":8220,"activeCount":103},[],{"trials":8222,"activeCount":103},[],{"intervention":8224,"totalTrials":184,"cells":8225},"Nitazoxanide",{"EARLY_PHASE1":8226,"PHASE1":8228,"PHASE2":8230,"PHASE3":8240,"PHASE4":8242,"NA":8244},{"trials":8227,"activeCount":103},[],{"trials":8229,"activeCount":103},[],{"trials":8231,"activeCount":103},[8232],{"nctId":8233,"briefTitle":8234,"status":156,"phases":8235,"primaryCompletion":8236,"completion":8236,"start":974,"enrollment":478,"conditions":8237,"interventions":8239},"NCT02684240","A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis",[92],"2018-04-11",[8238],"Tuberculosis",[8224],{"trials":8241,"activeCount":103},[],{"trials":8243,"activeCount":103},[],{"trials":8245,"activeCount":103},[],{"intervention":8247,"totalTrials":184,"cells":8248},"ixabepilone",{"EARLY_PHASE1":8249,"PHASE1":8251,"PHASE2":8253,"PHASE3":8261,"PHASE4":8263,"NA":8265},{"trials":8250,"activeCount":103},[],{"trials":8252,"activeCount":103},[],{"trials":8254,"activeCount":103},[8255],{"nctId":8256,"briefTitle":8257,"status":156,"phases":8258,"primaryCompletion":4458,"completion":4458,"start":1077,"enrollment":28,"conditions":8259,"interventions":8260},"NCT00627978","Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons",[92],[768],[8247],{"trials":8262,"activeCount":103},[],{"trials":8264,"activeCount":103},[],{"trials":8266,"activeCount":103},[],{"intervention":2889,"totalTrials":184,"cells":8268},{"EARLY_PHASE1":8269,"PHASE1":8271,"PHASE2":8273,"PHASE3":8279,"PHASE4":8281,"NA":8283},{"trials":8270,"activeCount":103},[],{"trials":8272,"activeCount":103},[],{"trials":8274,"activeCount":103},[8275],{"nctId":2881,"briefTitle":2882,"status":2883,"phases":8276,"primaryCompletion":243,"completion":243,"start":2885,"enrollment":2886,"conditions":8277,"interventions":8278},[92],[2878],[2889,2864],{"trials":8280,"activeCount":103},[],{"trials":8282,"activeCount":103},[],{"trials":8284,"activeCount":103},[],{"intervention":6313,"totalTrials":184,"cells":8286},{"EARLY_PHASE1":8287,"PHASE1":8289,"PHASE2":8291,"PHASE3":8297,"PHASE4":8299,"NA":8301},{"trials":8288,"activeCount":103},[],{"trials":8290,"activeCount":103},[],{"trials":8292,"activeCount":103},[8293],{"nctId":6305,"briefTitle":6306,"status":494,"phases":8294,"primaryCompletion":974,"completion":6308,"start":848,"enrollment":103,"conditions":8295,"interventions":8296},[92],[6310,6311],[6313,6285,6314,6315],{"trials":8298,"activeCount":103},[],{"trials":8300,"activeCount":103},[],{"trials":8302,"activeCount":103},[],{"intervention":6314,"totalTrials":184,"cells":8304},{"EARLY_PHASE1":8305,"PHASE1":8307,"PHASE2":8309,"PHASE3":8315,"PHASE4":8317,"NA":8319},{"trials":8306,"activeCount":103},[],{"trials":8308,"activeCount":103},[],{"trials":8310,"activeCount":103},[8311],{"nctId":6305,"briefTitle":6306,"status":494,"phases":8312,"primaryCompletion":974,"completion":6308,"start":848,"enrollment":103,"conditions":8313,"interventions":8314},[92],[6310,6311],[6313,6285,6314,6315],{"trials":8316,"activeCount":103},[],{"trials":8318,"activeCount":103},[],{"trials":8320,"activeCount":103},[],{"intervention":6315,"totalTrials":184,"cells":8322},{"EARLY_PHASE1":8323,"PHASE1":8325,"PHASE2":8327,"PHASE3":8333,"PHASE4":8335,"NA":8337},{"trials":8324,"activeCount":103},[],{"trials":8326,"activeCount":103},[],{"trials":8328,"activeCount":103},[8329],{"nctId":6305,"briefTitle":6306,"status":494,"phases":8330,"primaryCompletion":974,"completion":6308,"start":848,"enrollment":103,"conditions":8331,"interventions":8332},[92],[6310,6311],[6313,6285,6314,6315],{"trials":8334,"activeCount":103},[],{"trials":8336,"activeCount":103},[],{"trials":8338,"activeCount":103},[],{"intervention":6344,"totalTrials":184,"cells":8340},{"EARLY_PHASE1":8341,"PHASE1":8343,"PHASE2":8345,"PHASE3":8351,"PHASE4":8353,"NA":8355},{"trials":8342,"activeCount":103},[],{"trials":8344,"activeCount":103},[],{"trials":8346,"activeCount":103},[8347],{"nctId":6335,"briefTitle":6336,"status":786,"phases":8348,"primaryCompletion":6338,"completion":6339,"start":6340,"enrollment":184,"conditions":8349,"interventions":8350},[92],[6342],[6301,6344],{"trials":8352,"activeCount":103},[],{"trials":8354,"activeCount":103},[],{"trials":8356,"activeCount":103},[],{"intervention":8358,"totalTrials":184,"cells":8359},"177Lu Radiolabeled Monoclonal Antibody HuJ591",{"EARLY_PHASE1":8360,"PHASE1":8362,"PHASE2":8364,"PHASE3":8373,"PHASE4":8375,"NA":8377},{"trials":8361,"activeCount":103},[],{"trials":8363,"activeCount":103},[],{"trials":8365,"activeCount":103},[8366],{"nctId":8367,"briefTitle":8368,"status":156,"phases":8369,"primaryCompletion":8370,"completion":1052,"start":5171,"enrollment":16,"conditions":8371,"interventions":8372},"NCT00195039","Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer",[92],"2012-02",[18],[8358],{"trials":8374,"activeCount":103},[],{"trials":8376,"activeCount":103},[],{"trials":8378,"activeCount":103},[],{"intervention":817,"totalTrials":184,"cells":8380},{"EARLY_PHASE1":8381,"PHASE1":8383,"PHASE2":8385,"PHASE3":8391,"PHASE4":8393,"NA":8395},{"trials":8382,"activeCount":103},[],{"trials":8384,"activeCount":103},[],{"trials":8386,"activeCount":103},[8387],{"nctId":806,"briefTitle":807,"status":786,"phases":8388,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":8389,"interventions":8390},[92],[813,814],[816,817,48],{"trials":8392,"activeCount":103},[],{"trials":8394,"activeCount":103},[],{"trials":8396,"activeCount":103},[],{"intervention":8398,"totalTrials":184,"cells":8399},"SIACI of Erbitux and Bevacizumab",{"EARLY_PHASE1":8400,"PHASE1":8402,"PHASE2":8404,"PHASE3":8421,"PHASE4":8423,"NA":8425},{"trials":8401,"activeCount":103},[],{"trials":8403,"activeCount":103},[],{"trials":8405,"activeCount":103},[8406],{"nctId":8407,"briefTitle":8408,"status":786,"phases":8409,"primaryCompletion":8410,"completion":8410,"start":1802,"enrollment":34,"conditions":8411,"interventions":8420},"NCT01884740","Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed\u002FRefractory Intracranial Glioma In Patients Under 22",[91,92],"2018-10",[8412,8413,8414,8415,8416,8417,8418,8419],"Glioblastoma Multiforme","Fibrillary Astrocytoma of Brain","Glioma of Brainstem","Anaplastic Astrocytoma","Pilomyxoid Astrocytoma","Mixed Oligodendroglioma-Astrocytoma","Brain Stem Glioma","Diffuse Intrinsic Pontine Glioma",[8398],{"trials":8422,"activeCount":103},[],{"trials":8424,"activeCount":103},[],{"trials":8426,"activeCount":103},[],{"intervention":8428,"totalTrials":184,"cells":8429},"Clomiphene Citrate 25mg",{"EARLY_PHASE1":8430,"PHASE1":8432,"PHASE2":8434,"PHASE3":8446,"PHASE4":8448,"NA":8450},{"trials":8431,"activeCount":103},[],{"trials":8433,"activeCount":103},[],{"trials":8435,"activeCount":103},[8436],{"nctId":8437,"briefTitle":8438,"status":494,"phases":8439,"primaryCompletion":8440,"completion":8440,"start":8441,"enrollment":103,"conditions":8442,"interventions":8444},"NCT05096169","Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate",[92],"2025-01","2022-05-01",[8443],"Testosterone Deficiency",[8428,8445],"Clomiphene Citrate 50mg",{"trials":8447,"activeCount":103},[],{"trials":8449,"activeCount":103},[],{"trials":8451,"activeCount":103},[],{"intervention":8445,"totalTrials":184,"cells":8453},{"EARLY_PHASE1":8454,"PHASE1":8456,"PHASE2":8458,"PHASE3":8464,"PHASE4":8466,"NA":8468},{"trials":8455,"activeCount":103},[],{"trials":8457,"activeCount":103},[],{"trials":8459,"activeCount":103},[8460],{"nctId":8437,"briefTitle":8438,"status":494,"phases":8461,"primaryCompletion":8440,"completion":8440,"start":8441,"enrollment":103,"conditions":8462,"interventions":8463},[92],[8443],[8428,8445],{"trials":8465,"activeCount":103},[],{"trials":8467,"activeCount":103},[],{"trials":8469,"activeCount":103},[],{"intervention":8471,"totalTrials":184,"cells":8472},"Gleevec",{"EARLY_PHASE1":8473,"PHASE1":8475,"PHASE2":8477,"PHASE3":8488,"PHASE4":8490,"NA":8492},{"trials":8474,"activeCount":103},[],{"trials":8476,"activeCount":103},[],{"trials":8478,"activeCount":103},[8479],{"nctId":8480,"briefTitle":8481,"status":156,"phases":8482,"primaryCompletion":8483,"completion":8484,"start":8485,"enrollment":19,"conditions":8486,"interventions":8487},"NCT01120821","Treatment of Polycythemia Vera With Gleevec",[92],"2007-01","2007-06","2002-08",[6198],[8471],{"trials":8489,"activeCount":103},[],{"trials":8491,"activeCount":103},[],{"trials":8493,"activeCount":103},[],{"intervention":8495,"totalTrials":184,"cells":8496},"90Y-epratuzumab tetraxetan",{"EARLY_PHASE1":8497,"PHASE1":8499,"PHASE2":8501,"PHASE3":8513,"PHASE4":8515,"NA":8517},{"trials":8498,"activeCount":103},[],{"trials":8500,"activeCount":103},[],{"trials":8502,"activeCount":103},[8503],{"nctId":8504,"briefTitle":8505,"status":786,"phases":8506,"primaryCompletion":8507,"completion":8508,"start":8509,"enrollment":896,"conditions":8510,"interventions":8511},"NCT01147393","Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma",[91,92],"2013-08-06","2015-07-31","2010-10",[1692],[8495,8512],"veltuzumab",{"trials":8514,"activeCount":103},[],{"trials":8516,"activeCount":103},[],{"trials":8518,"activeCount":103},[],{"intervention":8512,"totalTrials":184,"cells":8520},{"EARLY_PHASE1":8521,"PHASE1":8523,"PHASE2":8525,"PHASE3":8531,"PHASE4":8533,"NA":8535},{"trials":8522,"activeCount":103},[],{"trials":8524,"activeCount":103},[],{"trials":8526,"activeCount":103},[8527],{"nctId":8504,"briefTitle":8505,"status":786,"phases":8528,"primaryCompletion":8507,"completion":8508,"start":8509,"enrollment":896,"conditions":8529,"interventions":8530},[91,92],[1692],[8495,8512],{"trials":8532,"activeCount":103},[],{"trials":8534,"activeCount":103},[],{"trials":8536,"activeCount":103},[],{"intervention":1337,"totalTrials":184,"cells":8538},{"EARLY_PHASE1":8539,"PHASE1":8541,"PHASE2":8543,"PHASE3":8549,"PHASE4":8551,"NA":8553},{"trials":8540,"activeCount":103},[],{"trials":8542,"activeCount":103},[],{"trials":8544,"activeCount":103},[8545],{"nctId":1328,"briefTitle":1329,"status":156,"phases":8546,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":218,"conditions":8547,"interventions":8548},[92],[1335,1250],[1337,73,1090,1131],{"trials":8550,"activeCount":103},[],{"trials":8552,"activeCount":103},[],{"trials":8554,"activeCount":103},[],{"intervention":8556,"totalTrials":99,"cells":8557},"huJ591",{"EARLY_PHASE1":8558,"PHASE1":8560,"PHASE2":8580,"PHASE3":8582,"PHASE4":8584,"NA":8586},{"trials":8559,"activeCount":103},[],{"trials":8561,"activeCount":103},[8562,8570],{"nctId":8563,"briefTitle":8564,"status":156,"phases":8565,"primaryCompletion":8566,"completion":8567,"start":3436,"enrollment":1236,"conditions":8568,"interventions":8569},"NCT02552394","J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts",[91],"2019-11-14","2021-01-03",[18],[8556],{"nctId":8571,"briefTitle":8572,"status":156,"phases":8573,"primaryCompletion":8574,"completion":8575,"start":8576,"enrollment":722,"conditions":8577,"interventions":8578},"NCT02693860","Neoadjuvant J591 Treatment for Prostate Cancer",[91],"2017-02-10","2020-02-02","2016-02-04",[18],[8556,8579],"89Zr-J591",{"trials":8581,"activeCount":103},[],{"trials":8583,"activeCount":103},[],{"trials":8585,"activeCount":103},[],{"trials":8587,"activeCount":103},[],{"intervention":1021,"totalTrials":99,"cells":8589},{"EARLY_PHASE1":8590,"PHASE1":8592,"PHASE2":8608,"PHASE3":8610,"PHASE4":8612,"NA":8614},{"trials":8591,"activeCount":103},[],{"trials":8593,"activeCount":103},[8594,8604],{"nctId":8595,"briefTitle":8596,"status":786,"phases":8597,"primaryCompletion":8598,"completion":8598,"start":8599,"enrollment":141,"conditions":8600,"interventions":8602},"NCT05618366","Tazemetostat and Venetoclax in Relapsed\u002FRefractory Non-Hodgkin Lymphoma",[91],"2026-02-27","2023-06-07",[8601,1065,1692],"Lymphoma, Non-Hodgkin",[1021,8603],"Tazemetostat",{"nctId":1012,"briefTitle":1013,"status":156,"phases":8605,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":8606,"interventions":8607},[91],[862,1019],[1021,865,866,1022,1023,1024,1025],{"trials":8609,"activeCount":103},[],{"trials":8611,"activeCount":103},[],{"trials":8613,"activeCount":103},[],{"trials":8615,"activeCount":103},[],{"intervention":1376,"totalTrials":99,"cells":8617},{"EARLY_PHASE1":8618,"PHASE1":8620,"PHASE2":8630,"PHASE3":8632,"PHASE4":8634,"NA":8636},{"trials":8619,"activeCount":103},[],{"trials":8621,"activeCount":103},[8622,8626],{"nctId":1369,"briefTitle":1370,"status":156,"phases":8623,"primaryCompletion":1372,"completion":1263,"start":1373,"enrollment":28,"conditions":8624,"interventions":8625},[91],[18],[1376,1024,63,63,63,63,63],{"nctId":1378,"briefTitle":1379,"status":156,"phases":8627,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":825,"conditions":8628,"interventions":8629},[91],[1385],[1387,1388,1376,1024],{"trials":8631,"activeCount":103},[],{"trials":8633,"activeCount":103},[],{"trials":8635,"activeCount":103},[],{"trials":8637,"activeCount":103},[],{"intervention":5744,"totalTrials":184,"cells":8639},{"EARLY_PHASE1":8640,"PHASE1":8642,"PHASE2":8648,"PHASE3":8650,"PHASE4":8652,"NA":8654},{"trials":8641,"activeCount":103},[],{"trials":8643,"activeCount":103},[8644],{"nctId":5736,"briefTitle":5737,"status":786,"phases":8645,"primaryCompletion":5739,"completion":5740,"start":5741,"enrollment":37,"conditions":8646,"interventions":8647},[91],[5223],[1255,5744],{"trials":8649,"activeCount":103},[],{"trials":8651,"activeCount":103},[],{"trials":8653,"activeCount":103},[],{"trials":8655,"activeCount":103},[],{"intervention":8657,"totalTrials":184,"cells":8658},"CW 002",{"EARLY_PHASE1":8659,"PHASE1":8661,"PHASE2":8669,"PHASE3":8671,"PHASE4":8673,"NA":8675},{"trials":8660,"activeCount":103},[],{"trials":8662,"activeCount":103},[8663],{"nctId":8664,"briefTitle":8665,"status":786,"phases":8666,"primaryCompletion":1052,"completion":916,"start":5412,"enrollment":4900,"conditions":8667,"interventions":8668},"NCT01338935","Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002",[91],[3646],[8657,8657,8657],{"trials":8670,"activeCount":103},[],{"trials":8672,"activeCount":103},[],{"trials":8674,"activeCount":103},[],{"trials":8676,"activeCount":103},[],{"intervention":8678,"totalTrials":184,"cells":8679},"Actinium-J591",{"EARLY_PHASE1":8680,"PHASE1":8682,"PHASE2":8693,"PHASE3":8695,"PHASE4":8697,"NA":8699},{"trials":8681,"activeCount":103},[],{"trials":8683,"activeCount":103},[8684],{"nctId":8685,"briefTitle":8686,"status":494,"phases":8687,"primaryCompletion":8440,"completion":8688,"start":8689,"enrollment":103,"conditions":8690,"interventions":8691},"NCT05567770","ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer",[91],"2030-01","2023-12",[1385],[8678,8692],"Androgen Deprivation Therapy",{"trials":8694,"activeCount":103},[],{"trials":8696,"activeCount":103},[],{"trials":8698,"activeCount":103},[],{"trials":8700,"activeCount":103},[],{"intervention":8692,"totalTrials":184,"cells":8702},{"EARLY_PHASE1":8703,"PHASE1":8705,"PHASE2":8711,"PHASE3":8713,"PHASE4":8715,"NA":8717},{"trials":8704,"activeCount":103},[],{"trials":8706,"activeCount":103},[8707],{"nctId":8685,"briefTitle":8686,"status":494,"phases":8708,"primaryCompletion":8440,"completion":8688,"start":8689,"enrollment":103,"conditions":8709,"interventions":8710},[91],[1385],[8678,8692],{"trials":8712,"activeCount":103},[],{"trials":8714,"activeCount":103},[],{"trials":8716,"activeCount":103},[],{"trials":8718,"activeCount":103},[],{"intervention":8720,"totalTrials":184,"cells":8721},"hLL1",{"EARLY_PHASE1":8722,"PHASE1":8724,"PHASE2":8734,"PHASE3":8736,"PHASE4":8738,"NA":8740},{"trials":8723,"activeCount":103},[],{"trials":8725,"activeCount":103},[8726],{"nctId":8727,"briefTitle":8728,"status":156,"phases":8729,"primaryCompletion":8730,"completion":8731,"start":8484,"enrollment":1703,"conditions":8732,"interventions":8733},"NCT00504972","Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies",[91],"2011-04-01","2015-10-07",[1126,1102],[8720],{"trials":8735,"activeCount":103},[],{"trials":8737,"activeCount":103},[],{"trials":8739,"activeCount":103},[],{"trials":8741,"activeCount":103},[],{"intervention":8743,"totalTrials":184,"cells":8744},"AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies",{"EARLY_PHASE1":8745,"PHASE1":8747,"PHASE2":8760,"PHASE3":8762,"PHASE4":8764,"NA":8766},{"trials":8746,"activeCount":103},[],{"trials":8748,"activeCount":103},[8749],{"nctId":8750,"briefTitle":8751,"status":156,"phases":8752,"primaryCompletion":8753,"completion":8754,"start":8755,"enrollment":975,"conditions":8756,"interventions":8758},"NCT01161576","Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)",[91],"2016-01-05","2020-12-31","2010-08-19",[6806,8757],"Late-Infantile Neuronal Ceroid Lipofuscinosis",[8743,8759],"AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies",{"trials":8761,"activeCount":103},[],{"trials":8763,"activeCount":103},[],{"trials":8765,"activeCount":103},[],{"trials":8767,"activeCount":103},[],{"intervention":8759,"totalTrials":184,"cells":8769},{"EARLY_PHASE1":8770,"PHASE1":8772,"PHASE2":8778,"PHASE3":8780,"PHASE4":8782,"NA":8784},{"trials":8771,"activeCount":103},[],{"trials":8773,"activeCount":103},[8774],{"nctId":8750,"briefTitle":8751,"status":156,"phases":8775,"primaryCompletion":8753,"completion":8754,"start":8755,"enrollment":975,"conditions":8776,"interventions":8777},[91],[6806,8757],[8743,8759],{"trials":8779,"activeCount":103},[],{"trials":8781,"activeCount":103},[],{"trials":8783,"activeCount":103},[],{"trials":8785,"activeCount":103},[],{"intervention":8787,"totalTrials":184,"cells":8788},"Islet Cell Transplantation",{"EARLY_PHASE1":8789,"PHASE1":8791,"PHASE2":8803,"PHASE3":8805,"PHASE4":8807,"NA":8809},{"trials":8790,"activeCount":103},[],{"trials":8792,"activeCount":103},[8793],{"nctId":8794,"briefTitle":8795,"status":786,"phases":8796,"primaryCompletion":8797,"completion":8798,"start":8799,"enrollment":141,"conditions":8800,"interventions":8802},"NCT00303134","Islet Cell Transplants for Diabetes",[91],"2007-10-23","2010-06-24","2003-08-01",[8801],"Diabetes Mellitus, Type 1",[8787],{"trials":8804,"activeCount":103},[],{"trials":8806,"activeCount":103},[],{"trials":8808,"activeCount":103},[],{"trials":8810,"activeCount":103},[],{"intervention":1256,"totalTrials":184,"cells":8812},{"EARLY_PHASE1":8813,"PHASE1":8815,"PHASE2":8821,"PHASE3":8823,"PHASE4":8825,"NA":8827},{"trials":8814,"activeCount":103},[],{"trials":8816,"activeCount":103},[8817],{"nctId":1243,"briefTitle":1244,"status":156,"phases":8818,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":31,"conditions":8819,"interventions":8820},[91],[1250,1251,1252,1253],[1255,73,1090,1256,1257],{"trials":8822,"activeCount":103},[],{"trials":8824,"activeCount":103},[],{"trials":8826,"activeCount":103},[],{"trials":8828,"activeCount":103},[],{"intervention":1257,"totalTrials":184,"cells":8830},{"EARLY_PHASE1":8831,"PHASE1":8833,"PHASE2":8839,"PHASE3":8841,"PHASE4":8843,"NA":8845},{"trials":8832,"activeCount":103},[],{"trials":8834,"activeCount":103},[8835],{"nctId":1243,"briefTitle":1244,"status":156,"phases":8836,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":31,"conditions":8837,"interventions":8838},[91],[1250,1251,1252,1253],[1255,73,1090,1256,1257],{"trials":8840,"activeCount":103},[],{"trials":8842,"activeCount":103},[],{"trials":8844,"activeCount":103},[],{"trials":8846,"activeCount":103},[],{"intervention":8848,"totalTrials":184,"cells":8849},"18F-FMISO PET",{"EARLY_PHASE1":8850,"PHASE1":8852,"PHASE2":8863,"PHASE3":8865,"PHASE4":8867,"NA":8869},{"trials":8851,"activeCount":103},[],{"trials":8853,"activeCount":103},[8854],{"nctId":8855,"briefTitle":8856,"status":2883,"phases":8857,"primaryCompletion":1213,"completion":1617,"start":8858,"enrollment":722,"conditions":8859,"interventions":8861},"NCT04309552","Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma",[91],"2021-02-01",[8860],"Glioma",[8848,8862],"18F-FLT PET",{"trials":8864,"activeCount":103},[],{"trials":8866,"activeCount":103},[],{"trials":8868,"activeCount":103},[],{"trials":8870,"activeCount":103},[],{"intervention":8862,"totalTrials":184,"cells":8872},{"EARLY_PHASE1":8873,"PHASE1":8875,"PHASE2":8881,"PHASE3":8883,"PHASE4":8885,"NA":8887},{"trials":8874,"activeCount":103},[],{"trials":8876,"activeCount":103},[8877],{"nctId":8855,"briefTitle":8856,"status":2883,"phases":8878,"primaryCompletion":1213,"completion":1617,"start":8858,"enrollment":722,"conditions":8879,"interventions":8880},[91],[8860],[8848,8862],{"trials":8882,"activeCount":103},[],{"trials":8884,"activeCount":103},[],{"trials":8886,"activeCount":103},[],{"trials":8888,"activeCount":103},[],{"intervention":8890,"totalTrials":184,"cells":8891},"monoclonal antibody muJ591",{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8903,"PHASE3":8905,"PHASE4":8907,"NA":8909},{"trials":8893,"activeCount":103},[],{"trials":8895,"activeCount":103},[8896],{"nctId":8897,"briefTitle":8898,"status":156,"phases":8899,"start":8900,"enrollment":478,"conditions":8901,"interventions":8902},"NCT00003391","Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",[91],"1998-06",[18],[8890],{"trials":8904,"activeCount":103},[],{"trials":8906,"activeCount":103},[],{"trials":8908,"activeCount":103},[],{"trials":8910,"activeCount":103},[],{"intervention":8603,"totalTrials":184,"cells":8912},{"EARLY_PHASE1":8913,"PHASE1":8915,"PHASE2":8921,"PHASE3":8923,"PHASE4":8925,"NA":8927},{"trials":8914,"activeCount":103},[],{"trials":8916,"activeCount":103},[8917],{"nctId":8595,"briefTitle":8596,"status":786,"phases":8918,"primaryCompletion":8598,"completion":8598,"start":8599,"enrollment":141,"conditions":8919,"interventions":8920},[91],[8601,1065,1692],[1021,8603],{"trials":8922,"activeCount":103},[],{"trials":8924,"activeCount":103},[],{"trials":8926,"activeCount":103},[],{"trials":8928,"activeCount":103},[],{"intervention":5893,"totalTrials":184,"cells":8930},{"EARLY_PHASE1":8931,"PHASE1":8933,"PHASE2":8939,"PHASE3":8941,"PHASE4":8943,"NA":8945},{"trials":8932,"activeCount":103},[],{"trials":8934,"activeCount":103},[8935],{"nctId":5887,"briefTitle":5888,"status":786,"phases":8936,"primaryCompletion":5170,"completion":5096,"start":5890,"enrollment":745,"conditions":8937,"interventions":8938},[91],[3387],[5893,5872,5894,5895,5896],{"trials":8940,"activeCount":103},[],{"trials":8942,"activeCount":103},[],{"trials":8944,"activeCount":103},[],{"trials":8946,"activeCount":103},[],{"intervention":5894,"totalTrials":184,"cells":8948},{"EARLY_PHASE1":8949,"PHASE1":8951,"PHASE2":8957,"PHASE3":8959,"PHASE4":8961,"NA":8963},{"trials":8950,"activeCount":103},[],{"trials":8952,"activeCount":103},[8953],{"nctId":5887,"briefTitle":5888,"status":786,"phases":8954,"primaryCompletion":5170,"completion":5096,"start":5890,"enrollment":745,"conditions":8955,"interventions":8956},[91],[3387],[5893,5872,5894,5895,5896],{"trials":8958,"activeCount":103},[],{"trials":8960,"activeCount":103},[],{"trials":8962,"activeCount":103},[],{"trials":8964,"activeCount":103},[],{"intervention":5895,"totalTrials":184,"cells":8966},{"EARLY_PHASE1":8967,"PHASE1":8969,"PHASE2":8975,"PHASE3":8977,"PHASE4":8979,"NA":8981},{"trials":8968,"activeCount":103},[],{"trials":8970,"activeCount":103},[8971],{"nctId":5887,"briefTitle":5888,"status":786,"phases":8972,"primaryCompletion":5170,"completion":5096,"start":5890,"enrollment":745,"conditions":8973,"interventions":8974},[91],[3387],[5893,5872,5894,5895,5896],{"trials":8976,"activeCount":103},[],{"trials":8978,"activeCount":103},[],{"trials":8980,"activeCount":103},[],{"trials":8982,"activeCount":103},[],{"intervention":5896,"totalTrials":184,"cells":8984},{"EARLY_PHASE1":8985,"PHASE1":8987,"PHASE2":8993,"PHASE3":8995,"PHASE4":8997,"NA":8999},{"trials":8986,"activeCount":103},[],{"trials":8988,"activeCount":103},[8989],{"nctId":5887,"briefTitle":5888,"status":786,"phases":8990,"primaryCompletion":5170,"completion":5096,"start":5890,"enrollment":745,"conditions":8991,"interventions":8992},[91],[3387],[5893,5872,5894,5895,5896],{"trials":8994,"activeCount":103},[],{"trials":8996,"activeCount":103},[],{"trials":8998,"activeCount":103},[],{"trials":9000,"activeCount":103},[],{"intervention":9002,"totalTrials":184,"cells":9003},"Tissue Plasminogen Activator",{"EARLY_PHASE1":9004,"PHASE1":9006,"PHASE2":9015,"PHASE3":9017,"PHASE4":9019,"NA":9021},{"trials":9005,"activeCount":103},[],{"trials":9007,"activeCount":103},[9008],{"nctId":9009,"briefTitle":9010,"status":156,"phases":9011,"primaryCompletion":6081,"completion":6081,"start":4745,"enrollment":184,"conditions":9012,"interventions":9014},"NCT01581411","Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion",[91],[9013],"Central Retinal Vein Occlusion",[9002],{"trials":9016,"activeCount":103},[],{"trials":9018,"activeCount":103},[],{"trials":9020,"activeCount":103},[],{"trials":9022,"activeCount":103},[],{"intervention":851,"totalTrials":184,"cells":9024},{"EARLY_PHASE1":9025,"PHASE1":9027,"PHASE2":9033,"PHASE3":9035,"PHASE4":9037,"NA":9039},{"trials":9026,"activeCount":103},[],{"trials":9028,"activeCount":103},[9029],{"nctId":844,"briefTitle":845,"status":786,"phases":9030,"primaryCompletion":847,"completion":847,"start":848,"enrollment":160,"conditions":9031,"interventions":9032},[91],[30],[851,504,852],{"trials":9034,"activeCount":103},[],{"trials":9036,"activeCount":103},[],{"trials":9038,"activeCount":103},[],{"trials":9040,"activeCount":103},[],{"intervention":8579,"totalTrials":184,"cells":9042},{"EARLY_PHASE1":9043,"PHASE1":9045,"PHASE2":9051,"PHASE3":9053,"PHASE4":9055,"NA":9057},{"trials":9044,"activeCount":103},[],{"trials":9046,"activeCount":103},[9047],{"nctId":8571,"briefTitle":8572,"status":156,"phases":9048,"primaryCompletion":8574,"completion":8575,"start":8576,"enrollment":722,"conditions":9049,"interventions":9050},[91],[18],[8556,8579],{"trials":9052,"activeCount":103},[],{"trials":9054,"activeCount":103},[],{"trials":9056,"activeCount":103},[],{"trials":9058,"activeCount":103},[],{"intervention":864,"totalTrials":184,"cells":9060},{"EARLY_PHASE1":9061,"PHASE1":9063,"PHASE2":9069,"PHASE3":9071,"PHASE4":9073,"NA":9075},{"trials":9062,"activeCount":103},[],{"trials":9064,"activeCount":103},[9065],{"nctId":854,"briefTitle":855,"status":156,"phases":9066,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":9067,"interventions":9068},[91],[862],[864,865,866,759,867,504],{"trials":9070,"activeCount":103},[],{"trials":9072,"activeCount":103},[],{"trials":9074,"activeCount":103},[],{"trials":9076,"activeCount":103},[],{"intervention":867,"totalTrials":184,"cells":9078},{"EARLY_PHASE1":9079,"PHASE1":9081,"PHASE2":9087,"PHASE3":9089,"PHASE4":9091,"NA":9093},{"trials":9080,"activeCount":103},[],{"trials":9082,"activeCount":103},[9083],{"nctId":854,"briefTitle":855,"status":156,"phases":9084,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":9085,"interventions":9086},[91],[862],[864,865,866,759,867,504],{"trials":9088,"activeCount":103},[],{"trials":9090,"activeCount":103},[],{"trials":9092,"activeCount":103},[],{"trials":9094,"activeCount":103},[],{"intervention":9096,"totalTrials":184,"cells":9097},"AAV2CUhCLN2",{"EARLY_PHASE1":9098,"PHASE1":9100,"PHASE2":9110,"PHASE3":9112,"PHASE4":9114,"NA":9116},{"trials":9099,"activeCount":103},[],{"trials":9101,"activeCount":103},[9102],{"nctId":9103,"briefTitle":9104,"status":156,"phases":9105,"primaryCompletion":9106,"completion":9106,"start":9107,"enrollment":1236,"conditions":9108,"interventions":9109},"NCT00151216","Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis",[91],"2019-06","2004-06",[6806,6805],[9096],{"trials":9111,"activeCount":103},[],{"trials":9113,"activeCount":103},[],{"trials":9115,"activeCount":103},[],{"trials":9117,"activeCount":103},[],{"intervention":1022,"totalTrials":184,"cells":9119},{"EARLY_PHASE1":9120,"PHASE1":9122,"PHASE2":9128,"PHASE3":9130,"PHASE4":9132,"NA":9134},{"trials":9121,"activeCount":103},[],{"trials":9123,"activeCount":103},[9124],{"nctId":1012,"briefTitle":1013,"status":156,"phases":9125,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":9126,"interventions":9127},[91],[862,1019],[1021,865,866,1022,1023,1024,1025],{"trials":9129,"activeCount":103},[],{"trials":9131,"activeCount":103},[],{"trials":9133,"activeCount":103},[],{"trials":9135,"activeCount":103},[],{"intervention":1025,"totalTrials":184,"cells":9137},{"EARLY_PHASE1":9138,"PHASE1":9140,"PHASE2":9146,"PHASE3":9148,"PHASE4":9150,"NA":9152},{"trials":9139,"activeCount":103},[],{"trials":9141,"activeCount":103},[9142],{"nctId":1012,"briefTitle":1013,"status":156,"phases":9143,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":9144,"interventions":9145},[91],[862,1019],[1021,865,866,1022,1023,1024,1025],{"trials":9147,"activeCount":103},[],{"trials":9149,"activeCount":103},[],{"trials":9151,"activeCount":103},[],{"trials":9153,"activeCount":103},[],{"intervention":9155,"totalTrials":184,"cells":9156},"CD40 Gene Transfer",{"EARLY_PHASE1":9157,"PHASE1":9159,"PHASE2":9167,"PHASE3":9169,"PHASE4":9171,"NA":9173},{"trials":9158,"activeCount":103},[],{"trials":9160,"activeCount":103},[9161],{"nctId":9162,"briefTitle":9163,"status":494,"phases":9164,"primaryCompletion":944,"completion":944,"start":1140,"enrollment":103,"conditions":9165,"interventions":9166},"NCT00328887","Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma",[91],[7531],[9155],{"trials":9168,"activeCount":103},[],{"trials":9170,"activeCount":103},[],{"trials":9172,"activeCount":103},[],{"trials":9174,"activeCount":103},[],{"intervention":9176,"totalTrials":184,"cells":9177},"CHOP and alemtuzumab",{"EARLY_PHASE1":9178,"PHASE1":9180,"PHASE2":9190,"PHASE3":9192,"PHASE4":9194,"NA":9196},{"trials":9179,"activeCount":103},[],{"trials":9181,"activeCount":103},[9182],{"nctId":9183,"briefTitle":9184,"status":156,"phases":9185,"start":8155,"conditions":9186,"interventions":9189},"NCT00161590","Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma",[91],[9187,9188],"T-Cell Lymphoma","Lymphoma, Non-Hodgkin's",[9176],{"trials":9191,"activeCount":103},[],{"trials":9193,"activeCount":103},[],{"trials":9195,"activeCount":103},[],{"trials":9197,"activeCount":103},[],{"intervention":9199,"totalTrials":184,"cells":9200},"bortezomib, tositumomab",{"EARLY_PHASE1":9201,"PHASE1":9203,"PHASE2":9213,"PHASE3":9215,"PHASE4":9217,"NA":9219},{"trials":9202,"activeCount":103},[],{"trials":9204,"activeCount":103},[9205],{"nctId":9206,"briefTitle":9207,"status":156,"phases":9208,"primaryCompletion":9209,"completion":9209,"start":9210,"enrollment":1017,"conditions":9211,"interventions":9212},"NCT00777114","Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy",[91],"2012-12-18","2007-04-01",[1126],[9199],{"trials":9214,"activeCount":103},[],{"trials":9216,"activeCount":103},[],{"trials":9218,"activeCount":103},[],{"trials":9220,"activeCount":103},[],{"intervention":9222,"totalTrials":184,"cells":9223},"117Lu-J591",{"EARLY_PHASE1":9224,"PHASE1":9226,"PHASE2":9235,"PHASE3":9237,"PHASE4":9239,"NA":9241},{"trials":9225,"activeCount":103},[],{"trials":9227,"activeCount":103},[9228],{"nctId":9229,"briefTitle":9230,"status":156,"phases":9231,"primaryCompletion":9232,"completion":4483,"start":5263,"enrollment":1994,"conditions":9233,"interventions":9234},"NCT00538668","Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody",[91],"2015-10",[18],[9222],{"trials":9236,"activeCount":103},[],{"trials":9238,"activeCount":103},[],{"trials":9240,"activeCount":103},[],{"trials":9242,"activeCount":103},[],{"intervention":1387,"totalTrials":184,"cells":9244},{"EARLY_PHASE1":9245,"PHASE1":9247,"PHASE2":9253,"PHASE3":9255,"PHASE4":9257,"NA":9259},{"trials":9246,"activeCount":103},[],{"trials":9248,"activeCount":103},[9249],{"nctId":1378,"briefTitle":1379,"status":156,"phases":9250,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":825,"conditions":9251,"interventions":9252},[91],[1385],[1387,1388,1376,1024],{"trials":9254,"activeCount":103},[],{"trials":9256,"activeCount":103},[],{"trials":9258,"activeCount":103},[],{"trials":9260,"activeCount":103},[],{"intervention":1388,"totalTrials":184,"cells":9262},{"EARLY_PHASE1":9263,"PHASE1":9265,"PHASE2":9271,"PHASE3":9273,"PHASE4":9275,"NA":9277},{"trials":9264,"activeCount":103},[],{"trials":9266,"activeCount":103},[9267],{"nctId":1378,"briefTitle":1379,"status":156,"phases":9268,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":825,"conditions":9269,"interventions":9270},[91],[1385],[1387,1388,1376,1024],{"trials":9272,"activeCount":103},[],{"trials":9274,"activeCount":103},[],{"trials":9276,"activeCount":103},[],{"trials":9278,"activeCount":103},[],{"intervention":5192,"totalTrials":184,"cells":9280},{"EARLY_PHASE1":9281,"PHASE1":9283,"PHASE2":9289,"PHASE3":9291,"PHASE4":9293,"NA":9295},{"trials":9282,"activeCount":103},[],{"trials":9284,"activeCount":103},[9285],{"nctId":5184,"briefTitle":5185,"status":786,"phases":9286,"primaryCompletion":5187,"completion":5188,"start":5189,"enrollment":22,"conditions":9287,"interventions":9288},[91],[1036],[5192,1840],{"trials":9290,"activeCount":103},[],{"trials":9292,"activeCount":103},[],{"trials":9294,"activeCount":103},[],{"trials":9296,"activeCount":103},[],{"intervention":736,"totalTrials":184,"cells":9298},{"EARLY_PHASE1":9299,"PHASE1":9301,"PHASE2":9307,"PHASE3":9309,"PHASE4":9311,"NA":9313},{"trials":9300,"activeCount":103},[],{"trials":9302,"activeCount":103},[9303],{"nctId":729,"briefTitle":730,"status":494,"phases":9304,"primaryCompletion":373,"completion":626,"start":732,"enrollment":103,"conditions":9305,"interventions":9306},[91],[734],[736,48,737],{"trials":9308,"activeCount":103},[],{"trials":9310,"activeCount":103},[],{"trials":9312,"activeCount":103},[],{"trials":9314,"activeCount":103},[],{"intervention":6299,"totalTrials":184,"cells":9316},{"EARLY_PHASE1":9317,"PHASE1":9319,"PHASE2":9325,"PHASE3":9327,"PHASE4":9329,"NA":9331},{"trials":9318,"activeCount":103},[],{"trials":9320,"activeCount":103},[9321],{"nctId":6292,"briefTitle":6293,"status":156,"phases":9322,"primaryCompletion":6295,"completion":5411,"start":3319,"enrollment":975,"conditions":9323,"interventions":9324},[91],[1915,6297],[6299,6285,6300,6301],{"trials":9326,"activeCount":103},[],{"trials":9328,"activeCount":103},[],{"trials":9330,"activeCount":103},[],{"trials":9332,"activeCount":103},[],{"intervention":6300,"totalTrials":184,"cells":9334},{"EARLY_PHASE1":9335,"PHASE1":9337,"PHASE2":9343,"PHASE3":9345,"PHASE4":9347,"NA":9349},{"trials":9336,"activeCount":103},[],{"trials":9338,"activeCount":103},[9339],{"nctId":6292,"briefTitle":6293,"status":156,"phases":9340,"primaryCompletion":6295,"completion":5411,"start":3319,"enrollment":975,"conditions":9341,"interventions":9342},[91],[1915,6297],[6299,6285,6300,6301],{"trials":9344,"activeCount":103},[],{"trials":9346,"activeCount":103},[],{"trials":9348,"activeCount":103},[],{"trials":9350,"activeCount":103},[],{"intervention":9352,"totalTrials":184,"cells":9353},"Dried Cranberry",{"EARLY_PHASE1":9354,"PHASE1":9356,"PHASE2":9366,"PHASE3":9368,"PHASE4":9370,"NA":9372},{"trials":9355,"activeCount":103},[],{"trials":9357,"activeCount":103},[9358],{"nctId":9359,"briefTitle":9360,"status":156,"phases":9361,"primaryCompletion":9362,"completion":9362,"start":9363,"enrollment":8022,"conditions":9364,"interventions":9365},"NCT03017170","Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB",[91],"2018-07","2016-04",[3322],[9352],{"trials":9367,"activeCount":103},[],{"trials":9369,"activeCount":103},[],{"trials":9371,"activeCount":103},[],{"trials":9373,"activeCount":103},[],{"intervention":9375,"totalTrials":184,"cells":9376},"ATRA-IV",{"EARLY_PHASE1":9377,"PHASE1":9379,"PHASE2":9390,"PHASE3":9392,"PHASE4":9394,"NA":9396},{"trials":9378,"activeCount":103},[],{"trials":9380,"activeCount":103},[9381],{"nctId":9382,"briefTitle":9383,"status":786,"phases":9384,"start":9385,"conditions":9386,"interventions":9388},"NCT00195156","Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies",[91],"2003-07",[9387],"Solid Tumor Malignancies",[9375,9389],"Depakote",{"trials":9391,"activeCount":103},[],{"trials":9393,"activeCount":103},[],{"trials":9395,"activeCount":103},[],{"trials":9397,"activeCount":103},[],{"intervention":9389,"totalTrials":184,"cells":9399},{"EARLY_PHASE1":9400,"PHASE1":9402,"PHASE2":9408,"PHASE3":9410,"PHASE4":9412,"NA":9414},{"trials":9401,"activeCount":103},[],{"trials":9403,"activeCount":103},[9404],{"nctId":9382,"briefTitle":9383,"status":786,"phases":9405,"start":9385,"conditions":9406,"interventions":9407},[91],[9387],[9375,9389],{"trials":9409,"activeCount":103},[],{"trials":9411,"activeCount":103},[],{"trials":9413,"activeCount":103},[],{"trials":9415,"activeCount":103},[],{"intervention":9417,"totalTrials":99,"cells":9418},"Clonidine Pill",{"EARLY_PHASE1":9419,"PHASE1":9439,"PHASE2":9441,"PHASE3":9443,"PHASE4":9445,"NA":9447},{"trials":9420,"activeCount":103},[9421,9430],{"nctId":9422,"briefTitle":9423,"status":494,"phases":9424,"primaryCompletion":9425,"completion":9425,"start":9426,"enrollment":103,"conditions":9427,"interventions":9429},"NCT04032691","PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol",[90],"2021-05-24","2019-08-27",[9428],"Healthy Volunteers",[9417],{"nctId":9431,"briefTitle":9432,"status":786,"phases":9433,"primaryCompletion":2648,"completion":2648,"start":9434,"enrollment":141,"conditions":9435,"interventions":9438},"NCT04030572","Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies",[90],"2019-12-10",[9436,9437],"Neuro-Degenerative Disease","Cancer",[9417],{"trials":9440,"activeCount":103},[],{"trials":9442,"activeCount":103},[],{"trials":9444,"activeCount":103},[],{"trials":9446,"activeCount":103},[],{"trials":9448,"activeCount":103},[],{"intervention":9450,"totalTrials":184,"cells":9451},"Carbon 11 Butanol",{"EARLY_PHASE1":9452,"PHASE1":9460,"PHASE2":9462,"PHASE3":9464,"PHASE4":9466,"NA":9468},{"trials":9453,"activeCount":103},[9454],{"nctId":9455,"briefTitle":9456,"status":156,"phases":9457,"primaryCompletion":1099,"completion":4593,"start":945,"enrollment":178,"conditions":9458,"interventions":9459},"NCT04050800","Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety",[90],[9436],[9450],{"trials":9461,"activeCount":103},[],{"trials":9463,"activeCount":103},[],{"trials":9465,"activeCount":103},[],{"trials":9467,"activeCount":103},[],{"trials":9469,"activeCount":103},[],{"intervention":9471,"totalTrials":184,"cells":9472},"Amantadine + L-DOPA",{"EARLY_PHASE1":9473,"PHASE1":9486,"PHASE2":9488,"PHASE3":9490,"PHASE4":9492,"NA":9494},{"trials":9474,"activeCount":103},[9475],{"nctId":9476,"briefTitle":9477,"status":2883,"phases":9478,"primaryCompletion":9479,"completion":7994,"start":9480,"enrollment":478,"conditions":9481,"interventions":9484},"NCT04244058","Changes in Glutamatergic Neurotransmission of Severe TBI Patients",[90],"2023-05-30","2020-09-23",[9482,9483],"Disorder of Consciousness","Traumatic Brain Injury",[9471,9485],"NMDA blocker",{"trials":9487,"activeCount":103},[],{"trials":9489,"activeCount":103},[],{"trials":9491,"activeCount":103},[],{"trials":9493,"activeCount":103},[],{"trials":9495,"activeCount":103},[],{"intervention":9485,"totalTrials":184,"cells":9497},{"EARLY_PHASE1":9498,"PHASE1":9504,"PHASE2":9506,"PHASE3":9508,"PHASE4":9510,"NA":9512},{"trials":9499,"activeCount":103},[9500],{"nctId":9476,"briefTitle":9477,"status":2883,"phases":9501,"primaryCompletion":9479,"completion":7994,"start":9480,"enrollment":478,"conditions":9502,"interventions":9503},[90],[9482,9483],[9471,9485],{"trials":9505,"activeCount":103},[],{"trials":9507,"activeCount":103},[],{"trials":9509,"activeCount":103},[],{"trials":9511,"activeCount":103},[],{"trials":9513,"activeCount":103},[],{"intervention":9515,"totalTrials":184,"cells":9516},"Triamcinolone",{"EARLY_PHASE1":9517,"PHASE1":9528,"PHASE2":9530,"PHASE3":9532,"PHASE4":9534,"NA":9536},{"trials":9518,"activeCount":103},[9519],{"nctId":9520,"briefTitle":9521,"status":494,"phases":9522,"primaryCompletion":9523,"completion":9523,"start":4482,"enrollment":103,"conditions":9524,"interventions":9527},"NCT03729310","Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis",[90],"2020-05-26",[9525,9526],"Chronic Sinusitis","Rhinosinusitis",[9515],{"trials":9529,"activeCount":103},[],{"trials":9531,"activeCount":103},[],{"trials":9533,"activeCount":103},[],{"trials":9535,"activeCount":103},[],{"trials":9537,"activeCount":103},[],{"intervention":9539,"totalTrials":811,"cells":9540},"Escitalopram",{"EARLY_PHASE1":9541,"PHASE1":9543,"PHASE2":9545,"PHASE3":9556,"PHASE4":9558,"NA":9576},{"trials":9542,"activeCount":103},[],{"trials":9544,"activeCount":103},[],{"trials":9546,"activeCount":103},[9547],{"nctId":9548,"briefTitle":9549,"status":786,"phases":9550,"primaryCompletion":9551,"completion":82,"start":9552,"enrollment":4531,"conditions":9553,"interventions":9555},"NCT03527043","Impact of Escitalopram on Sperm DNA Fragmentation",[92],"2023-04-04","2017-10-01",[9554,7491],"Sperm DNA Fragmentation",[9539],{"trials":9557,"activeCount":103},[],{"trials":9559,"activeCount":103},[9560,9568],{"nctId":9561,"briefTitle":9562,"status":156,"phases":9563,"primaryCompletion":9564,"completion":9564,"start":9565,"enrollment":927,"conditions":9566,"interventions":9567},"NCT01728194","Emotional and Cognitive Control in Late-Onset Depression",[94],"2019-07-31","2012-07",[15],[9539],{"nctId":9569,"briefTitle":9570,"status":156,"phases":9571,"primaryCompletion":4001,"completion":4001,"start":9572,"enrollment":9573,"conditions":9574,"interventions":9575},"NCT00918684","Aging Brain Changes, Executive Dysfunction and Depression",[94],"2002-12",116,[15],[9539],{"trials":9577,"activeCount":103},[9578,9586,9594],{"nctId":9579,"briefTitle":9580,"status":156,"phases":9581,"primaryCompletion":7775,"completion":1911,"start":9582,"enrollment":375,"conditions":9583,"interventions":9584},"NCT00194948","Treatment Choices for Improving Adherence and Outcome",[95],"2003-09",[3471],[9585],"escitalopram",{"nctId":9587,"briefTitle":9588,"status":156,"phases":9589,"primaryCompletion":9590,"completion":9590,"start":1911,"enrollment":9591,"conditions":9592,"interventions":9593},"NCT00754936","Treatment Response of Geriatric Depression",[95],"2015-05",106,[15],[9539],{"nctId":9595,"briefTitle":9596,"status":156,"phases":9597,"primaryCompletion":4001,"completion":4001,"start":9598,"enrollment":6756,"conditions":9599,"interventions":9600},"NCT00926653","Assessing Anterior Cingulate Brain Activity in People With Late-Life Depression",[],"2005-07",[15],[9539],{"intervention":9602,"totalTrials":99,"cells":9603},"Antibiotic",{"EARLY_PHASE1":9604,"PHASE1":9606,"PHASE2":9608,"PHASE3":9610,"PHASE4":9612,"NA":9614},{"trials":9605,"activeCount":103},[],{"trials":9607,"activeCount":103},[],{"trials":9609,"activeCount":103},[],{"trials":9611,"activeCount":103},[],{"trials":9613,"activeCount":103},[],{"trials":9615,"activeCount":103},[9616,9626],{"nctId":9617,"briefTitle":9618,"status":156,"phases":9619,"primaryCompletion":9620,"completion":9620,"start":9621,"enrollment":9622,"conditions":9623,"interventions":9625},"NCT04843566","PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy",[95],"2024-04-19","2021-03-22",687,[9624],"Infection",[9602],{"nctId":9627,"briefTitle":9628,"status":156,"phases":9629,"primaryCompletion":9630,"completion":9630,"start":9631,"enrollment":9632,"conditions":9633,"interventions":9634},"NCT04815876","PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2",[95],"2025-10-11","2021-06-24",1030,[9624],[9602],{"intervention":9636,"totalTrials":99,"cells":9637},"Minocycline",{"EARLY_PHASE1":9638,"PHASE1":9640,"PHASE2":9642,"PHASE3":9644,"PHASE4":9646,"NA":9648},{"trials":9639,"activeCount":103},[],{"trials":9641,"activeCount":103},[],{"trials":9643,"activeCount":103},[],{"trials":9645,"activeCount":103},[],{"trials":9647,"activeCount":103},[],{"trials":9649,"activeCount":103},[9650,9657],{"nctId":9651,"briefTitle":9652,"status":156,"phases":9653,"primaryCompletion":9654,"completion":9654,"start":3809,"enrollment":825,"conditions":9655,"interventions":9656},"NCT01659320","Open Treatment of Minocycline in Geriatric Depression",[95],"2015-04",[15],[9636],{"nctId":9658,"briefTitle":9659,"status":156,"phases":9660,"primaryCompletion":9661,"completion":9661,"start":9662,"enrollment":1313,"conditions":9663,"interventions":9664},"NCT02765100","Depression, Obesity and Inflammatory Markers",[95],"2019-10","2014-10",[3743,15,4172],[9636],{"intervention":4073,"totalTrials":99,"cells":9666},{"EARLY_PHASE1":9667,"PHASE1":9669,"PHASE2":9671,"PHASE3":9673,"PHASE4":9675,"NA":9681},{"trials":9668,"activeCount":103},[],{"trials":9670,"activeCount":103},[],{"trials":9672,"activeCount":103},[],{"trials":9674,"activeCount":103},[],{"trials":9676,"activeCount":103},[9677],{"nctId":4066,"briefTitle":4067,"status":156,"phases":9678,"primaryCompletion":4069,"completion":4069,"start":4070,"enrollment":37,"conditions":9679,"interventions":9680},[94],[246,3696],[4073,4053,4074,4075,4076],{"trials":9682,"activeCount":103},[9683],{"nctId":9684,"briefTitle":9685,"status":156,"phases":9686,"primaryCompletion":5412,"completion":5412,"start":3717,"enrollment":9687,"conditions":9688,"interventions":9690},"NCT00767767","The Effect of Intravenous Anesthetics on Fear Learning and Memory",[95],67,[9689],"Phobias",[4073,9691,9692,9693,9694],"Propofol 0.45mcg\u002FmL","Propofol 0.90mcg\u002FmL","Thiopental 1.5mcg\u002FmL","Thiopental 3mcg\u002FmL",{"intervention":9696,"totalTrials":99,"cells":9697},"Celecoxib",{"EARLY_PHASE1":9698,"PHASE1":9700,"PHASE2":9702,"PHASE3":9708,"PHASE4":9710,"NA":9712},{"trials":9699,"activeCount":103},[],{"trials":9701,"activeCount":103},[],{"trials":9703,"activeCount":103},[9704],{"nctId":1908,"briefTitle":1909,"status":156,"phases":9705,"primaryCompletion":1911,"start":1912,"enrollment":1913,"conditions":9706,"interventions":9707},[92],[1915],[1917,1918,1919],{"trials":9709,"activeCount":103},[],{"trials":9711,"activeCount":103},[],{"trials":9713,"activeCount":103},[9714],{"nctId":9715,"briefTitle":9716,"status":786,"phases":9717,"primaryCompletion":3383,"completion":9718,"start":4458,"enrollment":9719,"conditions":9720,"interventions":9722},"NCT01323595","Effectiveness of Celecoxib After Surgical Sperm Retrieval",[95],"2013-03",78,[9721],"Pain",[9696,9723],"Sugar Pill",{"intervention":9725,"totalTrials":184,"cells":9726},"paroxetine",{"EARLY_PHASE1":9727,"PHASE1":9729,"PHASE2":9731,"PHASE3":9733,"PHASE4":9735,"NA":9737},{"trials":9728,"activeCount":103},[],{"trials":9730,"activeCount":103},[],{"trials":9732,"activeCount":103},[],{"trials":9734,"activeCount":103},[],{"trials":9736,"activeCount":103},[],{"trials":9738,"activeCount":103},[9739],{"nctId":9740,"briefTitle":9741,"status":156,"phases":9742,"primaryCompletion":9743,"completion":9743,"start":8483,"enrollment":9,"conditions":9744,"interventions":9745},"NCT00385762","SSRI Effects on Semen Parameters in Men",[],"2007-09",[3646],[9725],{"intervention":9747,"totalTrials":184,"cells":9748},"Indinavir sulfate",{"EARLY_PHASE1":9749,"PHASE1":9751,"PHASE2":9753,"PHASE3":9755,"PHASE4":9757,"NA":9759},{"trials":9750,"activeCount":103},[],{"trials":9752,"activeCount":103},[],{"trials":9754,"activeCount":103},[],{"trials":9756,"activeCount":103},[],{"trials":9758,"activeCount":103},[],{"trials":9760,"activeCount":103},[9761],{"nctId":9762,"briefTitle":9763,"status":156,"phases":9764,"conditions":9765,"interventions":9766},"NCT00002407","A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs",[95],[3670],[9747,9767,9768,9769,9770],"Nevirapine","Lamivudine","Stavudine","Didanosine",{"intervention":9767,"totalTrials":184,"cells":9772},{"EARLY_PHASE1":9773,"PHASE1":9775,"PHASE2":9777,"PHASE3":9779,"PHASE4":9781,"NA":9783},{"trials":9774,"activeCount":103},[],{"trials":9776,"activeCount":103},[],{"trials":9778,"activeCount":103},[],{"trials":9780,"activeCount":103},[],{"trials":9782,"activeCount":103},[],{"trials":9784,"activeCount":103},[9785],{"nctId":9762,"briefTitle":9763,"status":156,"phases":9786,"conditions":9787,"interventions":9788},[95],[3670],[9747,9767,9768,9769,9770],{"intervention":9768,"totalTrials":184,"cells":9790},{"EARLY_PHASE1":9791,"PHASE1":9793,"PHASE2":9795,"PHASE3":9797,"PHASE4":9799,"NA":9801},{"trials":9792,"activeCount":103},[],{"trials":9794,"activeCount":103},[],{"trials":9796,"activeCount":103},[],{"trials":9798,"activeCount":103},[],{"trials":9800,"activeCount":103},[],{"trials":9802,"activeCount":103},[9803],{"nctId":9762,"briefTitle":9763,"status":156,"phases":9804,"conditions":9805,"interventions":9806},[95],[3670],[9747,9767,9768,9769,9770],{"intervention":9769,"totalTrials":184,"cells":9808},{"EARLY_PHASE1":9809,"PHASE1":9811,"PHASE2":9813,"PHASE3":9815,"PHASE4":9817,"NA":9819},{"trials":9810,"activeCount":103},[],{"trials":9812,"activeCount":103},[],{"trials":9814,"activeCount":103},[],{"trials":9816,"activeCount":103},[],{"trials":9818,"activeCount":103},[],{"trials":9820,"activeCount":103},[9821],{"nctId":9762,"briefTitle":9763,"status":156,"phases":9822,"conditions":9823,"interventions":9824},[95],[3670],[9747,9767,9768,9769,9770],{"intervention":9770,"totalTrials":184,"cells":9826},{"EARLY_PHASE1":9827,"PHASE1":9829,"PHASE2":9831,"PHASE3":9833,"PHASE4":9835,"NA":9837},{"trials":9828,"activeCount":103},[],{"trials":9830,"activeCount":103},[],{"trials":9832,"activeCount":103},[],{"trials":9834,"activeCount":103},[],{"trials":9836,"activeCount":103},[],{"trials":9838,"activeCount":103},[9839],{"nctId":9762,"briefTitle":9763,"status":156,"phases":9840,"conditions":9841,"interventions":9842},[95],[3670],[9747,9767,9768,9769,9770],{"intervention":9844,"totalTrials":184,"cells":9845},"Blood Samples for Biomarkers",{"EARLY_PHASE1":9846,"PHASE1":9848,"PHASE2":9850,"PHASE3":9852,"PHASE4":9854,"NA":9856},{"trials":9847,"activeCount":103},[],{"trials":9849,"activeCount":103},[],{"trials":9851,"activeCount":103},[],{"trials":9853,"activeCount":103},[],{"trials":9855,"activeCount":103},[],{"trials":9857,"activeCount":103},[9858],{"nctId":9859,"briefTitle":9860,"status":156,"phases":9861,"primaryCompletion":9862,"completion":9862,"start":9863,"enrollment":1156,"conditions":9864,"interventions":9865},"NCT05074875","COVID-19 Respiratory Outcomes Registry",[],"2023-05-09","2021-01-15",[7665],[9844],{"intervention":9867,"totalTrials":184,"cells":9868},"ABVD chemotherapy",{"EARLY_PHASE1":9869,"PHASE1":9871,"PHASE2":9873,"PHASE3":9875,"PHASE4":9877,"NA":9879},{"trials":9870,"activeCount":103},[],{"trials":9872,"activeCount":103},[],{"trials":9874,"activeCount":103},[],{"trials":9876,"activeCount":103},[],{"trials":9878,"activeCount":103},[],{"trials":9880,"activeCount":103},[9881],{"nctId":9882,"briefTitle":9883,"status":786,"phases":9884,"primaryCompletion":9885,"completion":6204,"start":3717,"enrollment":811,"conditions":9886,"interventions":9887},"NCT00901303","Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma",[95],"2010-06",[1125],[9867],{"intervention":9889,"totalTrials":184,"cells":9890},"7 days of amoxicillin",{"EARLY_PHASE1":9891,"PHASE1":9893,"PHASE2":9895,"PHASE3":9897,"PHASE4":9899,"NA":9901},{"trials":9892,"activeCount":103},[],{"trials":9894,"activeCount":103},[],{"trials":9896,"activeCount":103},[],{"trials":9898,"activeCount":103},[],{"trials":9900,"activeCount":103},[],{"trials":9902,"activeCount":103},[9903],{"nctId":9904,"briefTitle":9905,"status":156,"phases":9906,"primaryCompletion":1911,"completion":1911,"start":9907,"enrollment":1583,"conditions":9908,"interventions":9910},"NCT00662987","Effect of Duration of Antibiotic Therapy on Recovery Following Tonsillectomy",[95],"2005-09",[9909],"Tonsillectomy",[9889,9911],"3 days of amoxcillin followed by 4 days of placebo",{"intervention":9911,"totalTrials":184,"cells":9913},{"EARLY_PHASE1":9914,"PHASE1":9916,"PHASE2":9918,"PHASE3":9920,"PHASE4":9922,"NA":9924},{"trials":9915,"activeCount":103},[],{"trials":9917,"activeCount":103},[],{"trials":9919,"activeCount":103},[],{"trials":9921,"activeCount":103},[],{"trials":9923,"activeCount":103},[],{"trials":9925,"activeCount":103},[9926],{"nctId":9904,"briefTitle":9905,"status":156,"phases":9927,"primaryCompletion":1911,"completion":1911,"start":9907,"enrollment":1583,"conditions":9928,"interventions":9929},[95],[9909],[9889,9911],{"intervention":9931,"totalTrials":184,"cells":9932},"Discontinuation of eltrombopag",{"EARLY_PHASE1":9933,"PHASE1":9935,"PHASE2":9937,"PHASE3":9939,"PHASE4":9941,"NA":9943},{"trials":9934,"activeCount":103},[],{"trials":9936,"activeCount":103},[],{"trials":9938,"activeCount":103},[],{"trials":9940,"activeCount":103},[],{"trials":9942,"activeCount":103},[],{"trials":9944,"activeCount":103},[9945],{"nctId":9946,"briefTitle":9947,"status":786,"phases":9948,"primaryCompletion":6104,"start":3319,"enrollment":9,"conditions":9949,"interventions":9950},"NCT01386723","End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia",[],[984],[9931],{"intervention":9952,"totalTrials":184,"cells":9953},"Acetaminophen 975 mg",{"EARLY_PHASE1":9954,"PHASE1":9956,"PHASE2":9958,"PHASE3":9960,"PHASE4":9962,"NA":9964},{"trials":9955,"activeCount":103},[],{"trials":9957,"activeCount":103},[],{"trials":9959,"activeCount":103},[],{"trials":9961,"activeCount":103},[],{"trials":9963,"activeCount":103},[],{"trials":9965,"activeCount":103},[9966],{"nctId":9967,"briefTitle":9968,"status":786,"phases":9969,"primaryCompletion":1193,"completion":1193,"start":4947,"enrollment":34,"conditions":9970,"interventions":9973},"NCT00377832","Acetaminophen for Fetal Tachycardia: a Randomized Pilot Trial",[95],[9971,9972],"Fever","Heart Rate, Fetal (FHR)",[9952],{"intervention":9975,"totalTrials":184,"cells":9976},"Genomind®Professional PGx Express TM",{"EARLY_PHASE1":9977,"PHASE1":9979,"PHASE2":9981,"PHASE3":9983,"PHASE4":9985,"NA":9987},{"trials":9978,"activeCount":103},[],{"trials":9980,"activeCount":103},[],{"trials":9982,"activeCount":103},[],{"trials":9984,"activeCount":103},[],{"trials":9986,"activeCount":103},[],{"trials":9988,"activeCount":103},[9989],{"nctId":9990,"briefTitle":9991,"status":494,"phases":9992,"primaryCompletion":9993,"completion":9994,"start":9995,"enrollment":103,"conditions":9996,"interventions":9997},"NCT03952494","Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support",[95],"2023-02-28","2023-12-31","2022-03-01",[15],[9975],{"intervention":9999,"totalTrials":184,"cells":10000},"Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]",{"EARLY_PHASE1":10001,"PHASE1":10003,"PHASE2":10005,"PHASE3":10007,"PHASE4":10009,"NA":10011},{"trials":10002,"activeCount":103},[],{"trials":10004,"activeCount":103},[],{"trials":10006,"activeCount":103},[],{"trials":10008,"activeCount":103},[],{"trials":10010,"activeCount":103},[],{"trials":10012,"activeCount":103},[10013],{"nctId":10014,"briefTitle":10015,"status":156,"phases":10016,"primaryCompletion":5411,"completion":1263,"start":9718,"enrollment":1737,"conditions":10017,"interventions":10020},"NCT03212326","Contrast ICE for Myocardial Scar in VT Ablations",[95],[10018,10019],"Ventricular Tachycardia","Ischemic Cardiomyopathy",[9999],{"intervention":10022,"totalTrials":184,"cells":10023},"Voclosporin",{"EARLY_PHASE1":10024,"PHASE1":10026,"PHASE2":10028,"PHASE3":10030,"PHASE4":10032,"NA":10034},{"trials":10025,"activeCount":103},[],{"trials":10027,"activeCount":103},[],{"trials":10029,"activeCount":103},[],{"trials":10031,"activeCount":103},[],{"trials":10033,"activeCount":103},[],{"trials":10035,"activeCount":103},[10036],{"nctId":10037,"briefTitle":10038,"status":10039,"phases":10040,"conditions":10041,"interventions":10043},"NCT01236287","Special Access for the Use of Voclosporin for Kidney Transplantation","NO_LONGER_AVAILABLE",[],[1806,10042],"Transplantation, Kidney",[10022],{"intervention":10045,"totalTrials":184,"cells":10046},"RiaSTAP",{"EARLY_PHASE1":10047,"PHASE1":10049,"PHASE2":10051,"PHASE3":10053,"PHASE4":10055,"NA":10057},{"trials":10048,"activeCount":103},[],{"trials":10050,"activeCount":103},[],{"trials":10052,"activeCount":103},[],{"trials":10054,"activeCount":103},[],{"trials":10056,"activeCount":103},[],{"trials":10058,"activeCount":103},[10059],{"nctId":10060,"briefTitle":10061,"status":786,"phases":10062,"primaryCompletion":847,"completion":10063,"start":9232,"enrollment":25,"conditions":10064,"interventions":10066},"NCT02540434","Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions",[95],"2017-12",[10065],"Coagulopathy",[10045],{"intervention":10068,"totalTrials":184,"cells":10069},"RenuGel",{"EARLY_PHASE1":10070,"PHASE1":10072,"PHASE2":10074,"PHASE3":10076,"PHASE4":10078,"NA":10080},{"trials":10071,"activeCount":103},[],{"trials":10073,"activeCount":103},[],{"trials":10075,"activeCount":103},[],{"trials":10077,"activeCount":103},[],{"trials":10079,"activeCount":103},[],{"trials":10081,"activeCount":103},[10082],{"nctId":10083,"briefTitle":10084,"status":156,"phases":10085,"primaryCompletion":10086,"completion":10086,"start":10087,"enrollment":722,"conditions":10088,"interventions":10090},"NCT02711995","Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation",[95],"2016-09-29","2015-12-15",[10089],"Essential Tremor",[10068,10091],"Botulinum Toxin",{"intervention":10091,"totalTrials":184,"cells":10093},{"EARLY_PHASE1":10094,"PHASE1":10096,"PHASE2":10098,"PHASE3":10100,"PHASE4":10102,"NA":10104},{"trials":10095,"activeCount":103},[],{"trials":10097,"activeCount":103},[],{"trials":10099,"activeCount":103},[],{"trials":10101,"activeCount":103},[],{"trials":10103,"activeCount":103},[],{"trials":10105,"activeCount":103},[10106],{"nctId":10083,"briefTitle":10084,"status":156,"phases":10107,"primaryCompletion":10086,"completion":10086,"start":10087,"enrollment":722,"conditions":10108,"interventions":10109},[95],[10089],[10068,10091],{"intervention":9723,"totalTrials":184,"cells":10111},{"EARLY_PHASE1":10112,"PHASE1":10114,"PHASE2":10116,"PHASE3":10118,"PHASE4":10120,"NA":10122},{"trials":10113,"activeCount":103},[],{"trials":10115,"activeCount":103},[],{"trials":10117,"activeCount":103},[],{"trials":10119,"activeCount":103},[],{"trials":10121,"activeCount":103},[],{"trials":10123,"activeCount":103},[10124],{"nctId":9715,"briefTitle":9716,"status":786,"phases":10125,"primaryCompletion":3383,"completion":9718,"start":4458,"enrollment":9719,"conditions":10126,"interventions":10127},[95],[9721],[9696,9723],{"intervention":10129,"totalTrials":184,"cells":10130},"DCS",{"EARLY_PHASE1":10131,"PHASE1":10133,"PHASE2":10135,"PHASE3":10137,"PHASE4":10139,"NA":10141},{"trials":10132,"activeCount":103},[],{"trials":10134,"activeCount":103},[],{"trials":10136,"activeCount":103},[],{"trials":10138,"activeCount":103},[],{"trials":10140,"activeCount":103},[],{"trials":10142,"activeCount":103},[10143],{"nctId":10144,"briefTitle":10145,"status":786,"phases":10146,"primaryCompletion":10147,"completion":10147,"start":4702,"enrollment":766,"conditions":10148,"interventions":10150},"NCT00875342","Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)",[95],"2018-02-28",[10149],"Posttraumatic Stress Disorder",[10129],{"intervention":10152,"totalTrials":184,"cells":10153},"Ramipril",{"EARLY_PHASE1":10154,"PHASE1":10156,"PHASE2":10158,"PHASE3":10160,"PHASE4":10162,"NA":10164},{"trials":10155,"activeCount":103},[],{"trials":10157,"activeCount":103},[],{"trials":10159,"activeCount":103},[],{"trials":10161,"activeCount":103},[],{"trials":10163,"activeCount":103},[],{"trials":10165,"activeCount":103},[10166],{"nctId":10167,"briefTitle":10168,"status":786,"phases":10169,"primaryCompletion":3523,"completion":3523,"start":1803,"enrollment":99,"conditions":10170,"interventions":10174},"NCT01856361","Ramipril for the Treatment of Oligospermia",[95],[10171,10172,10173,4244],"Oligospermia","Teratospermia","Asthenozoospermia",[10152],{"intervention":10176,"totalTrials":184,"cells":10177},"Amiodarone",{"EARLY_PHASE1":10178,"PHASE1":10180,"PHASE2":10182,"PHASE3":10184,"PHASE4":10186,"NA":10188},{"trials":10179,"activeCount":103},[],{"trials":10181,"activeCount":103},[],{"trials":10183,"activeCount":103},[],{"trials":10185,"activeCount":103},[],{"trials":10187,"activeCount":103},[],{"trials":10189,"activeCount":103},[10190],{"nctId":10191,"briefTitle":10192,"status":786,"phases":10193,"primaryCompletion":9718,"completion":9718,"start":3809,"enrollment":184,"conditions":10194,"interventions":10196},"NCT01558128","Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery",[95],[10195],"Cardiac Disease",[10176],{"intervention":10198,"totalTrials":184,"cells":10199},"[C11]PK-1195 PET scan",{"EARLY_PHASE1":10200,"PHASE1":10202,"PHASE2":10204,"PHASE3":10206,"PHASE4":10208,"NA":10210},{"trials":10201,"activeCount":103},[],{"trials":10203,"activeCount":103},[],{"trials":10205,"activeCount":103},[],{"trials":10207,"activeCount":103},[],{"trials":10209,"activeCount":103},[],{"trials":10211,"activeCount":103},[10212],{"nctId":10213,"briefTitle":10214,"status":156,"phases":10215,"primaryCompletion":6486,"completion":6486,"start":10216,"enrollment":1583,"conditions":10217,"interventions":10219},"NCT02207075","Measuring Active Microglia in Progressive Multiple Sclerosis",[],"2014-07",[10218],"Secondary Progressive Multiple Sclerosis",[10198],{"intervention":10221,"totalTrials":184,"cells":10222},"Treatment of depression",{"EARLY_PHASE1":10223,"PHASE1":10225,"PHASE2":10227,"PHASE3":10229,"PHASE4":10231,"NA":10233},{"trials":10224,"activeCount":103},[],{"trials":10226,"activeCount":103},[],{"trials":10228,"activeCount":103},[],{"trials":10230,"activeCount":103},[],{"trials":10232,"activeCount":103},[],{"trials":10234,"activeCount":103},[10235],{"nctId":10236,"briefTitle":10237,"status":156,"phases":10238,"completion":10239,"start":10240,"conditions":10241,"interventions":10242},"NCT00000367","Prevention of Suicide in the Elderly",[95],"2003-08","1998-09",[15],[10221,10243],"Suicide prevention treatment",{"intervention":10243,"totalTrials":184,"cells":10245},{"EARLY_PHASE1":10246,"PHASE1":10248,"PHASE2":10250,"PHASE3":10252,"PHASE4":10254,"NA":10256},{"trials":10247,"activeCount":103},[],{"trials":10249,"activeCount":103},[],{"trials":10251,"activeCount":103},[],{"trials":10253,"activeCount":103},[],{"trials":10255,"activeCount":103},[],{"trials":10257,"activeCount":103},[10258],{"nctId":10236,"briefTitle":10237,"status":156,"phases":10259,"completion":10239,"start":10240,"conditions":10260,"interventions":10261},[95],[15],[10221,10243],{"intervention":10263,"totalTrials":184,"cells":10264},"D-Cycloserine",{"EARLY_PHASE1":10265,"PHASE1":10267,"PHASE2":10269,"PHASE3":10271,"PHASE4":10273,"NA":10275},{"trials":10266,"activeCount":103},[],{"trials":10268,"activeCount":103},[],{"trials":10270,"activeCount":103},[],{"trials":10272,"activeCount":103},[],{"trials":10274,"activeCount":103},[],{"trials":10276,"activeCount":103},[10277],{"nctId":10278,"briefTitle":10279,"status":156,"phases":10280,"primaryCompletion":3383,"completion":3383,"start":10281,"enrollment":532,"conditions":10282,"interventions":10283},"NCT00632632","Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)",[95],"2005-01",[10149],[10263],{"intervention":9691,"totalTrials":184,"cells":10285},{"EARLY_PHASE1":10286,"PHASE1":10288,"PHASE2":10290,"PHASE3":10292,"PHASE4":10294,"NA":10296},{"trials":10287,"activeCount":103},[],{"trials":10289,"activeCount":103},[],{"trials":10291,"activeCount":103},[],{"trials":10293,"activeCount":103},[],{"trials":10295,"activeCount":103},[],{"trials":10297,"activeCount":103},[10298],{"nctId":9684,"briefTitle":9685,"status":156,"phases":10299,"primaryCompletion":5412,"completion":5412,"start":3717,"enrollment":9687,"conditions":10300,"interventions":10301},[95],[9689],[4073,9691,9692,9693,9694],{"intervention":9692,"totalTrials":184,"cells":10303},{"EARLY_PHASE1":10304,"PHASE1":10306,"PHASE2":10308,"PHASE3":10310,"PHASE4":10312,"NA":10314},{"trials":10305,"activeCount":103},[],{"trials":10307,"activeCount":103},[],{"trials":10309,"activeCount":103},[],{"trials":10311,"activeCount":103},[],{"trials":10313,"activeCount":103},[],{"trials":10315,"activeCount":103},[10316],{"nctId":9684,"briefTitle":9685,"status":156,"phases":10317,"primaryCompletion":5412,"completion":5412,"start":3717,"enrollment":9687,"conditions":10318,"interventions":10319},[95],[9689],[4073,9691,9692,9693,9694],{"intervention":9693,"totalTrials":184,"cells":10321},{"EARLY_PHASE1":10322,"PHASE1":10324,"PHASE2":10326,"PHASE3":10328,"PHASE4":10330,"NA":10332},{"trials":10323,"activeCount":103},[],{"trials":10325,"activeCount":103},[],{"trials":10327,"activeCount":103},[],{"trials":10329,"activeCount":103},[],{"trials":10331,"activeCount":103},[],{"trials":10333,"activeCount":103},[10334],{"nctId":9684,"briefTitle":9685,"status":156,"phases":10335,"primaryCompletion":5412,"completion":5412,"start":3717,"enrollment":9687,"conditions":10336,"interventions":10337},[95],[9689],[4073,9691,9692,9693,9694],{"intervention":9694,"totalTrials":184,"cells":10339},{"EARLY_PHASE1":10340,"PHASE1":10342,"PHASE2":10344,"PHASE3":10346,"PHASE4":10348,"NA":10350},{"trials":10341,"activeCount":103},[],{"trials":10343,"activeCount":103},[],{"trials":10345,"activeCount":103},[],{"trials":10347,"activeCount":103},[],{"trials":10349,"activeCount":103},[],{"trials":10351,"activeCount":103},[10352],{"nctId":9684,"briefTitle":9685,"status":156,"phases":10353,"primaryCompletion":5412,"completion":5412,"start":3717,"enrollment":9687,"conditions":10354,"interventions":10355},[95],[9689],[4073,9691,9692,9693,9694],{"intervention":10357,"totalTrials":184,"cells":10358},"Marcaine- 0.25%",{"EARLY_PHASE1":10359,"PHASE1":10361,"PHASE2":10363,"PHASE3":10365,"PHASE4":10367,"NA":10369},{"trials":10360,"activeCount":103},[],{"trials":10362,"activeCount":103},[],{"trials":10364,"activeCount":103},[],{"trials":10366,"activeCount":103},[],{"trials":10368,"activeCount":103},[],{"trials":10370,"activeCount":103},[10371],{"nctId":10372,"briefTitle":10373,"status":786,"phases":10374,"primaryCompletion":4899,"completion":4899,"start":9885,"enrollment":777,"conditions":10375,"interventions":10377},"NCT01861665","Marcaine Use in Laparoscopic Gynecological Surgery",[95],[10376],"Post-operative Pain",[10357,10378],"Marcaine 0.25%.",{"intervention":10378,"totalTrials":184,"cells":10380},{"EARLY_PHASE1":10381,"PHASE1":10383,"PHASE2":10385,"PHASE3":10387,"PHASE4":10389,"NA":10391},{"trials":10382,"activeCount":103},[],{"trials":10384,"activeCount":103},[],{"trials":10386,"activeCount":103},[],{"trials":10388,"activeCount":103},[],{"trials":10390,"activeCount":103},[],{"trials":10392,"activeCount":103},[10393],{"nctId":10372,"briefTitle":10373,"status":786,"phases":10394,"primaryCompletion":4899,"completion":4899,"start":9885,"enrollment":777,"conditions":10395,"interventions":10396},[95],[10376],[10357,10378],{"intervention":10398,"totalTrials":184,"cells":10399},"dinoprostone",{"EARLY_PHASE1":10400,"PHASE1":10402,"PHASE2":10404,"PHASE3":10406,"PHASE4":10408,"NA":10410},{"trials":10401,"activeCount":103},[],{"trials":10403,"activeCount":103},[],{"trials":10405,"activeCount":103},[],{"trials":10407,"activeCount":103},[],{"trials":10409,"activeCount":103},[],{"trials":10411,"activeCount":103},[10412],{"nctId":10413,"briefTitle":10414,"status":156,"phases":10415,"completion":7775,"start":10416,"enrollment":10417,"conditions":10418,"interventions":10420},"NCT00504465","Combined Agent Randomized Trial of Induction of Labor",[95],"2002-05",210,[378,10419],"Cervical Ripening",[10398],{"intervention":10422,"totalTrials":184,"cells":10423},"Group 1",{"EARLY_PHASE1":10424,"PHASE1":10426,"PHASE2":10428,"PHASE3":10430,"PHASE4":10432,"NA":10434},{"trials":10425,"activeCount":103},[],{"trials":10427,"activeCount":103},[],{"trials":10429,"activeCount":103},[],{"trials":10431,"activeCount":103},[],{"trials":10433,"activeCount":103},[],{"trials":10435,"activeCount":103},[10436],{"nctId":10437,"briefTitle":10438,"status":786,"phases":10439,"primaryCompletion":10440,"completion":10440,"start":5147,"enrollment":777,"conditions":10441,"interventions":10443},"NCT01982149","Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer",[],"2019-05",[10442,36],"Chronic Obstructive Pulmonary Disease",[10422,10444,10445],"Group 2","Group 3",{"intervention":10444,"totalTrials":184,"cells":10447},{"EARLY_PHASE1":10448,"PHASE1":10450,"PHASE2":10452,"PHASE3":10454,"PHASE4":10456,"NA":10458},{"trials":10449,"activeCount":103},[],{"trials":10451,"activeCount":103},[],{"trials":10453,"activeCount":103},[],{"trials":10455,"activeCount":103},[],{"trials":10457,"activeCount":103},[],{"trials":10459,"activeCount":103},[10460],{"nctId":10437,"briefTitle":10438,"status":786,"phases":10461,"primaryCompletion":10440,"completion":10440,"start":5147,"enrollment":777,"conditions":10462,"interventions":10463},[],[10442,36],[10422,10444,10445],{"intervention":10445,"totalTrials":184,"cells":10465},{"EARLY_PHASE1":10466,"PHASE1":10468,"PHASE2":10470,"PHASE3":10472,"PHASE4":10474,"NA":10476},{"trials":10467,"activeCount":103},[],{"trials":10469,"activeCount":103},[],{"trials":10471,"activeCount":103},[],{"trials":10473,"activeCount":103},[],{"trials":10475,"activeCount":103},[],{"trials":10477,"activeCount":103},[10478],{"nctId":10437,"briefTitle":10438,"status":786,"phases":10479,"primaryCompletion":10440,"completion":10440,"start":5147,"enrollment":777,"conditions":10480,"interventions":10481},[],[10442,36],[10422,10444,10445],{"intervention":2907,"totalTrials":184,"cells":10483},{"EARLY_PHASE1":10484,"PHASE1":10486,"PHASE2":10488,"PHASE3":10490,"PHASE4":10492,"NA":10494},{"trials":10485,"activeCount":103},[],{"trials":10487,"activeCount":103},[],{"trials":10489,"activeCount":103},[],{"trials":10491,"activeCount":103},[],{"trials":10493,"activeCount":103},[],{"trials":10495,"activeCount":103},[10496],{"nctId":2897,"briefTitle":2898,"status":156,"phases":10497,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":2902,"conditions":10498,"interventions":10499},[],[2904,2905],[2864,2907,2908,2909,2910],{"intervention":2908,"totalTrials":184,"cells":10501},{"EARLY_PHASE1":10502,"PHASE1":10504,"PHASE2":10506,"PHASE3":10508,"PHASE4":10510,"NA":10512},{"trials":10503,"activeCount":103},[],{"trials":10505,"activeCount":103},[],{"trials":10507,"activeCount":103},[],{"trials":10509,"activeCount":103},[],{"trials":10511,"activeCount":103},[],{"trials":10513,"activeCount":103},[10514],{"nctId":2897,"briefTitle":2898,"status":156,"phases":10515,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":2902,"conditions":10516,"interventions":10517},[],[2904,2905],[2864,2907,2908,2909,2910],{"intervention":2909,"totalTrials":184,"cells":10519},{"EARLY_PHASE1":10520,"PHASE1":10522,"PHASE2":10524,"PHASE3":10526,"PHASE4":10528,"NA":10530},{"trials":10521,"activeCount":103},[],{"trials":10523,"activeCount":103},[],{"trials":10525,"activeCount":103},[],{"trials":10527,"activeCount":103},[],{"trials":10529,"activeCount":103},[],{"trials":10531,"activeCount":103},[10532],{"nctId":2897,"briefTitle":2898,"status":156,"phases":10533,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":2902,"conditions":10534,"interventions":10535},[],[2904,2905],[2864,2907,2908,2909,2910],{"intervention":2910,"totalTrials":184,"cells":10537},{"EARLY_PHASE1":10538,"PHASE1":10540,"PHASE2":10542,"PHASE3":10544,"PHASE4":10546,"NA":10548},{"trials":10539,"activeCount":103},[],{"trials":10541,"activeCount":103},[],{"trials":10543,"activeCount":103},[],{"trials":10545,"activeCount":103},[],{"trials":10547,"activeCount":103},[],{"trials":10549,"activeCount":103},[10550],{"nctId":2897,"briefTitle":2898,"status":156,"phases":10551,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":2902,"conditions":10552,"interventions":10553},[],[2904,2905],[2864,2907,2908,2909,2910],{"intervention":10555,"totalTrials":184,"cells":10556},"eculizumab",{"EARLY_PHASE1":10557,"PHASE1":10559,"PHASE2":10561,"PHASE3":10563,"PHASE4":10565,"NA":10567},{"trials":10558,"activeCount":103},[],{"trials":10560,"activeCount":103},[],{"trials":10562,"activeCount":103},[],{"trials":10564,"activeCount":103},[],{"trials":10566,"activeCount":103},[],{"trials":10568,"activeCount":103},[10569],{"nctId":10570,"briefTitle":10571,"status":156,"phases":10572,"primaryCompletion":10573,"completion":10573,"start":993,"enrollment":203,"conditions":10574,"interventions":10577},"NCT02604420","Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants",[],"2018-03-28",[10575,10576],"Thrombotic Microangiopathy","Disorder Related to Bone Marrow Transplantation",[10555]]